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CHAPTER 1
GENERAL INTRODUCTION, AIMS, AND
DESIGN OF THE STUDY




The manifestations of peripheral arterial occlusive disease (PAOD) range from mild
limitations in walking capacity. as in intermittent claudication (IC), to gangrenous tissue loss
of the lower limb with ultimately the risk of amputation. The surgical treatment of PAOD
has been characterised by endeavours to overcome the obstacles  of arterial blood  flow.  With
the development of vascular surgical techniques and subsequent better long term-results,
invasive treatment became popular, though sometimes    at    the    cost of complications'-3
Recognising the generally benign course of IC for the legs. the hazards of invasive
treatment, and the high mortality of patients with atherosclerosis, a more conservative
approach was adopted for patients with mild symptoms, in the last decades of the 206
century4.5
Because of the initial emphasis on invasive therapy, the vascular literature has been
dominated for a long time by technical issues disregarding disease impact and treatment
results as experienced by patients. Although hard endpoints and the means to achieve them
are  important  from a traditional surgical point of view,  it can be debated whether they have a
relationship with patients' perception of disease and treatment results6. This becomes even
more important if one considers that IC is a herald of potentially life-threatening
atherosclerotic complications: This questions the appropriateness of the arguments on
which treatment plans are currently based. For instance, do these arguments represent the
actual problems for which the patient seeks help? Does treatment provide a solution for
those problems? The staff of the vascular unit of the Department of Surgery at the St.
Elisabeth Hospital in Tilburg, The Netherlands realised that treatment decisions in patients
with IC were not always based on consistent arguments and wanted to systematically study
the patients' perception of disease impact and treatment results. Based on the literature, it
was assumed that the impact of IC on daily life should be assessed by means of quality of
life (QOL) measures.  With the  aim to optimise the methodology of the study, efforts were
joined with the Department of Psychology and Health of Tilburg University, Tilburg, The
Netherlands, which has a specific interest for and wide experience with the development and
application of QOL measures.
INTERM[TTENT CLAUDICATION
Intermittent claudication (IC) is the clinical condition of lower extremity muscle pain
induced by exercise and relieved by short periods of rest8. The pain never starts at rest nor
disappears while walking. IC is a manifestation of peripheral arterial occlusive disease
(PAOD).  caused by the atherosclerotic process of progressive narrowing of arteries. Failure
of the arterial system to supply an adequate blood flow to meet the metabolic demands of
exercising muscles, results in a progressive oxygen debt, experienced by the patient as
11
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cramping muscle pain. The development and course of PAOD  and  IC are accelerated  by the
same cardiovascular risk factors that are associated with other expressions of atherosclerotic
disease, such as coronary heart disease and cerebrovascular disease. There is convincing
evidence for an association between IC and the traditional atherosclerotic risk factors
smoking, diabetes mellitus, hypertension, and hyperlipidaernia, as well as more recently
identified factors like plasma fibrinogen levels, insulin tolerance and hyperhomo-
9,10cysteinaemia
Epidemiology of intermittent claudication
The incidence and prevalence of PAOD and IC are difficult to calculate, because of the
different criteria used and the varying size and methodology of studies. Besides, not all
patients with PAOD will report symptoms of IC. A low activity level may not provoke
symptoms and elderly patients often consider their complaint as part of ageing and
consequently do not report symptoms. Since only a small proportion of patients will seek
medical advice, of which a minority will be referred for further evaluation, incidence based
on hospital referrals probably underestimates  the real incidence  of IC".  The  incidence of IC
in men increases with age from 2  per  1000 per year in the age 35-39 years to  7 per  1000 per
year in the age 70-74 years (Fig. 1). In the Netherlands, the incidence in men ranges12-16
between 4 (55-59 years) and 13 per 1000 per year (>85 years). In women, the numbers range







Weighted mean incidence of intermittent claudication in men found in five large population-based studies
(Reprinted from TASC working group. Management of peripheral arterial disease. Epidemiology. natural
history, risk factors.  Eur J Vasc Endovasc  Surg 2000; 19:S4-S30, with permission from Elsevier)
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The prevalence of IC increases with age, and men are more affected than women18-24 In large
international studies. the prevalence of IC in men around the age of 60 years is estimated
between 3% and 6% (Fig. 2). In the Netherlands, symptomatic PAOD has a prevalence of 4.7
per   1000   (5.1   in   men.   4.2 in women)   for   all age categoriesz: The prevalence   of  both
symptomatic and asymptomatic PAOD for all age categories is estimated around 2%.
increasing  with age  to  6.9% (men 7.2%, women 6.5%)  in the category 45-75 years, of which
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Figure 2
Weighted mean prevalence of intermittent claudication in men in large population-based studies (Reprinted
from TASC working group. Management of peripheral arterial disease. Epidemiology, natural history. risk
factors. Eur J Vasc Endovasc Surg 2000;19:S4-S30, with permission from Elsevier)
The medical expenditure as a result of IC is illustrated by the fact that. in the year 2000.
PAOD accounted for 6% of all hospital admittances for cardiovascular disease in the
Netherlands, ofwhich 1.3% for IC (> 3400 patients hospitalised and > 2100 patients admitted
27in one day-care)  . The number, character, and costs of diagnostic procedures vary widely
between hospitals and countries and are diflicult to compare. Treatment strategies for IC
range between cheap non-supervised exercise training and expensive surgical or
endovascular procedures. Similarly. the low costs for antiplatelet therapy to prevent further
atherosclerotic events will increase significantly with the prescription of additional
antihypertensive drugs, statins. and more or less effective agents to improve the walking
distance.  As a consequence, the costs of diagnosis and treatment of IC, and those of follow-
up and secondary prevention are difficult to calculate, but probably substantialis.
13
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Natural history of intermittent claudication
Although PAOD is progressive, IC generally has a benign course for the legs. In more than
half of the patients, symptoms will improve or disappear after five years. One fourth of the
patients will deteriorate, most often in the first year after diagnosis (6%-9%), falling to 2%-
3% per year thereafter . Major amputation is a rare outcome for claudication, with a risk29-31
of 1 to 3% over a 5-year period32-34
Since atherosclerosis is a systemic disease affecting all arteries, symptoms are not confined to
the lower limbs. There is an important overlap between PAOD, coronary heart disease, and
cerebrovascular disease (Fig. 3).
35,36
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Figure 3
Overlap between peripheral arterial occlusive disease, coronary artery disease (CAD), and cerebrovascular
(CVD)  disease  in 1886 patients  aged  > 62 years,  37%  of whom  had no clinical evidence  of CHD.  CVD  or
PAOD. Adapted from Aronow and Ahn35 and CAPRIE36 (Reprinted from Dormandy J, Heeck L, Vig S. The
natural history of claudication: Risk to life and limb. Sem Vasc Surg 1999,12:123-137, with permission from
Elsevier)
Overall.  up to  60%  of the patients with IC  will have coronary or cerebrovascular disease and
in one fifth fatal cardiac or cerebrovascular complications will occur within five years after
the onset of symptoms. Conversely, about 40% of the patients with coronary or
cerebrovascular disease also will have PAOD . As  a result, the mortality  of patients  with29.30.37
IC is two to three times higher than in the age-matched healthy population. i.e., 30% at five
years. 50%  at ten years,  and  70% at 15 years. This decreases the  mean life expectancy of
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Figure 4
Mean survival curves of patients with intermittent claudication and matched controls within 15 years follow-
up (Reprinted from Dormandy J. Heeck L, Vig S. The natural history of claudication: Risk to life and limb.
Sem Vasc Surg 1999,12:123-137. with permission from Elsevier)
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Figure 5
Summary of fate of the claudicant over 5 years from presentation (Reprinted from Dormandy J, Heeck  L,  Vig
S. The natural history of claudication: Risk to life and limb. Sem Vasc Surg 1999;12:123-137. with
permission from Elsevier)
Diagnostic procedures for intermittent claudication
The diagnosis IC is based on history and physical examination and may be confirmed by
functional tests. A history of cramping muscle pain, usually in the calves, after walking a
certain distance. that disappears gradually after cessation  of the exercise is suggestive  for IC.
Questionnaires for the identification of IC have been developed, like the World Health
Organisation/ Rose Questionnaire and the Edinburgh Claudication Questionnaire39,40 (Table
1)
15
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Table 1
Edinburgh modification ofthe Rose questionnaire
1. Do you get a pain or discomfort in your leg(s) when you walk?
(No: stop)
2. Does the pain ever begin when you are standing still or sitting?
3. Do you get it if you walk uphill or hurry?
4.  Do you get it when you walk at an ordinary pace on the level? (Used for grading the severity of I.C.)
5. What happens to it if you stand still?
Usually continues more than 10 minutes
Usually disappears in 10 minutes or less
6. Where do you get this pain or discomfort?
On physical examination, the absence of peripheral pulses and bruits over the femoral artery
are suggestive for the diagnosis. However, there may be palpable peripheral pulses in
symptomatic patients with moderate disease. A useful non-invasive test for diagnosing IC is
the Doppler ankle/ brachial blood pressure index (ABPI).  At a cut off value of 0.9. the ABPI
appeared   up  to 95% sensitive in detecting angiogram-positive disease and almost   100%
specific in identifying apparently healthy individuals4146- The key modality to the diagnosis
of symptomatic IC is the treadmill test4748. For the diagnosis IC, the exercise must provoke
the  typical  pain and  show a concomitant  ABPI  drop  of at least  20  mm  Hg  on the symptomatic
side49 Although there are doubts about the reliability of measuring claudication distances
with a treadmill, because of daily fluctuations in severity of IC and the influence of vascular
technicians, the test offers the possibility to differentiate between patients with a walking
limitation as a result of IC and those who are limited by other complaints like back, hip, and
knee symptoms, and cardiopulmonary disease50
The degree of IC, the severity of the walking impairment, is traditionally expressed in the
stages HA and IlB ofthe Leriche-Fontaine classification (Table 2).
Table 2
Leriche-Fontaine classification of peripheral arterial occlusive disease
Stage i Disease on angiography, no symptoms
Stage lI Intermittent claudication
1IA Pain free walking distance 2 100 m.
IIB Pain free walking distance <  100 m.
Stage III Rest pain or pain at night
Stage IV Tissue loss
More recently, the International Society for Vascular Surgery/ The North American Chapter
of the International Society for Cardiovascular Surgery (SVS/ISCVS) has proposed an
alternative classification based on treadmill performance and ankle blood pressures before




Suggested classification for grading the severity of chronic arterial occlusive disease (SVS/ISCVS45
Grade Category Clinical description Objective criteria
00 Asymptomatic-no haemodynamically Normal treadmill or reactive
significant occlusive disease hyperaemia test
0              1 Mild claudication Completes treadmill exercise*
AP after exercise >50 mm Hg
but at least 20 mm Hg lower than resting
value
12 Moderate claudication Between categories 1 and 313 Severe claudication Cannot complete standard
treadmill exercise* and AP
after exercise <50 mm Hg
24 ischaemic rest pain Resting AP <40 mm Hg, flat/
barely pulsatile ankle or
metatarsal PVR:TP <30mmHg
35 Minor tissue loss-non-healing ulcer, Resting AP <60 mm Hg, ankle
focal gangrene with diffuse pedal or metatarsal PVR flat/ barely
ischaemia pulsatile; TP <40 mm Hg
36 Major tissue loss-extending above Same as category 5
TM level, functional foot no longer
salvageable
*Five minutes at 2 mph on a 12% incline. Note:  AP = ankle pressure, TP = toe pressure, PVR = pulse volume
recording, TM = transmetatarsal
Complementary to the objective assessment of IC, the Walking Impairment Questionnaire
(WIQ) has been developed, permitting patients to quantify their walking ability in terms of
defined distances and speeds and to rate the severity of claudication pain during usual
walking activities5:
Treatment of intermittent claudication
Most  important  for the management  o f patients  with IC  is to recognise that they are  at  risk of
developing severe and often fatal cardiovascular complications. The first priority should be to
modify the known risk factors for the progression of atherosclerosis and development of
subsequent complications. It is important to explain to the patient the rationale for this
strategy and that it is not designed to improve the claudication distance520
The cornerstone of treatment for patients with IC is cessation of smoking, exercise training,
and anti-platelet medication for the secondary prevention of atherosclerotic events53-57 It has
been reported that smoking cessation is associated with a declining incidence of IC and that
5859the risk of IC for ex-smokers might decrease after one year  ' . Exercise training is most
effective in a supervised setting, 3 to 5 times a week 35 to 50 minutes, for at least six months.
In  addition  to  a   100  to 150% improvement  o f the maximum walking distance, the regimen
confers also some health status benefits . Sanitation of cardiovascular risk factors53.56.57,60,61
and treatment of comorbidity, like adequate regulation of hypertension, diabetes mellitus,
17
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62.63hyperlipidaemia, and overweight, will contribute to a better physical condition too
Despite reports on statistically significant, but clinically moderate benefits for walking (less




The decision to consider interventional therapy should be based on the actual handicap.
which may vary substantially between patients, and is difficult to assess. Assessment at the
most individual level, e.g. by means of quality of life (QOL) measurements, may contribute
to patient-tailored treatment. If conservative treatment fails, short isolated lesions in the iliac
arteries, and to a lesser extent in the femoropopliteal segment, may be treated with
percutaneous transluminal angioplasty (PTA). The procedure has low morbidity and
mortality risks (<0.5%) and, at 5 years. patency rates have been reported of 80 to 90% for
iliac lesions and 60 to 70% femoropopliteal lesions . However. a meta-analysis on PTA69-71
with or without additional stem placement in the iliac arteries reported patency rates that
72were much lower  . The long-term results of femoropopliteal PTA in claudicants appeared
also disappointing73 Walking improvements are comparable with those of exercise training
and health status improvements approach those of surgery . Longer or multi-level57.61.74,75
lesions require operative interventions ,  which. at the cost of a certain morbidity (5-10%)
57.76
and  mortality  (2-3%), may provide  a  75  to 100% improvement  of the maximum walking
distance57. It has been shown that additional exercise training after bypass surgery enhances
the walking benefits77.
QUALITY OF LIFE RESEARCH
Increasingly, clinicians recognise that illness does not exist in a vacuum. but should be
regarded in the context of daily life78. This is especially the case in chronic non-lethal
diseases with an important impact on daily life. like inflammatory bowel disease79. chronic
lung disease80, rheumatoid arthritis81, and peripheral vascular disease82. In order to assess this
personal context QOL measures could be used8: The term has a certain attraction since it has
become accepted that health means more than the absence of disease and infirmity. but also
reflects a state of physical, psychological. and social well-being84. Moreover. it has been
recognised that the impact of disease on patients' daily life cannot always be assessed
adequately with the traditional instruments85.86
To understand reports on QOL, it is necessary to know what is meant by QOL, because the
term is frequently used in a confusing way in the medical literature for concepts like health
status, health-related QOL, and QOL. In contrast with broad QOL instruments. health-related
QOL instruments focus only on health-related issues. Health status assesses the objective
influence of disease on physical, psychological, and social functioning87, whereas QOL is
defined  by the WHO as "an individual's perception of his/her position in life in the context of
the culture and value systems in which he/she lives and in relation to his/her goals. expectations.
18
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standards and concerns. It is a broad ranging concept incorporating in a complex way the
individual's physical health, psychological state, level of independence, social relationships,
personal beliefs, and relationships to salient features in the environment'48. QOL measures are
increasingly regarded as a supplement to objective clinical measures of disease, for the
assessment of the quality of service, the need for health care, the effectiveness of
interventions, and evaluations of economic aspects8990. The potential benefit for the patients
is that their problems are identified and dealt with, and that treatment decisions are based on
individual priorities and preferences. In other words, the reason for using QOL measures in
clinical practice is to ensure that treatment plans and evaluations focus on the patient rather
than on the disease. This patient-centred perspective of disease impact and treatment results
may contribute to tailor common therapies to the needs of individuals or specific patient groups.
In vascular disease, the traditional outcome measures are walking distance, ankle-brachial
blood pressure indices, patency of revascularisation procedures, amputation, and sunival49
Recognising that atherosclerosis is a chronic progressive and still incurable disease, the
treatment of patients with IC is palliative, at best. Practically, this means that the alleviation
of symptoms and limitation or modification of disease impact on the patient's daily life
remain as goals of treatment . A wealth of literature reporting on "QOL" in patients with82.91
IC is presently available. Unfortunately, the term QOL is seldom specified in reports that
claim to measure QOL. Because high or low scores on measures of functional status or health
status are often erroneously equated with good or bad QOL92. the impact of IC and the
influence of various treatment modalities on QOL in patients with  IC  are still unclear.
AIMS AND DESIGN OF THE STUDY
Considering the inappropriateness of traditional outcome measures for the claudicant's
perception  o f disease and treatment results  and the confusion about  the  use and interpretation
of the term "QOL" in the literature, it was decided to perform a study that aims (i) to assess
the impact of IC on patients' daily life by means of defined QOL measures, (ii) to identify
factors that are of particular importance for QOL in patients with IC, (iii) to explore the
similarities and differences between health status and QOL as defined by the WHO, and (iv)
to report on the results of conservative treatment in patients with IC, with regard to walking
performance, QOL. and health status.
Between January  1999  and  June  2001,  QOL and health status were assessed prospectively
and longitudinally in all patients with IC that were referred to the vascular outpatient clinic of
the Department of Surgery at the St. Elisabeth Hospital in Tilburg, The Netherlands and who
agreed to participate in the study by informed consent. The diagnosis IC was suspected on
history and physical examination in 215 patients and could be confirmed by treadmill
performance and ankle brachial pressure indices in 207 patients. Seven patients refused or
were not capable (demented, blind. deaf) to participate. Thus. two hundred patients
19
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completed the World Health Organisation Quality of Life Assessment Instrument-100
(WHOQOL-100) (Appendix I)93,94. The WHOQOL-100 was chosen, because it corresponds
best with the subjective character of the WHO definition of QOL88. It is a generic,
multidimensional self-report measure assessing 24 facets of QOL within six domains (Physical
health, Psychological health Level of independence, Social relationships, Environment, and
Spirituality/religion/personal beliefs), and a generic evaluative facet "Overall QOL and general
health". The instrument   has been developed simultaneously and cross-culturally  in 15 centres
88 95around the world and has good psychometric properties '. Because the chosen QOL measure.
WHOQOL-100, was expected to be too long for the elderly IC population, the first step was
to select the aspects ofdaily life that are relevant for patients with PAOD.
Health status was assessed with the RAND-36 item health survey (Appendix II) which is96.97
practically identical to the Medical Outcome Study/Short Form-36 (SF-36)98. The instrument
was chosen because of its proven applicability in PAOD and to comply with the recommended
standardisation of reporting health status in vascular disease82.99,100. The RAND-36 is a 36-
questions generic health status measure, assessing health in eight dimensions: Physical
functioning, Social functioning, Limitations in usual role activities due to physical problems
(Role physical), Limitations in usual role activities due to emotional problems (Role emotional),
Mental health, Vitality, Bodily pain, and General health perception.
To place the results in perspective, patients were matched for age and sex with healthy
controls. The scores of the matched controls were collected from the WHOQOL data base of
the Department of Psychology and Health of Tilburg University. Tilburg, The Netherlands and
from the RAND-36 database  of the Northern Centre for Health Care  Research.  Groningen.  The
Netherlands. In all patients, risk factors and comorbidity were recorded according to the
recommended standards for reports dealing with lower extremity ischaemia49.
OUTLINE OF THE THESIS
The aforementioned study aims and results will be presented in the thesis in the following
chapters. Chapter 2 contains a review of the present literature on health status and QOL in
patients with IC. In the review, an attempt is made to (i) clarify the differences between
several concepts that are labelled QOL, (ii) describe the measures that are used to assess
these concepts in patients  with IC, (iii) provide an overview of the published study results  in
patients with IC, and (iv) prelude on the implementation of subjective outcome measures in
the treatment ofpatients with IC.
Chapter 3 concerns a pilot study that was performed to analyse the process of measuring
QOL and health status, using the WHOQOL-100 and the RAND-36 questionnaires in
patients with varying degrees of lower limb ischaemia. The main question concerned the
appropriateness of the WHOQOL-100 for the assessment of QOL in patients with PAOD.
The second goal of the study was to shorten the questionnaire to reduce patient burden by
20
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removing aspects that were not relevant to patients with PAOD. Finally, special attention was
given to practical problems that were encountered during completion ofthe questionnaires.
Chapter 4 addresses similarities and differences between QOL and health status, and the
possible advantages of combined use  for the assessment of disease impact in patients with IC.
At the first visit to the vascular outpatient clinic, 200 patients completed the reduced version
of the WHOQOL-100 and the RAND-36. Patients' results on these measures were compared
with each other and with the results of age and sex-matched healthy persons.
Chapter 5 contains the first report on QOL, as measured with the reduced version of the
WHOQOL-100,  in 151 patients  with  IC. In addition, the effects  of the severity  o f IC  on  QOL
were examined.
Chapter 6 deals with the key question for QOL in claudicants, i.e., which are the factors that
are  responsible  for the  QOL of patients with IC? Is QOL determined by the walking problem
or are there other factors that influence QOL in patients with IC? Using multiple regression
analyses, the predictive value of age, sex, degree of IC, cardiovascular risk factors and
comorbidity, as well as the presence of back. hip. and knee symptoms for QOL in patients
with IC were examined.
Chapter 7 reports  on the effects of one  year  of conservative treatment with regard to walking
performance, QOL, and health status in patients with IC. In addition, QOL and health status
scores before and after treatment were compared with those of age and sex matched healthy
persons.
A general discussion on the study results, questions, and considerations that have raised from
this  study is presented in Chapter  8.  The  last two chapters contain summaries  of this thesis  in
English, and in Dutch for the non-medical reader.
21
General introduction, aims, and design ofthe study
REFERENCES
1.   Szilagyi DE, Elliott JP Jr, Smith RF, Reddy 8.   Taylor LM, Porter JM. Natural history and
DJ, McPharlin M. A thirty-year survey ofthe nonoperative treatment of chronic lower
reconstructive surgical treatment of extremity ischemia. In: Rutherford RB. ed.
aortoiliac occlusive disease. J Vasc Surg Vascular Surgery 4th ed, Saunders Company,
1986 Mar:3(3):421-36 Philadelphia, 1997
2.  Schepers A, Klinkert P, Vrancken Peeters 9.   Dormandy J. Heeck L, Vig S. Predictors of
MP, Breslau PJ. Complication registration in early disease in the lower limbs. Sem Vasc
patients after peripheral arterial bypass Surg 1999;12:109-117
surgery. Ann Vasc Surg 2003:17(2):198-202
10. TASC working group. Management of
3.   Jamsen TS, Manninen Hl, Tulla HE, peripheral arterial disease. Epidemiology,
Jaakkola PA, Matsi PJ. Infrainguinal natural history, risk factors. Eur J Vasc
revascularization because of claudication: Endovasc Surg 2000;19:S4-S30
Total long-term outcome of endovascular
and surgical treatment. J Vasc Surg 2003 11. Dormandy J, Mahir M, Ascady G. et al. Fate
Apr;37(4):808-15 of the patient with chronic leg ischemia.  J
Cardiovasc Surg 1989;30:50-57
4.    Coffman JD. lntermittent claudication - Be
conservative. N Engl J Med 1991;325:577-578 12. Widmer LK. Da Silva A. Historical
perspectives and the Basle study. In: Fowkes
5.   Phillipps MJ, Cowan AR, Johnson CD. FGR. ed. Epidemiology of peripheral
Intermittent claudication should not be vascular disease. London: Springer Verlag
treated by surgery. Ann R Coll Surg Engl 1991:69-83
1997;79:264-267
13.  Leng GC. Questionnaires. ln: Fowkes FGR,
6.   Chetter IC, Dolan P, Spark JI, Scott DJA, ed. Epidemiology of peripheral vascular
Kester RC. Correlating clinical indicators of disease. London: Springer Verlag,  1991 :29-
lower limb ischaemia with quality of li fe.                                  40
Cardiovasc Surg 1997;5:361-366
14. Bainton D, Sweetman P, Baker I. Elwood P.
7.   Dormandy J, Heeck L, Vig S. Intermittent Peripheral arterial disease: consequences for
claudication: A condition with underrated survival and association with risk factors in
risks.  Sem Vasc Surg 1999,12:96-108 the Speedwell prospective heart disease
study. Br Heart J 1994.72:128-132
22
Chapter 1
15.  Bowlin SJ. Medalie JH. Flocke SA, 22.  Stoffers HEJH, Kaiser V, Knottnerus JA.
Zyzanski SJ, Goldbourt U. Epidemiology of Prevalence in general practice. In Fowkes
intermittent claudication in middle-aged FGR, ed. Epidemiology of peripheral
men. Am J Epidemiol 1994.140:418-430 vascular disease. London: Springer Verlag,
1991:109-115
16.  Murabito JM, D'Agostino RB, Silbershatz
H, Wilson WF. Intermittent claudication: A 23. Smith WCS, Woodward M, Tunstall-Pedoe
risk profile from the Framingham heart H. Intermittent claudication in Scotland. In:
study. Circulation 1997;96:44-49 Fowkes FGR, ed. Epidemiology of
peripheral vascular disease. London:
17. Meyer WT, Cost B, Bernsen RM, Hoes AW. Springer Verlag, 1991:117-123
Incidence and management of intermittent
claudication in primary care in the 24. Novo S, Avellone G, Di Garbo G. et al.
Netherlands. Scan J Prim Health Care Prevalence of risk factors in patients with
2002;20:33-34 peripheral arterial disease: A clinical and
epidemiological evaluation. International
18.  Hughson WG, Mann JI, Garrod A. Angiology 1992;11:218-229
Intermittent claudication: Prevalence and
risk factors. Br Med J 1978,1:1379-1381 25. Oskam SA, Brouwer HJ, Mohr J. TRANS,
an interactional access program for standard
19.  De Backer IG. Kornitzer M, Sobolski J, output  of the transition project. Amsterdam.
Denolin H. intermittent claudication: Department of General Practice,  1994
Epidemiology and natural history. Acta
Cardiol 1979;34:115-124 26.  Rauwerda JA. Ed. Chronische arteriele
obstructieve vaatziekten. In: Vaatpatienten in
20. Reunanen A, Takkunen H, Aromaa A. beeld. Nederlandse Hartstichting, 1998
Prevalence of intermittent claudication and
its effects on mortality. Acta Ned Scand 27.  Koek HL, Van Leest LATM, Verschuren
1982:211:249-256 WMM. Bots ML. Hart- en vaatziekten in
Nederland 2003, cijfers over leefstijl en
21. Fowkes FGR, Housley E, Cadwood EH, risicofactoren, ziekte en sterfte. Den Haag:
Macintyre CC, Ruckley CV, Prescott RJ. Nederlandse Hartstichting, 2003
Edinburgh artery study: Prevalence of
asymptomatic and symptomatic peripheral 28. TASC working group. Management of
arterial disease in the general population. Int peripheral arterial disease. Economic aspects
J Epidemiol 1991.20:384-392 of intermittent claudication. Eur J  Vasc
Endovasc Surg 2000,1 9  : S 104- S 10 8
23
General introduction, aims, and design ofthe study
29. O'Riordain DS, O'Donnel JA. Realistic 36. CAPRIE Steering committee: A randomised,
expectations for the patient with intermittent blinded, trial of clopidogrel versus aspirin  in
claudication. Br J Surg 1991:78:861-863 patients at risk of ischemic events
(CAPRIE). Lancet 1996;348:1329-1339
30.   Hertzer NR. The natural history of vascular
disease. Circulation 1991;83(suppl I):1-12-1- 37.  Dormandy JA, Murray GD. The fate ofthe
19                                                                                                                 claudicant - A prospective study of 1969
claudicants. Eur J Vasc Surg 1991:5:131-133
31.  Leng GC, Lee Al, Fowkes FG. et al.
Incidence, natural history and cardiovascular 38. Dormandy J, Heeck L, Vig S. The natural
events in symptomatic and asymptomatic history of claudication: Risk to life and limb.
peripheral arterial disease in the general Sem Vasc Surg 1999:12:123-137
population. int J Epidemiol 1996;25:1172-
1181 39.   Rose GA. The diagnosis of ischaemic heart
pain and intermittent claudication in field
32.  Breslau PJ, Jorning PG, Dassen P. The surveys. Bull WHO 1962:27:645-658
natural history of intermittent claudication,  a
prospective study. Presented at the 2Od 40.  Leng GC, Fowkes FGR. The Edinburgh
International Vascular Symposium. Claudication Questionnaire: An improved
September 1986 version of the WHO/Rose Questionnaire  for
use in epidemiological surveys. J Clin
33. Gilliland LE, Liewellyn CD, Goss DE. et al. Epidemiol 1992:45:1101-1109
The morbidity and mortality of stable
claudicants Results of five year follow-up. 41.  Winsor T. Influence of arterial disease on the
Presented at the 2™' International Vascular systolic blood pressure gradients ofthe
Symposium. September 1986 extremity. Am J Med Sci 1950:220:117-126
34. McDaniel MD, Cronenwett JL. Basic data 42. Carter SA. Indirect systolic pressures and
related to the natural history of intermittent pulse waves in arterial occlusive disease of
claudication. Ann Vasc Surg 1989;3:273-277 the lower extremities. Circulation
1968,37:624-638
35. Aronow WS, Ahn C. Prevalence of
coexistence of coronary artery disease. 43.  Yao ST. New techniques ofobjective arterial
peripheral arterial disease, and evaluation. Arch Surg 1973;106:600-604
atherothrombotic brain infarction in men and
women 262 years of age.  Am J Cardiol 44. Hummel BW, Hummel BA, Mowbry A. et
1994;74:64-65 al. Reactive hyperaemia vs. treadmill




45. Ouriel K, McDonnel AE, Metz CE. et al. 52. TASC working group. Management of
A critical evaluation of stress testing in the peripheral arterial disease. Treatment of
diagnosis of peripheral vascular disease. intermittent claudication. Eur J Vasc
Surgery 1982;91:686-693 Endovasc Surg 2000.19 :S67-S76
46.  Laing S, Greenhaigh RM. The detection and 53. Gardner AW, Poehlman ET. Exercise
progression of asymptomatic peripheral rehabilitation programs for the treatment of
arterial disease.  Br J Surg 1983;70:628-630 claudication pain. A meta-analysis. JAMA
1995 Sep 27.274( 12):975-80
47. Hiatt. WR, Hirsch AT, Regensteiner JG,
Brass EP. Clinical trials for claudication. 54. Remijnse-Tamerius HC, Duprez D, De
Assessment of exercise performance. Buyzere M, Oeseburg B, Clement DL. Why
functional status and clinical endpoints. is training effective in the treatment of
Circulation 1995,92:614-621 patients with intermittent claudication? Int
Angiol 1999 Jun. 18(2):103-12
48. Cachovan M, Rogatti W, Creutzig A. et al.
Treadmill testing for evaluation of 55. Tan KH, De Cossart L, Edwards PR.
claudication: Comparison of constant-load Exercise training and peripheral vascular
and graded-exercise tests. Eur J Vasc disease. Br J Surg 2000 May;87(5):553-62
Endovasc Surg 1997;14:238-243
56.  Leng GC, Fowler B, Ernst E. Exercise for
49.  Rutherford RB, Baker JD, Ernst C. et al. intermittent claudication. Cochrane database
Recommended standards for reports dealing Syst Rev 2000;2:CDO00990
with lower extremity ischemia: Revised
version. J Vasc Surg 1997.26.517-538 57.  Stewart KJ, Hiatt WR, Regensteiner JG,
Hirsch AT. Exercise training for
50.  Watson CJE, Phillips D, Hands L, Collin J. claudication. N Engl J Med 2002;347:1941-
Claudication distance is poorly estimated and 1950
inappropriately measured. Br J Surg
1997;84:1107-1109 58. Ingolfsson IO, Sigurdson G, Sigvaldason H.
Thorgeirsson G, Sigdusson N. A marked
51.  Regensteiner JG, Steiner JF, Panzer RJ, Hiatt decline in the prevalence and incidence of
WR.  Evaluation of walking impairment by intermittent claudication in Icelandic men
questionnaire in patients with peripheral 1968-1986: A strong relationship to smoking
arterial disease. J Vasc Biol 1990.2:142-152 and serum cholesterol- The Reykjavik Study.
J Clin Epidemiol 1994;47:1237-1243
25
General introduction, aims, and design ofthe study
59.  Dagenais GR, Maurice S, Robitaille NM, 66. Brevetti G, Annecchini R, Bucur R.
Gingras S, Lupien PJ. Intermittent Intermittent claudication.
claudication in Quebec men from 1974- Pharmacoeconomic quality  of life aspects of
1986: The Quebec Cardiovascular Study. treatment. Pharmacoeconomics
Clin Invest Med 1991;14:93-100 2002;20(3):169-181
60. Regensteiner JG, Hargarten ME, Rutherford 67. Tjon JA, Riemann LE. Treatment of
RB, Hiatt WR. Functional benefits of intermittent claudication with pentoxifylline
peripheral vascular bypass surgery for and cilostazol. Am J Health Syst Pharm 2001
patients with intermittent claudication. Mar 15:58(6):485-93
Angiology 1993;4:1-10
68.   Hiatt WR. Medical treatment of peripheral
61. Feinglass J, McCarthy WJ, Slavensky R, arterial disease and claudication. New Engl J
Manheim LM, Martin GJ. Functional status Med 2001:344:1608-1621
and walking ability after lower extremity
bypass grafting or angioplasty for 69. Gallino A, Mahler F, Probst P, Nachbur B.
intermittent claudication: Results from a Percutaneous transluminal angioplasty  of the
prospective outcomes study. J Vasc Surg arteries ofthe lower limbs; A five year
2000;31:93-103 follow-up. Circulation  1984;70:619-623
62. Creager MA. Medical management of 70. Van Andel GJ, Van Erp WFM, Krepel VM,
peripheral arterial disease. Cardiol Rev 2001 Breslau PJ. Percutaneous transluminal
Jul-Aug;9(4):238-45 dilatation of the iliac artey. Long-term
results. Radiology 1985:156:321-323
63.  Regensteiner JG, Hiatt WR. Current medical
therapy for patients with peripheral arterial 71. Krepel VM, Van Andel GJ, Van Erp WFM,
disease: A critical review. Am J Med Breslau PJ. Percutaneous transluminal
2002;112:49-57 angioplasty ofthe femoropopliteal artery.
Initial and long-term results. Radiology
64. Beebe HG, Dawson DL, Cutler BS. et al. A 1985:156:325-328
new pharmacological treatment for
intermittent claudication: Results of a 72.  Bosch JL, Hunink MG. Meta-analysis ofthe
randomized, multicenter trial. Arch Intern results of percutaneous transluminal
Med  1999 Sep 27;159(17):2041-50 angioplasty and stent placement for
aortoiliac occlusive disease. Radiology. 1997
65. Dawson DL, Cutler BS, Hiatt WR. et al. A Jul,204(1 ):87-96
comparison of cilostazol and pentoxi fylline




73. Jamsen TS. Manninen HI. Jaakkola PA, 80. Curtis JR, Martin DP, Martin TR. Patient-
Matsi PJ. Long-term outcome of patients assessed health outcomes in chronic lung
with claudication after balloon angioplasty of disease. Am J Respir Crit Care Med
the femoropopliteal arteries. Radiology. 1997:156:1032-1039
2002 Nov:225(2):345-52
81. Guillemin F. Functional disability and
74. Creasy TS, MeMillan PJ, Fletcher EWL. quality-of-life assessment in clinical practice.
Collin J, Morris PJ. Is percutaneous Rheumatology 2000;39 (suppl. 1):17-23
angioplasty better than exercise for
claudication? Preliminary results from a 82. McDaniel MD, Nehler MR, Santilli SM. et
prospective trial. Eur J Vasc Surg al. Extended outcome assessment in the care
1990:4:135-140 of vascular diseases: revising the paradigm
for the 21 st century. J Vasc Surg  2000
75.  Whyman MR, Fowkes FGR, Kerracher EMG. Dec:32(6):1239-50
et al. Is intermittent claudication improved by
PTA? A randomised controlled trial. J Vasc 83. Bowling A. Measuring disease: A review of
Surg 1997,26:551-557 disease-specific quality of life measurement
scales. Buckingham: Open University
76. Comerota AJ. Endovascular and surgical Press: 1985
revascularization for patients with
intermittent claudication. Am J Cardiol 84. World Health Organisation. l'he constitution
2000:87(12A):34D-43D ofthe WHO. WHO chronicle 1947;1:29
77.  Lundgren F, Dahllof A, Lundholm K. 85.  O'Boyle CA. Assessment of quality of life in
Schersten T, Volkmann R. lntermittent surgery. Br J Surg 1992;79:395-398
claudication- Surgical reconstruction or
physical training? Ann Surg 1989:209:346- 86.  Fraser SCA. Quality of life measurement in
355 surgical practice. Br J Surg 1993:80:163-169
78.  Higginson IJ, Carr AJ. Using quality of life 87.  Bergner DK. Measurement of health status.
measures in the clinical setting. BMJ Med Care 1985;23:696-704
2001:322:1297-1300
88. WHOQOL group (1994). Development of
79. Maunder RG, Cohen Z, McLeod RS, the WHOQOL: Rationale and current status.
Greenberg GR. Effect of intervention in Int J Ment Health 1994,23:24-56
inflammatory bowel disease on health-
related quality of life. Dis Colon Rectum
1995.38: 1147- 1161
27
General introduction, aims, and design ofthe study
89.  Hays RD, Shapiro MF. An overview of 97.  Van der Zee KI, Sanderman R. Measuring
generic health-related quality of life general health status with the RAND-36: A
measures for HIV Research. Qual Life Res manual. Groningen: Northern Centre for
1992.1:91-97 Health Care Research; 1993
90.  Carr AJ, Higginson IJ. Measuring quality of 98.  Ware JE, Sherbourne CD. The SF-36 Short
life: Are quality of life measures patient Form Health status survey 1, conceptual
centred? BMJ 2001,322: 1356-1360 framework and item selection. Med Care
1992;30:473-483
91. Chetter IC. Scott DJA. Kester RC. An
introduction to quality of life analysis: The 99. Chetter IC, Spark JI. Dolan P. et al. Quality
new outcome measure in vascular surgery. of life analysis in patients with lower limb
Eur J Vasc Endovasc Surg 1998;15:4-6 ischaemia: Suggestions for European
standardization. Eur J Vasc Endovasc Surg
92.  O'Boyle CA. The schedule for the 1997:13:597-60
evaluation of individual quality of life
(SEIQOL). Int J Ment Health 1994;23:3-23 100.TASC working group. Treatment of
intermittent claudication. J Vasc Surg
93. WHOQOL group (1995). The World 2000;31: S77-S89
Health Organization Quality of Life
assessment (WHOQOL): Position paper
from the World Health Organisation. Soc Sci
Med 1995;41:1403-1409
94. De Vries J, Van Heck GL. Nederlandse
WHOQOL-100 [Dutch WHOQOL-100].
Tilburg: Tilburg University; 1995
95. WHOQOL group. The WHOQOL
assessment. (WHOQOL: Development
and generic psychometric properties).
Soc Sci Med 1998;46:1569-1585
96.  Hays RD, Sherbourne CD, Mazel RM. The











Dept.  ofSurgery, Martini Hospital, Groningen,  The Netherlands
Dept. of Psychology and Health, Tilburg University, Tilburg, The Netherlands*






Background: Quality of life (QOL) is increasingly used as an outcome measure in patients
with intermittent claudication (IC). Different definitions and measures of QOL often prevent
a clear interpretation and comparison of study results.
Material and methods: A Medline search until June 2002. using the key words "IC",
"QOL" and "health status", was done to identify publications on the development of QOL
assessment in patients with IC, and on QOL assessment before and after treatment.
Additional publications were obtained from reference lists.
Results and conclusion: Studies on QOL and IC vary with regard to study design, inclusion
criteria.  size of patient groups, and duration of follow-up.  IC  has a broad impact on every day
life that goes beyond the physical impairments and functional disabilities that are associated
with the walking problem. Increasing IC is mainly responsible for the deterioration of the
physical aspects  o f QOL. Treatment may alleviate symptoms and improve aspects of physical
functioning and functional status. However. QOL levels after treatment hardly ever approach
those of a non-diseased population. Presently. there are no data on the implementation of




Intermittent claudication (IC) is a common expression of peripheral arterial occlusive disease
(PAOD), usually with a benign course for the legs: Although the presenting complaint may
seem innocent concomitant coronary and cerebrovascular disease are serious threats to the
claudicant' s lifez. The severity of IC is usually assessed by means of treadmill performance and
ankle brachial pressure index (ABPI)3. However, these objective parameters have a weak
correlation with the impact on daily life .5 and their measurement is often not reliable6.
Increasingly, the patients' perception of physical impairment is regarded as a more appropriate
way to assess the consequences of disease and effects of treatment7-9. This subjective. patient-
oriented outcome is generally referred to as quality of life (QOL). The interpretation of studies
on QOL is difficult because the term 'VOL" is ollen used as a container concept, labelling
concepts like functional status, health status, and quality of life as QOL
10.11
. To avoid confusing
terminology, the term QOL is used throughout the present text, unless authors explicitly used
other terms.
Unlike the traditional outcome measures in patients with lower limb ischaemia3, there are no
rules for reports dealing with subjective outcome in these patients, although suggestions have
been made . The choice and development of instruments to assess QOL mainly depend on9,12,13
the investigators' preference, which carries the risk of a gap between academic interest and
clinical applicability. However. clinical practice must be supplemented with subjective outcome
measurements for the assessment of disease severity.  for the evaluation of treatment results. and
8.13to identify patients' problems other than physical dysfunction
This review aims (i) to clarify the differences between several concepts that are labelled
QOL, (ii) to describe the measures that are used to assess these concepts in patients with IC.
(iii) to provide an overview of the published study results on QOL in patients with IC. and
(iv) to  prelude on the implementation of patient-oriented outcome measures in the treatment
of patients with IC.
METHOD
A Medline search until June 2002 was performed to identify all publications on the development
of QOL assessment in patients with IC, and on QOL assessments before and after treatment,
using the key words "IC "QOL" and "health status". The reference lists of publications were
scanned for additional papers on the topic.
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DEFINITIONS OF QUALITY OF LIFE
The term QOL is generally used for three concepts: (i) functional status, (ii) health status or
health-related QOL, and (Hi) QOL as defined by the World Health Organisation (WHO).
14.15Functional status concerns physical functioning and refers to the level of performance
e.g., the walking ability in claudicants. Functional status can be assessed objectively and
subjectively in the sense that patients indicate their ability or impairment to perform certain
activities. The assessment ofdisease impact is limited to the physical part of healthls.
Health smtus is the impact of disease on patients' physical, social, and emotional
functioningl 6.17 Health status measures allow patients to indicate objectively which
impairments follow from their disease. For instance, the impaired walking ability in
claudicants may interfere with social activities and patients' mood. The scores on health
status questionnaires are interpreted by health care professionals as good or bad against
reference scores from a healthy population.
Ouality Of Life, as defined by the WHO. is a broader concept comprising the personal
evaluation of functioning with regard to physical health, psychological state, level of
independence, social relationships, personal beliefs, and relationships to salient features in
the environment'8. In addition to objective functional assessment, QOL allows for personal
appraisal of functioning in the perspective of the individual's own expectations and goals in
life as well as his/her cultural frame of reference. This means that two patients with
comparable restrictions in physical, psychological, and social functioning, and thus a
comparable health status, do not necessarily have the same QOL. For instance, the
importance of feeling impaired to participate in social activities also depends on individual
preferences, which contributes to a person's QOL.
Other concepts that are referred to as QOL are cost-utility and health-utility measures.
Quality-adjusted life year (QALY)19 is an example of a cost-utility measure. A QALY
incorporates the value, duration, and probability of a certain health state. The probability of
different therapies to achieve this health state can be calculated, permitting economic
evaluations.
Health utility measures such as the Rosser index classify health states according to the degree
of   mobility/disability and pain20-21 Since utilities    do not permit to evaluate the physical,
psychological, and social components of health. these measures may not be regarded as QOL
instruments and consequently will not be discussed.
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QUALITY OF LIFE ASSESSMENT INSTRUMENTS
General aspects
The WHO has defined health as not being the mere absence of infirmity. but as a state of
physical, psychological, and social well-being22. To cover this definition. the questionnaires
for the assessment of health status and QOL contain at least physical. psychological, and
social domains. These domains may be subdivided into smaller components, containing
questions that assess a specific element of a domain. The existing measures can be divided into
generic. disease-specific, and symptom-specific instrumentsz3.24
Generic instruments have been designed to assess QOL across a variety of diseases and
populations, allowing comparisons between different diseases and with healthy persons.
However, these instruments may be less sensitive to subtle changes in particular aspects of life
for a specific patient group.
Disease-spec(tic instruments have been developed for use in a particular patient population or a
group of comparable diseases. These instruments consist of domains that concern relevant
aspects for patients with a certain disease. Consequently. it is assumed that they may be more
sensitive than generic instruments in detecting differences between certain degrees of the
particular disease, or may be more responsive to change over time or following treatment.
Impact of the disease on aspects of life that  are not directly related to the particular disease may
be missed.
Symptom-specific instruments allow for a more detailed analysis of a particular symptom in
certain diseases (e.g., the Walking Impairment Questionnaire for the assessment of the walking
ability in patients with IeS). Since the concepts of QOL have been designed to include at least
the three above-mentioned domains, symptom-specilic measures cannot be regarded as
measures ofQOL.
Structure of the instruments
For the completion of questionnaires, respondents are requested to consider a certain time
frame, usually two to four weeks. Response scales are either more point scales, offering 5-7
alternative responses 6, or visual analogue scales (VAS). which ask the respondent to put a
cross  on  a   1 0  cm line, ranging  from 0 (worst possible)  to   1 0 0 (best possible). The answers
can be expressed  as a profile of scores for separate domains and subscales of the instrument.
or as a total index score. A profile provides an insight into the aspects that are impaired and
thus can be improved. A total index score merely indicates whether QOL is affected, and
may be used for calculating cost-utility. The questionnaires may be self-completed,




Before application. a measure is subjected to a validation process, testing the instrument for
validity, reliability, and responsiveness27. Validity reflects how well an instrument actually
measures what it intends to measure. Reliability indicates to what extent a measure is free of
error. Responsiveness/sensitivity to change represents the ability of an instrument to
discriminate between different degrees of severity of a disease or detect meaningful changes
over time. Furthermore. an instrument should be practical and comprehensive. The questions
should not be confusing in order to assure that the content is well understood and the
questionnaire is fully completed. The instrument must comply with an elderly population and
also be suitable for patients with a low educational level.
The application of measures into other languages than the original version requires forward-
backward translation. consideration of the relevance of aspects that are of particular importance
for the new population to be studied. and full revalidation to make the instrument applicable in
another country or culture28.
Finally, study results will only be relevant if they can be interpreted and translated into clinical
consequences, e.g., to adjust treatment options to the aspects of QOL that are of particular
importance for patients with IC.
INSTRUMENTS USED IN PATIENTS WITH INTERMITTENT CLAUDICATION
Functional status
Functional status in claudicants can be measured objectively with a treadmill and ABPI
measurements or subjectively with specific questionnaires. The walking impairment
questionnaire (WIQ)25 has been developed to assess treatment effects on claudication limited
walking ability. The instrument is interviewer-administered and consists of two questions to
discriminate between claudication and non-claudication related pain. The severity of
claudication pain is rated in questions concerning the impairment experienced in terms of
defined distances, speeds, and stair climbing. Summary scores are computed and expressed as a
percentage of the maximal score. The WIQ has proven to be valid, reliable, and sensitive to
change in patients with IC29,30
31,32
The peripheral arterial disease physical activity recall questionnaire (PAD-PAR) provides a
global measure of habitual physical activity levels by estimating the total energy expenditure of
the patient under various conditions. The instrument is self-completed and asks the respondent
to estimate the number of hours spent each week within the categories sleep, work, house. and
leisure.  In  addition. the intensity  of the activity is specified  with the  use  of a  list of activities  that
are classified into categories of intensity, except for sleep. The WIQ and the PAD-PAR only





The generic measures of health status, or health-related QOL, that are most often used in
patients with IC are the Medical Outcome Study/ Short Form-36 (SF-36)3334, the Euroqo135. the
Sickness Impact Profile (SIP)3637, the Nottingham Health Profile (NHP)38, and the MeMaster
Health Index Questionnaire (MHIQ)39 (Table  1).
The SF-36 is a 36-item generic measure assessing health status in eight dimensions and health
changes over the last year. The SF-36 may be self-administered or interviewer-administered,
either by phone or face-to-face. Responses are obtained by more point scales and yes/no
answers. In addition to scores for each dimension (a prolile), the testing yields a composite
health status index score on a scale from 0 (worst) to 100 (best). The SF-36 is short and sensitive
to intervening illness. It has a good reliability and validityw, also in patients with PAOD#.and
has been used frequently in patients with IC42-53
The Euroqol measures the salient features of health as perceived by the general population. The
instrument is self-completed and measures five dimensions of health on three levels in five
questions. producing a profile score. This profile can be translated  into a global index of health
status/QOL, using a time trade-off (TIO) derived matrix (based on societal preference)54. In
addition, the Euroqol incorporates a VAS on which respondents can rate their health status/QOL
on a scale from 0 (worst) to 100 (best), producing a second global index (patient's preference).
The Euroqol is a valid and reliable instrument that has been developed for use in combination
with other measures55.5: A disadvantage of the Euroqol is its large ceiling effect, limiting the
discriminatory power for improvements56. The instrument has been used in several studies
concerning patients     with IC' 1,57-61 , and appeared to be valid and reliable, although the
41.62responsiveness in these patients was poor
The SIP is a measure of sickness-related behavioural dysfunction. There are versions for
interviewer-administration and self-administration.    The SIP consists    of 136 yes/no items,
describing  limitations  experienced  'today"  in 12 subscales of daily activities. Composite scores
for the physical and psychosocial dimension, a total score, and subscales scores are calculated
and expressed as the percentage of maximum dysfunction. The higher the percentage, the more
severe the limitation. Validation studies showed that the SIP is a valid and reliable instrument.
and permits to describe similarities of patient groups as well as to differentiate between these
groupsN. The instrument has been criticised for being less sensitive to improvement than
deterioration63  The SIP has been used in two studies on health status in patients with IC64.65
The NHP is a generic, self-administered instrument assessing health status/QOL in six domains.
In a first part  of the instrument, 38 yes/no questions that reflect problems with health, produce
weighted scores  in the six domains (a profile), ranging  from 0 (best possible score)  to 100 (worst
possible score). The second part relates to the impact of perceived health on seven areas of
everyday activities: Paid employment, Housework, Family relationships, Sex life, Social life,
Hobbies, and Holidays. These are presented as the percentage of affirmative responses.
Validation studies indicated that the NHP is valid and reliable in a wide variety of diseases664
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and especially discriminates between severe and non-severe illness38. The responsiveness/
sensitivity of the NHP has been questioned with respect to its ability to differentiate mild
symptoms from a disease free state67. This so-called "floor effect" has been confirmed in
patients with varying degrees of IC for the domain Social isolation68. Since the NHP mainly
focuses on the negative aspects of health, it has been suggested that it should be considered a
measure of distress in the respective dimensions rather than a measure of healt1166.  The NHIP has
been  used to assess the impact of disease  and to evaluate the effects of treatment in patients  with
IC'1'68-73 . The instrument appeared to be valid, reliable, and responsive to change in patients with
IC 1.
The MHIQ is a self-completed valuational instrument assessing impairments in physical, social
and emotional functioning. There are 59 statements that can be answered with yes/no responses
or with a more point scale. The instrument produces an index for all possible combinations of
the three dimensions on different levels, representing a percentage of a state of ideal well-being
(0 is poor finction, 1 is good function) Validation studies showed good reliability and validity
for the three dimensions, and responsiveness for the physical dimension39. The instrument has
been used in several diseases, including IC74-76
In several countries and languages, IC-specific health status/QOL measures have been
developed and validated, like the Artemis, which consists of the SF-36 and six complementary
subscales identified to be of particular interest for patients with IC77, the Peripheral Arterial
Occlusive Disease-86 Questionnaire (PAVK-86)78, the Claudication Scale (CLAU-S)7942, the
Vascular Quality of Life Questionnaire (VascuQOD83, and the ST-2284. Except for some reports
on treatment effects in pharmacological studies , there is only scant literature on these new
85-89
instruments and their practical application .
Quality of life
The World Health Organisation QOL assessment instrument-100 (WHOQOL-100) is the
only measure of QOL, as defined by the WHO, that has been used in patients with IC. It is a
generic, multidimensional self-report measure, that can also be used interviewer-assisted or
interviewer-based. The instrument has been developed simultaneously and cross-culturally in
15 centres around the world. It consists  of 100 items assessing 24 facets  of QOL within  six
domains and a generic evaluative facet. Each facet is represented by four questions. Responses
are expressed in 5-point scales. Scores on each facet and domain can range from 4 to 20. The
instrument produces a profile for all domains and facets. The reliability, validity'l, and
sensitivity'i  of the instrument are high, also in healthy elderly': The WHOQOL-100 has been
used in a variety ofpatient groups and in a reduced version in claudicants,2-95
Recognising the incompleteness of the traditional parameters for rating disease severity and
treatment outcome, calls for the development and use of IC-specific health status/QOL
assessment instruments have been made repetitively '97. The Transatlantic Inter-Society
Consensus Document Working Group (TASC)13 has recommended the WIQ as a useful
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instrument for the assessment of functional outcome. Based on a literature review of generic
health status/OQL measures, Beattie et al.98 preferred the SF-36 over the NHP in assessing
health status/QOL in patients with vascular disease for being widely accepted, and more
sensitive to some levels of disease. In a comparative study in patients with critical as well as
non-critical ischaemia of the lower limbs, the SF-36, the NHP, and the Euroqol appeared to be
equally reliable''l. The validity of the SF-36 and the NHP were superior to the Euroqol and the
SF-36 was the most responsive measure. Therefore, the SF-36 has been recommended as the
most appropriate health status/QOL measure in these patients and the European standard. This
recommendation is supported by the Society for Vascular Surger>P and TASC.
DISEASE IMPACT ON QUALITY OF LIFE IN PATIENTS WITH INTERMITTENT
CLAUDICATION
Baseline results obtained with the SF-36 show that patients with IC have a reduced QOL
compared with healthy persons, in all dimensions434549.53.99 The differences are most striking in
the physical aspects of the instrument. Bodily pain and a decline in Physical fimctioning mainly
contribute to the reduction in QOL in older patients with IC48. The severity of IC, as measured
by maximum walking distance (MWD), is a significant predictor of health for all domains,
except for Mental health and Role emotiona143. The ABPI, higher education, and male sex are
positive predictors for the Physical function scores, while the presence of heart, lung. and
cerebrovascular disease, knee arthritis. and chronic back pain have a negative predictive value45
A Euroqol study on the results of percutaneous transluminal angioplasty (PTA) in patients with
IC, showed that patients scored significantly worse before treatment than the general population
on all but  one of the domains5: Chetter et al. demonstrated that increasing lower-limb ischaemia
resulted in a significant deterioration in global QOL and all Euroqol domains: Although the
correlations between QOL and clinical indicators of limb ischaemia were statistically
significant. the correlation coefficient was too low to assume that improvements in clinical
indicators would translate into similar QOL benefits. Therefore, it was suggested to assess QOL
in patients with lower limb ischaemia independent from its clinical indicators.
In one of the earlier studies on QOL and IC, Arfvidsson et al. used the SIP, excluding
claudicants with contraindications for reconstructive surgery64. A significant correlation was
found between incapacitating IC and a broadly impaired QOL. Compared with a historical
group of healthy women patients with a performance above 70 Watts only differed with regard
to Work and Ambulation. It was suggested that other dysfunctions, in addition to the walking
impairment, might have an impact on QOL. In a recent study by Taft et al.. SIP baseline values
conlirmed that claudicants are limited in daily functioning, most pronounced for Ambulation




Generic assessment instruments ofhealth status and OOL.
Instrument: Scales/ subscales Response scale Scores








Euroqol Pain/ discomfort 5 more point questions profile/




SIP Physical dimension 136 yes/no questions profile
Ambulation





















Instrument: Scales/ subscales Response scale Scores
MHIQ Physical functioning 59 yes/no and index



























Activities of daily living










Health and social care
Opportunities for acquiring new information and skills
Participation in and opportunities for recreation and leisure
Physical environment
Transport
Spiritualitv, religion, personal beliefs
IC = intermittent claudication, QOL = quality of life,  VAS = visual analogue scale
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Baseline NHP scores for claudicants were significantly worse than those of healthy controls in
all domains, except Social isolation. Mobility had a significant predictive value to discriminate
between patients and controls and thus was considered the underlying cause for the
differences69. Daily activities were only partially affected, although this appeared to be
influenced by comorbidity. Klevsgard et al. used the NHP in patients with varying degrees of
lower limb ischaemia68. The claudicants included in the study scored significantly worse in all
dimensions and indicated to have more problems in all areas of daily living than healthy
controls. It was concluded that QOL impairments represent an interplay between the grade of
ischaemia and the patient's sense of coherence. Pain, Physical mobility and Emotional reactions
discriminated patients from healthy controls. The absolute walking distance did not significantly
correlate with QOL. Although in contrast with other studies , the authors state that there is no43,64
linear correlation between objective measures of ischaemia and QOL, and correlations with
feelings of restriction as expressed in Mobility may be stronger. The results of this study may
have been affected by the fact that claudicants with other diseases restricting the walking
capacity were excluded.
Barletta et al. assessed QOL in a selected group of patients with IC using the MHIQ and
compared the results with laboratory exercise performance74. All patients with coronary or
cerebrovascular disease, and other medical problems limiting exercise capacity or known to
affect QOL were excluded. In comparison with matched healthy persons, a reduction in General
health with significantly lower scores for Physical Social and Emotional filnction was found,
which is concordant with the MH[Q results of Ponte et al.75 Beside a small, but significant
relationship between the MWD and the scores on Physical mnction, QOL impairments did not
correlate with treadmill performance. In patients over 70 years, fmctioning deteriorated on all
domains with ageing. Retired patients scored significantly worse than working patients, except
for Emotional function.
In  a study using a reduced version  of the WHOQOL-100, patients  with IC evaluated their  QOL
significantly worse than healthy controls with regard to overall QOL and physical aspects like
Pain, Energy, Mobility, Activities of daily living, and Working capacit) 4. In addition patients
experienced more negative feelings and indicated to feel dependent on medication and
treatments. Increasing IC only affected Mobility. Comorbidity appeared to have an important
predictive value for the QOL in patients with IC95.
In summary, although the multitude of instruments prevent a clear view on disease impact, all
instruments show a broad disease impact on QOL in patients with IC. The correlation
between objective parameters of IC and QOL is inconsistent. The correlation may be
absent(,8. too low to be predictive5, or signilicant in relation to mobmty9#, physical
functioning , or a range of domains . This variability may be due to differences in the45,74 43.64
sensitivity of the measures to detect meaningful changes with increasing IC,  and to variations
in study design, selection criteria, and characteristics ofthe measures.
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TREATMENT EFFECTS ON QUALITY OF LIFE IN PATIENTS WITH INTERM[TTENT
CLAUDICATION
Conservative treatment
Regensteiner et al.32 examined functional status in selected claudicants distributed over three
regimens: supervised treadmill exercise, strength training, and a non-exercise control group.
Assessments were performed with the WIQ, the PAD-PAR. the Vitalog activity monitor' 00,
and the Medical Outcome Study SF-20101,102 After 12 weeks of treadmill exercise, PAD-
PAR and Vitalog scores as well as Physical functioning improved, ABPI remained
unchanged. These gains were maintained at 24 weeks, and paralleled an increased treadmill
walking time and improved WIQ scores for walking distance and claudication pain.
Supervised treadmill training appeared to be more effective than the other regimens.
Patterson   et al. tested the effectiveness    of   a 1 2 weeks supervised or home-based exercise
program, using the SF-36 as a QOL measure46 Supervised programs provided better walking
results. The scores for the physical domains of the SF-36 improved equally for both
regimens. The authors conclude that a supervised program results in optimal walking
benefits, but a structured home-based program provides similar functional improvements and
may be a satisfactory alternative for patients with lesser walking requirements. The QOL
benefits in the home exercise group are in contrast with absent44 or minimal
improvement65,103. or even a deterioration' 7 as measured with the SF-36 in patients that had
been treated conservatively for comparison with patients treated with PTA and reconstructive
surgery.  As an explanation, the authors suggest that a high degree of interaction with health
care providers in the home exercise group might be responsible for the comparable outcome
in the two groups.
In a study among older claudicants Gardner et al. compared the effects of exercise rehabilitation
with usual care control'04 Treadmill performance and calf blood flow improved significantly in
the exercise group. The authors concluded that the concurrent improvements in accelerometer
derived physical activity in the community enabled patients to become more functionally
independent. However, self-reported walking ability as measured with the WIQ and SF-36
measured QOL failed to confirm this conclusion from a patient's point of view. Using a less
intensive exercise maintenance program, the gains in ambulatory function and physical activity
sustained    for 12 months"5.    Nevertheless, WIQ scores remained unchanged, which   may    be
explained by the limited statistical power of the study to detect changes in self-reported walking
ability. Alternatively, the authors suggest that improved treadmill walking might not translate
into improved perceived walking in the community setting.
In summary, there are some indications that a supervised exercise program may produce
improvements in functional status and the physical aspects of QOL. The relatively small size




Clinical trials with a variety of drugs have shown improvements in treadmill walking. In some
of these studies, QOL effects have been assessed, but the patients' perception of clinical
improvements are inconsistent. Since pharmacological treatment for IC is not widely accepted,
these studies will not be reviewed.
Invasive treatment
Most studies on the effects of invasive therapy with respect to QOL in patients with IC were
published when PTA promised to become the first treatment Option. Using the SF-36, Currie et
al. showed a significant improvement in Physical functioning and Pain, three months after
PTA44. The improvements were less explicit in women and elderly, and were unrelated to
changes in ABPI. These results were confirmed by Pell et al. after PTA and surgical
reconstruction for IC over a six months follow-up period47
Feinglass  et al. demonstrated that after  a mean follow-up  of 19 months significant improvements
in ABPI after successful PTA or bypass surgery translated into improved SF-36 Physical
functioning and Pain, and WIQ walking distance scores'03
In a prospective randomised study, originally designed for the comparison of primary or
selective stent placement in iliac arteries, an immediate and significant improvement was
reported in all RAND-36 (which is practically equivalent to the SF-36) domains, especially the
physical domains, and the TTO-derived Euroqol index630 However, the scores after
revascularisation did not reach the level of the general population. Except for General health
perception, there was no significant decrease in QOL scores to baseline values during two years
follow-up, although there was a trend. The correlation between QOL scores and haemodynamic
data was poor.
In another prospective study, QOL was assessed with the SF-36 and the global Euroqol indices
before, and one, three, and six months after PTA51. An immediate improvement in the SF-36
domains Physical functioning, Role physical, Pain, Vitality, Social fiinctioning, and Mental
health was found, with a trend to decline in most of the domains during the short follow-up.  The
global Euroqol indices showed the same pattern. In 20 to 30% of the patients there was no
change, or even a deterioration in claudication category or ABPI. During follow-up, a majority
of patients was unable to complete treadmill testing because of comorbidity, contralateral or
residual ipsilateral IC. Nevertheless, the authors conclude that PTA improves QOL, justifying its
use in the treatment of patients with IC. The same authors reported similar QOL effects after
successful PTA in claudicants. stratified for different types of arterial lesions49. Subgroup
analysis demonstrated that only patients with a single iliac lesion enjoyed QOL levels similar to
those of a healthy, age-matched population, one year after successful PTA. The deterioration of
the SF-36 domain General health perception in most of the patient groups was in contrast with
observed improvements in other domains as well as the Euroqol indices. The residual QOL
limitations, despite benefits with regard to walking distances and ABPI, were considered to be
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caused   by age, comorbidity,  residual, and recurrent IC. Admitting  that only about   10%  of the
claudicants have a lesion amenable to PTA and that only a subgroup may enjoy QOL benefits,
the authors' claim to have provided "evidence on which to base the medicine" for the treatment
ofpatients with IC seems overenthusiastic.
Six weeks after successful PTA for IC, Cook et al. demonstrated significant better walking
distances as measured with the WIQ, and concomitant improvements in all domains of the
Euroqol, except for Self care which could not be improved because of high pre-treatment
scores58. The walking benefits and QOL effects sustained for one year at the post-PTA level.
but the patients' general perception of QOL had declined59. It was assumed that increasing
comorbidity, revelation of other impairments because of improved walking, and higher
expectations associated with increased activity might be an explanation for these divergent
findings. The authors suggested that the Euroqol is adequate in assessing QOL in the short
term, but results should be considered with care in the long run.
Tall et al. evaluated QOL in patients with IC using a battery of measures, incorporating the
SIP65. After 12 months, invasively treated patients showed significant improvements in walking
ability and haemodynamic measures, whereas there were no objective improvements in patients
that had been randomised to exercise training or observationi 06. Compared with baseline,
invasively treated patients improved on the IC-specific SIP scale, Ambulation, Sleep and rest,
and Recreation and pastimes, whilst only the latter improved in the exercise group and no QOL
im rovements were recorded in the control group. Walking ability and clinical indicators
remained stable, and there was no significant deterioration of QOL in untreated patients,
illustrating the benign course  of IC. In general effect sizes were small to moderate, and levels of
physical dysfunction after treatment remained considerably higher than those of a healthy
reference group. This finding is in concordance  with the results of the Dutch Iliac Stent Trial6,
but contrasts with the findings by Chetter et al.49 for unilateral claudicants with an isolated
iliac lesion. The authors suggest that IC is only one expression of PAOD and comorbidity
might contribute to the disappointing results. It was concluded that the level of evidence
supporting invasive therapy is modest.
In an important and frequently quoted randomised controlled trial of PTA versus conventional
medical treatment  for  IC,  QOL was assessed  with the NHPm.  Only  10%  of the claudicants could
be randomised for either treatment. After six months, patients in the PTA group had longer
walking distances, a higher ABPI, less occluded or stenosed arterial segments, and lower NHP
pain scores. It was concluded that PTA produced better short-term improvements in walking and
QOL than medical treatment alone, and was associated with less disease progression. At two
years follow-up, despite more patent and less severely stenosed arterial segments in the PTA
group, there were no statistically significant differences in walking distance, ABPI, or QOL
between the two treatment groups71. The authors' conclusion that less extensive disease does not




In a study on QOL effects after successful intervention for lower limb ischaemia, claudicants
scored significantly better  in all NHP dimensions  and all  but  one  of the areas of daily living,  six
months after  PTA or surgery compared with baseline72.  For  some  of the dimensions, scores even
equalled those of healthy controls.  At 12 months, these results sustained  for all dimensions  that
were not normal at baseline73. A high ABPI and a high sense of coherence were significantly
associated with better QOL. Surprisingly, some improvements were also observed after
haemodynamically unsuccessful revascularisation. The authors suggest that in addition to a
possible placebo effect of PTA, this finding may be explained by the patients' need for greater
support and complementary care in those areas that are responsible for their lower QOL.
In summary, invasive therapy may improve the walking capacity, with beneficial effects for
functional status and those aspects  o f QOL  that  are of particular importance for patients  with
IC, for a limited period after the intervention. However, QOL levels after successful
treatment hardly ever approach those of healthy contemporaries.  At the moment, there are no
convincing data to prove long-term QOL benefits of invasive therapy for IC. Better walking46
or improvements in clinical indicators49 that do not translate into QOL benefits, and QOL
improvements after haemodynamically unsuccessful procedures72 seem to detract from the
importance of the walking problem for QOL in these patients.
DISCUSSION
IC is one of the stages of PAOD caused by atherosclerosis, a systemic, progressive, and
incurable disease. Therefore, symptomatic relief of complaints is the goal of treatment. If a
patient cannot be offered more than pal]iation and has to accept certain impairments, the impact
of disease and comorbidity on QOL are pivotal for treatment strategies. Traditionally, treatment
effects have been evaluated in terms of changes in ABPI, treadmill performance, and patency of
vessels. Since relief of complaints is most important in IC, treatment modalities and their
outcomes should primarily be evaluated in view of the patient's perception of health and QOL
instead of being judged by technical possibilities and clinical success. In other words, treatment
should focus  on the patient that presents with IC  as an expression of atherosclerosis rather than
on the walking distance or the ABPI. The traditional parameters for rating disease severity and
assessing treatment effects in IC have not been developed for these purposes.
There are many reports addressing the relevance of QOL  for the evaluation of patients with
IC. The most important obstruction for understanding and comparing study results is the
liberal use of the term "QOL" for different concepts. Most of these concepts and their
measures have been designed to assess the impact of disease on physical performance or
psychological and social functioning. The implicit assumption that impairments caused by a
disease can be subtracted from optimal functioning to indicate the patients' QOL has
important limitations. A doctor's interpretation of a patient's functional impairments as good
or bad QOL is not synonymous with a patient's personal evaluation of these
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impairments43,53,107. Such "objective" interpretation of functional impairments does not take
account of the individual's ability to cope with these impairments and to adjust his or her
goals in life. The dynamic balance between a person's expectations and experiences. as a way
to evaluate QOL'08, may not be valued by anyone, but the individual patient 109
The differences between instruments, size of the studies (between 29 and 555 patients),
duration of follow-up (two weeks to two years),  and the variability of the intervals between
assessments make it difficult to interpret and generalise the study results. Treatment effects
on QOL are influenced by experience, expectations, hopes, and fears concerning disease
progression and the method of treatment. Besides, these variables fuctuate over time and
within a disease process. For instance, during a disease process. the fear for future
deterioration of symptoms may decline while a certain degree of impairment becomes
acceptable. This so-called response-shift makes it difficult to compare the results of studies
using different assessment moments during follow-up' 10.
Only few reports on QOL and IC acknowledge atherosclerosis as a progressive disease with
more organs at risk than the lower limbs. The IC-related impairments may be treated well
with conservative means, or may even improve spontaneously , but cardiac and
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cerebrovascular events threaten the claudicant's life and will have a continzied impact on
QOL with ageing 1
16 Moreover, most studies  do  not take account  of the  role of comorbidity
for the QOL in patients with IC. In some studies, patients with comorbidity or other reasons
for impaired walking are even excluded64.68.74. However, there are convincing data
documenting the high incidence of comorbidity in patients with IC and its repercussion on
Q0L245.95. The exclusion of other factors than the walking impairment that may have a
potential impact  on  QOL in patients with IC neglects the complexity of the underlying cause
of IC and prevents offering treatment that may be beneficial for the patient. Disregarding the
majority of patients, it seems unlikely that the results of such studies contribute to an
adjustment of treatment that meets the real demands.
Compared with the traditional endpoints in vascular surgery, QOL measures may be regarded
soft. impractical to use. hard to value, and difficult to interpret. So, why should it be used?
Presently, several instruments for the assessment of functional status, health status, and QOL
have been validated in patients with IC. The reviewed studies have provided a rough picture
of the aspects of life that are responsible for the impaired health status and QOL in patients
with IC  and have revealed  some  of the eli-:ts that may be expected from different treatment
modalities. Despite the accumulated data, clinical practice is still based on objective clinical
parameters. Although the gap between the traditional parameters and subjective, patient-
centred outcome is increasingly recognised, the absence of reports on the clinical
im lementation of patient-centred outcome suggests a reserved attitude towards this
development in the clinical community. If it is the aim to provide optimal care for the patient
with IC as the presenting expression of atherosclerosis, this knowledge should stimulate
further research into subjective outcome in these patients.
46
Chapter 2
It seems unlikely that one instrument will capture all relevant information that is needed to
value the impact of IC on daily life and to select optimal treatment for individual patients.
Objective clinical data. an indication of the functional impairments with regard to walking,
appraisal of the influence of IC and associated comorbidity on physical, psychological, and
social functioning, and the evaluation of functioning by the patients themselves are
complementary and may assist in an optimal work-up and choice of treatment. A set of the
most relevant components of the respective measures of health status and QOL may be
administered at the vascular outpatient department or by (e-) mail at home. Incorporation of
subjective patient inbmiation into clinical practice should direct treatment options in a way
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MEASURING QUALITY OF LIFE AND
HEALTH STATUS IN PATIENTS WITH
PERIPHERAL ARTERIAL OCCLUSIVE






The impact of vascular disease on quality of life (QOL) is recommended as an independent
outcome measure and a guideline for treatment policy': However, most studies that claim to
assess QOL actually concern measurements of health status. QOL and health status are related but
distinct concepts of which the similarities and differences will be discussed in detail in chapter 4.
Health status, also known as health-related QOL, assesses the influence of disease on physical
sociaL and emotional functioning; it measures factual restrictions in functioning ': QOL, as defined
by the World Health Organisation (WHOMS. is a broader concept comprising the personal
evaluation of functioning with regard to physical health, psychological state. level of independence,
social relationships, personal belieth, and relationships to salient features in the environment.
Health status has been measured in a number of studies concerning intermittent claudication (IC)
6-11
and chronic critical  ischaemia  of the lower limbs , while  QOL, as defined  by the  WHO,  has  not
been studied in vascular disease before. With the purpose to conduct a study on QOL, the WHO
QOL assessment instrument-100 (WHOQOL-100)12 was chosen, because it corresponds best with
the subjective character of the WHO definition of QOL. Until now, the WHOQOL-100 has not
been used in patients with vascular disease. Therefore, it was decided to perform a pilot study on
the  appropriateness  of the instrument  for the assessment  of QOL in patients with peripheral arterial
occlusive disease (PAOD). To compare the results with a widely accepted and frequently used
health status measure in patients with PAOD, the RAND-36 was also administered. Because13,14
the  WHOQOL-100 was expected  to  be  too  laborious for an elderly group of patients, the second
goal of the study was to shorten the questionnaire to reduce patient burden. Finally, the actual
process ofcompleting the questionnaires was studied.
MATERIAL AND METHODS
Patients
Twenty-two patients presenting with various degrees of PAOD,  who were referred to the vascular
outpatient clinic of the Department of Surgery at the St. Elisabeth Hospital in Tilburg. The
Netherlands were asked to participate in this pilot study. The sample consisted of 14  men and  8
women with a mean age of 71 years (range: 49-88). The degree of ischaemia was recorded
according to a slightly modified version of the recommended standards for reports dealing
with lower extremity ischaemia as defined by the Society for Vascular Surgery and the North
American Chapter of the International Society for Cardiovascular Surgery (SVS/[SCS)15 (Table 1).
The medico-ethical commission of the St. Elisabeth Hospital approved the study. All patients




Degree of ischaemia according to the SVS/ISCVS15 in 22 patients with peripheral arterial occlusive disease of
the lower limbs
Mild claudication                           1
Moderate claudication                    7
Severe claudication                           5
Rest pain                                       1
Tissue loss                                    8
Mild claudication: Completes modified treadmill exercise*; ankle pressure after exercise  >  50  mm  Hg,  but  at
least 20 mm Hg lower than resting value. Moderate claudication: Between mild and severe. Severe
claudication: Cannot complete modified treadmill exercise and ankle pressure after exercise < 50 mm Hg.
Ischaemic rest pain: resting ankle pressure <40 mm Hg, flat or barely pulsatile ankle or metatarsal pulse
volume recording (PVR). Toe pressure <30 mm Hg. Tissue loss: resting ankle pressure <30 mm Hg, ankle or
metatarsal PVR flat or barely pulsatile; toe pressure <40 mm Hg. * 3,5 km/h on a 5% incline with a maximum
of 1000 m.
Instruments
The WHOQOL-100 is a generic, multidimensional self-report QOL measure that is easy to score.
1617It has good psychometric properties ' .The instrument has been developed simultaneously and
cross-culturally  in 15 centres around the world5. It consists  of 100 items assessing 24 meets  of
QOL within six domains (Physical health, Psychological health, Level of independence, Social
relationships, Environment, Spirituality/religion/personal beliefs) and a generic evaluative facet
(Overall QOL and general health)18. Each facet is represented by four items. The response scales
are 5-point Likert scalesig Scores on each ket and domain can range from 4 to 20.
The RAND-36, which is practically identical to the Medical Outcome Study/Short Form-36 (SF-
36)20, was chosen as a health status measure because of its proven applicability in PAOD.  The use
of this instrument meets the recommended standardisation of reporting health status in vascular
disease . The RAND-36 is a 36-item generic health status measure. It assesses health in eight
21-23
domains: Physical functioning, Social functioning, Limitations in usual role activities due to physical
problems (Role physical), Limitations in usual role activities due to emotional problems (Role
emotional), Mental health Vitality, Bodily pain, and General health perception. In addition, Health
changes over the last year are assessed. Beside scores for each subscale the testing yields a
composite health status score on a scale from 0 to 100. The RAND-36 is short and sensitive to
intervening illness, for instance among the relatively healthy elderly. It has a good reliability and
validity24
Procedure
Once the diagnosis PAOD was made, based on history, physical examination, ankle blood pressure
and, in case of IC, treadmill tests, the patient was asked to participate in our QOL/health status
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research project. All patients completed the WHOQOL-100 and RAND-36. The participants were
observed by a research assistant from the University Department ofPsychology and Health in order
to detect problems and external factors that could influence completion of the questionnaires in a
practical and/or substantial way. The assistant was allowed to explain questions in a standardised
way to the participants when necessary.
Statistics
The WHOQOL-100 and RAND-36 scores are presented in terms of means and standard
deviations. One sample T-tests  were  used for comparing patients with values of a reference group.
Probability values of less than 0.05 were considered to be statistically significant. Two measures of
response distribution were used. Kurtosis, which describes the peakedness of the distribution
(<0.00) and skewness, which means that the length ofone of the tails ofthe distribution, relative to
the central section. is disproportionate to the other (between -0.50 and 0.50)2: Internal
consistency, a measure for the reliability of the instrument, was calculated using Cronbach' s alpha
26coefficients.
RESULTS
QOL in PAOD patients appeared mainly affected in the domains Physical health and Level of
independence (Table 2).
Cronbach's alphas ranged from 0.63 for the social domain to 0.88 for the spiritual domain. At
the facet level, Cronbach's alphas ranged between 0.44 for Health and social care and 0.94 for
Working capacity (Table 3).
The response distribution of the WHOQOL-100 facets Energy and fatigue, Thinking, learning,
memory and concentration, Bodily image and appearance, Mobility, Activities ofdaily living, Social
support, Physical safety and security, Financial resources. Opportunities for acquiring new
inforrnation and skills. Physical environment. and Transport, as well as the Spiritual domain were
too small and/or skewed (Table 4, Fig. 1)
In the completion of the WHOQOL-100 some specific problems were encountered. Questions  on
work were regarded not applicable by many elderly patients, although the instruction that goes with
these questions stated  that the word "work" meant  "work you  feel take  up a major part  of your
time and energy". In addition, the questions about physical safety appeared to be too vague. A
question belonging to the facet Physical environment, "How healthy is your physical environment?"
(Facet  22.1. see Appendix  I).  was not clear  to the patients. It seemed equivocal whether  the
question referred to the health condition ofpersons in the patient's environment or to the quality of
the environment itself (e.g. pollution, noise). Finally. questions on social services (Facet   19,  see
Appendix I) were interpreted as getting welfare, in the sense of government support. and were thus




WHOQOL-100 scores of 22 patients with peripheral  arterial occlusive disease and of a reference group of elderly
persons*
Elderly persons Patients Significance
m sd m         sd
-Overall QOL and general health 15.6 2.6 13.7 2.9 P < .002
Physical health 14.5 2.6 12.4 3.0 P <.001
- Pain and discomfort 10.3 3.2 13.2 3.3 P <.001
- Energy and fatigue 14.5 3.0 11.4 3.3 P < .001
- Sleep and rest 15.2 37 14.9 4.6 ns
Psychological health 14.9 1.8 14.3 2.4 ns
- Positive feelings 14.0 2.2 12.9 2.7 P < .038
- Thinking, learning, memory, concentration 14.6 2.2 14.2 3.3 ns
- Self-esteem 14.5 2.1 13.7 2.8 ns
- Body image and appearance 17.0 2.8 17.0 3.3 ns
- Negative feelings 9.4 3.0 10.3 3.3 ns
Level of independence 15.4 2.8 10.9 2.9 P < .001
- Mobility 15.3 3.2 10.5 2.7 P < .001
-  Activities of daily living 15.8    3.1 11.9 3.4 P < .001
- Dependence on medication and treatments 8.9 3.3 13.8 3.3 P < .001
- Working capacity 15.5 3.3 11.1 4.3 P < .001
Social relationships 15.3 2.3 14.7 2.6 ns
- Personal relationships 16.1 2.6 15.5 2.9 ns
- Social support 15.8 3.1 15.9 3.4 ns
- Sexual activity 14.0 3.8 12.8 3.9 ns
Environment 15.7 1.7 15.2 1.9 ns
- Physical safety and security 15.5 2.4 16.0 2.2 ns
- Home environment 15.7 2.5 15.0 3.00 ns
- Financial resources 16.4        3.1 17.6 2.3 P < .032
- Health and social care 15.7 2.4 14.9 1.7 ns
- Opportunities for acquiring 15.0 2.5 13.0 2.4 P < .001
new information and skills
- Participation in and opportunities 15.1 2.9 14.0 3.5 ns
for recreation/leisure
- Physical environment 15.1 2.4 14.7 2.5 ns
- Transport 16.9 3.2 16.2 3.4 ns
Spirituality, religion, personal beliefs 13.7 3.5 11.2 3.5 P < .002
Note: m = mean, sci = standard deviation, ns = not significant
The scores on the facets Pain and discomfort, Negative feelings and Dependence on medication and treatments




Internal consistency ofthe WHOQOL-100 in 22 patients with peripheral arterial occlusive disease
Cronbach's alpha
-Overall QOL and general health                                              .82
Physical health .70
- Pain and discomfort .75
- Energy and fatigue .80
- Sleep and rest .87
Psychological health 83
- Positive feelings                                                                          .81
- Thinking, learning, memory, concentration                                  .81
- Self-esteem .73
- Body image and appearance .88
- Negative feelings .75
Level  of independence .86
- Mobility .72
- Activities ofdaily living .77
- Dependence on medication and treatments .73
- Working capacity .94
Social relationships .63
- Personal relationships .52
- Social support .88
- Sexual activity .80
Environment .84
- Physical safety and security .58
- Home environment .77
- Financial resources .85
- Health and social care .44
- Opportunities for acquiring new information and skills                   .65
- Participation in and opportunities for recreation/leisure                 .81
- Physical environment .46
- Transport .70




Response distribution of the WHOQOL-100 facets and domains in 22 patients with peripheral arterial occlusive
disease
Skewness sd Kurtosis                sd
-Overall QOL and general health -.13 .49 -.46 .95
Physical health .22 A9 -.36 .95
- Pain and discomfort -.17 .49 -.38 .95
- Energy and fatigue .53 .49 -.44 .95
- Sleep and rest -.29 .49 -1.62                       .95
Psychological health -.01 .49 -.35 .95
- Positive feelings -.06 49 ..27                       .95
- Thinking, learning, memory, concentration -.53 .49 ..58                       .95
- Self-esteem -.06 .49 ..17 .95
- Body image and appearance -1.99 .49 5.01 .95
- Negative feelings -.34 .49 -.61 .95
1£vel  of independence -.21 .49 -.69 .95
- Mobility -.46 .50                           .61                        .97
- Activities ofdaily living .34 .49 .04 .95
- Dependence on medication and treatments -.09 A9 -.36 .95
- Working capacity .05 .49 -.72 .95
Social relationships .12 .50 -.71 .97
- Personal relationships -.27 .50 ..81 97
- Social support -1.14 .50 2.04 .97
- Sexual activity
-.04 .97
15 .52 -.87 1.01
Environment -.16 .50
- Physical safety and security -.40 .49 .56 .95
- Home environment -.03 .49 -.97 .95
- Financial resources -1.77 .50 2.82 .97
- Health and social care -14 .50 -.70 .97
- Opportunities for acquiring                                    .38                        .50                              .53                          .97
new information and skills
- Participation in and opportunities .06 .50 -1.03 .97
for recreation/leisure
- Physical environment ..16 .50 .48 .97
- Transport -.51 .50 -.72 97
Spirituality, religions, personal beliKfs -.64 .49 .14             .95
Criteria: Skewness between -0.50 and 0.50, kurtosis <0.00
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Concerning health status, patients' scores were significantly worse for all RAND-36 domains
(Table 5).
Table 5
RAND-36 scores in 22 patients with peripheral arterial occlusive disease and a reference group of elderly
persons*
Elderly persons Patients Significance
m sd m           sd
Physical functioning 66.7 (26.0) 40.6 (25.1)    P <.001
Social functioning 83.2 (23.7) 55.7 (34.2)      P =.001
Role physical 69.1 (42.5) 27.6 (38.1)    P <.001
Role emotional 82.9 (33.8) 58.7 (45.8)     P = .025
Mental health 75.9 (17.3) 62.5 (23.2)    P = .014
Vitality
(28.0) 44.0 00.4)    P <.001
64.2 (22.0) 47.5 (21.9)    P = .002
Bodily pain 74.8
General health perception 60.1 (23.9) 45.9 (24.7)    P = .013
Note: m = mean, sd = standard deviation. * Dutch RAND-36 norm scores for the age group 65-75 years,
N = 118
Cronbach' s alphas ranged from 0.67 for Vitality to 0.92 for Bodily pain (Table 6). The RAND-36
domains Role physical and Vitality did not meet the distribution criteria (Table 7, Fig.1). The
following observations were made with respect to the completion ofthe RAND-36. One question
ofthe domain Physical functioning (34 see Appendix ID asks the patient to assess his/her personal
capacity to perform a number of vigorous activities such as running and sports. Patients responded
that they could not answer such questions because they avoided strenuous activities due to
impaired mobility and pain. In two other questions (3d and 3e, see Appendix II) the Dutch word
"trap", meaning step as well as staircase is used.
Table 6




Role physical                                                           .85
Role emotional .90
Mental health                                             .83
Vitality .67
Bodily pain .92




Response distribution ofthe RAND-36 domains in 22 patients with PAOD
Skewness sd Kurtosis             sd
Physical functioning -.080 .536 -1.269 1.038
Social functioning -.221 .491 -1.312 .953
Role physical 1.172 .524 ..131 1.014
Role emotional -.419 .501 -1.783 .972
Mental health -.236 .491 -.905 .953
Vitality .729 .491 .766 .953
Bodily pain .027 .491 -.871 .953
General health perception .299 .491 -1.003 .953
Criteria: Skewness between -0.50 and 0.50. kurtosis <0.00
Patients seemed to be confused as to what they were responding to: their ability to get up one step
or  climb a whole flight  of stairs. The purport  of two other questions  of the domains Role physical
(41)) and Role emotional (519 (did you, because of physical health or emotional problems
accomplished less than you would like?) seemed unclear and it was commented that these
questions were too vague. Finally. statements concerning General health perception. i.e. "I seem to
get sick a little easier than other people" (lla) and "I am as healthy as anybody I know" (llb) were
considered difficult to answer because patients did not know whether they should take people of
their own age as a point ofreference or not.
From observation it appeared that patients, when they were accompanied by their partner or a
relative, had the tendency to complete the questionnaires in collaboration with that person.
Especially male patients tended to let their spouse complete the questionnaires for them Middle-
aged patients needed some 20 minutes for completion of both the questionnaires. whereas elderly
patients needed 40 minutes or more. Reasons for this apparent difference were: visual problems.
patients had forgotten their reading glasses. elderly persons needed more time to select their
answers. elderly persons had more difficulty with understanding the purpose of some questions.
The necessity to read questions and answers to a patient because of visual problems, raised a
problem in patients hard of hearing. Furthermore, it appeared that, although demented patients
were excluded from the study, an impaired short-term memory in some elderly patients made them
forget the question concerning the answers they were reading. Ifthe research assistant had to read
questions, elderly patients frequently considered topics like relationships and sex as embarrassing




Response distribution histograms of WHOQOL-100 facets and domains and RAND-36 domains that did not
meet the criteria in 22 patients with PAOD
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Note: Facet 2 = Pain and discomfort, Facet 5 = Thinking, learning, memory and concentration, Facet 7 =
Bodily image, Facet 9= Mobility, Facet  10 = Activities of daily living, Facet  14 = Social support, Facet  1 6=
Physical safety and security, Facet   1 8 = Financial resources, facet  20 = Opportunities for acquiring  new
information and skills, Facet 22 = Physical environment, Facet 23 = Transport, Domain VI = Spirituality,
religion, personal beliefs
DISCUSSION
The internal consistency of the WHOQOL-100 appeared to be acceptable to good, with
Cronbach's alpha's being > 0.70 for most of the facets and domains. While the WHOQOL-100
measures QOL in a broad way, only the relevant aspects for a particular patient group may
contribute to a better understanding ofa patient's perception ofdisease. In order to retain the most
relevant aspects for PAOD patients, the WHOQOL-100 was reduced by means of the criteria for
kurtosis and skewness, the histograms, and a comparison of scores with those of a reference
group of elderly persons from the validation study of the Dutch version ofthe instrument27. As
a result, we suggest not to use the fheets Thinking, learning, memory, and concentration, Bodily
image and appearance (both from the domain Psychological health), Social support (from the
domain Social relationships), Physical safety and security, Financial resources, Availability ofhealth
and social care, and Physical environment (all from the domain Environment) and the spiritual
domain in future studies on PAOD patients.
Although the facets Energy and fatigue, Mobility, Activities of daily living, and Opportunity for
acquiring new information/skills neither met the response distribution criteria, they may be retained
because the scores on these facets were significantly worse in PAOD patients than in the reference
group. In other words, patients feel impaired on these facets and thus may improve after treatment.
The response distribution  of the facet Transport only minimally deviated with respect to kurtosis.
The facet was retained. also because of its expected value for persons with physical impairments.
Despite acceptable skewness and kurtosis, the facet Health and social care should be removed from
the instrument in future PAOD studies, because of a low internal consistency. By eliminating the
facets  that  do not provide additional information, the instrument  can be reduced  from  100  to  68
questions in PAOD studies, which is in accordance with the wish to shorten the questionnaire in
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view ofthe observed concentration problems in elderly patients.
The value ofthe RAND-36 as a health status measure in patients with PAOD has been highlighted
in previous studies, and has resulted in its recommended use for reporting health status in these
patients. Therefore, it was decided not to adapt this measure. Apart from the fact that some
questions were considered unclear, which may be solved by the presence ofa research assistant, the
Dutch translation ofthe RAND-36 appears useful
Questionnaires with large letters and the availability of reading glasses may overcome the
observed reading problems hindering the completion of the questionnaires. The tendency to
complete the questionnaires together with accompanying partners or relatives, or even to
leave completion entirely to  them is regarded undesirable, because the perception of patients'
28health by others may strongly differ from the patients' own view  .
To be sure that the completed questionnaires adequately reflect subjective QOL and patient-
perceived health status, it seems essential that the questionnaires are completed by the patient
alone. Ifquestions are not well understood or cannot be remembered long enough to select an
appropriate answer, a research assistant available for explanation and practical help may bring
relief. Ifquestions have to be read to the patient, a room giving privacy and a neutral attitude
of the assistant are important. These practical aspects have to be taken into account, because
they affect the measuring of QOL and health status and may introduce a bias in case they are
ignored.
Assessing  QOL in patients with chronic critical  as  well as non-critical ischaemia  of the lower
limbs may be regarded undesirable, because the patient groups may differ importantly with
respect  to age, life expectancy, prognosis, and degree of the handicap. Although this can be
regarded as a weakness ofthe study, the findings may be representative for both groups, since
the response distribution of the WHOQOL-100 and RAND-36 was quite similar in a
homogeneous group of 18 patients with IC. However, the first aim of the study was to evaluate
the  appropriateness of the WHOQOL-100  for the assessment of QOL in patients with PAOD
by means of parameters of internal consistency and response distribution. In order to obtain a
range of answers, a broad distribution of ischaemia was required, which gave reason to
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Objective: Quality of life (QOL) is a major outcome in patients with intermittent
claudication (IC). Reports on QOL are difficult to interpret and to compare, because the term
is often used in studies on health status. This study aims to describe similarities and
differences between health status and QOL. as defined by the World Health Organisation
(WHO). in patients with IC.
Design: A prospective study in the vascular outpatient clinic ofa teaching hospital.
Material and methods: Health status and QOL were assessed in 200 consecutive patients
with IC, using the RAND-36 and the WHO QOL assessment instrument. Results were
compared with those of sex- and age matched healthy controls. Data were analysed with
Mann-Whitney-U tests. A probability value of less than 0.01 was considered to be
statistically significant. Pearson correlations were calculated between health status and QOL
results. The upper and lower  10% of QOI. scores were compared  with the quartiles  of the
health status scores.
Results: Patients' health status was significantly impaired   in all domains.   QOL   was
significantly worse with respect to aspects of Physical health, Level of independence. and
Overall QOL and general health. Subjective evaluation of functioning disclosed patient-
reported problems that had not been identified in health status. Conversely, patients did not
regard all objective functional impairments as a problem. Pearson correlations ranged
between   0.20   and 0.74. There were patients with excellent   and  very  poor QOL scores   in
nearly all the response quartiles ofthe corresponding health status domains.
Conclusions: Health status reflects health-related functional restrictions as a result of
disease. QOL also incorporates the subjective appraisal of these restrictions, non-health
related aspects. and positive evaluations. Assessment of both objective functioning and




Increasingly, health care providers recognise the importance of the patient's perception of
disease and the need for a patient-oriented evaluation of treatment modalities, especially in
the chronically illl. The patient's perception is generally referred to as quality of life (QOL).
However, there is confusion about the terminology concerning QOL. The term is used in a
comprehensive way for quantitative objective functional assessment of QOL dimensions, like
functional status and health status, and for concepts that also incorporate qualitative
subjective personal appraisal of those dimensions2-5.   The   lack   of consensus about   the
definition of QOL and the instruments that claim to measure them has resulted in a plethora
of measures purporting to address  QOL2. The appropriateness and validity of these measures
are not always well established. Consequently.  the  use of these measures for the assessment
of unclear concepts that ultimately might affect decisions made about ill people has been
questioned6.  Much of the semantic confusion in reports on QOL is caused by the erroneous
use of only health status measures in studies that claim to assess QOL2.7.8. After all, for the
assessment of the personal perception and evaluation of functioning, which are essential for
QOL as defined by the World Health Organisation (WHO)9, measures should allow for at
least some form of subjective appraisal.
The aim of this study is to describe similarities and differences between health status and
QOL, and to illustrate the additional value of subjective appraisal to objective assessment in
patients with intermittent claudication (IC).
IC is a non-lethal mild expression of chronic progressive atherosclerosis. Despite its benign
course for the legs, IC has a major impact on daily lifelo and survival is severely threatened
by concomitant cardiac and cerebrovascular disease'  . Because treatment options are limited
to relieve complaints and to  slow down disease progression, QOL assessment  is of particular
interest for patients with IC. Traditionally, disease impact and treatment results for IC are
expressed in terms of walking distance, ankle brachial pressure indices (ABPI), and patency of
12revascularisation procedures . With the purpose to meet the patients' perception of disease
impact and treatment effects. the incorporation of health status (or health-related QOL)





Between January   1999  and  June 2000 health status  and  QOL were assessed  in all patients
presenting with IC at the vascular outpatient clinic of the Department of Surgery at the St.
Elisabeth Hospital in Tilburg, The Netherlands. The diagnosis was suspected on history and
physical examination in 215 patients and could be confirmed by treadmill performance
(median pain free and maximum walking distance 70 m. and 240 m.) and ABPI (mean 0.62,
range 0.33-0.95) in 207 patients. Seven patients refused or were not capable to participate.
Two hundred patients were included in the study, 135 men and 65 women with a mean age of
63 years (range 42-83). Risk factors and comorbidity were recorded according to the
recommended standards for reports dealing with lower extremity ischemiali (Table 1). All
patients were matched for age and sex with healthy controls.
Table 1
Distribution ofrisk factors and comorbidity, specified into "none'; "mild", "moderate" and "severe", according
to the SVS/ISCVS 12 in 200 patients with intermittent claudication studied for health status and quality of life
none mild moderate severe
Diabetes Mellitus 168 (84%) 11 (6%) 15 (8%) 6 (3%)
Tobacco use 25 (13%) 43 (22%) 73 (37%) 59 (30%)
Hypertension 106 (53%) 50 (25%) 34 (17%) 10 (5%)
Hyperlipidaemia 94 (47%) 38 (19%) 27 (14%) 41   (20%)
Cardiac status 136 (68%) 37 (19%) 25 (13%) 2 (1%)
Carotid status 172 (86%) 7 (4%) 15 (8%) 6 (3%)
Renal status 192 (96%) 3 (2%) 3 (2%) 2 (1%)
Pulmonary status 179 (90%) 12 (6%) 8 (4%) 1 (1%)
SVS/ISCVS grading system for cardiovascular risk factors and comorbidity: see Appendix lII
Definitions
The WHO has defined health as a state of complete physical„ mental„ and social well-being  and
not merely the absence of disease or infirmity'4. Accordingly, health status reflects the
influence of disease on physical, emotional, and social functioning. It measures objective
functional limitations as a result of diseasel: For instance, the walking problem in
claudicants not only affects mobility, but also may interfere with social activities and
patients' mood. In contrast with health status, subjective appraisal of functioning is also
incorporated in the measurement of QOL which has been defined by the WHO as "an
individual's perception of his/her position in life in the context  of the culture and value systems
in which he/she lives and in relation to his/her goals, expectations, standards, and concerns. It is
a broad ranging concept incorporating in a complex way the individual's physical health,
psychological state, level of independence, social relationships, personal beliefs, and
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relationships to salient features in the environment'". For example, the level to which a
person's QOL is affected by the ability to participate in certain activities also depends on a
person's individual preferences.
Instruments
The RAND-36 item health survey (RAND-36)16,17 which is practically identical to the Medical
Outcome Study/Short Form-36 (SF-36)18, was chosen as health status measure because of its
proven applicability in peripheral arielial occlusive disease (PAOD) and to comply with the
recommended standardisation of reporting health status/health-related QOL in vascular
disease!3,19,20. The RAND-36 is a 36-item generic multidimensional health status measure. It
assesses health in eight dimensions: Physical f.lnctioning, Social functioning, Limitations in
usual role activities due to physical problems (Role physical), Limitations in usual role activities
due to emotional problems (Role emotional), Mental health Vitality, Bodily pain, and General
health perception. In addition, Health changes over the last year may be assessed. Beside scores
for each subscale  on a scale  from  0  to   100, the testing yields a composite health status score.  A
high score indicates a good health status. The RAND-36 is short and sensitive to intervening
illness, for instance, among the relatively healthy elderly. It has a good reliability and validity21*
QOL was assessed using the WHO Quality of Life assessment instrument-100 (WHOQOL-
100)22,23 The instrument was chosen. because it corresponds best with the subjective character
of the WHO definition of QOL. The WHOQOL-100 is an easy to score generic
multidimensional self-report measure with good psychometric properties24. The instrument has
been developed simultaneously and cross-culturally  in 15 centres around the world'. It consists
of 100 questions assessing 24 facets of QOL within six domains (Physical health, Psychological
health, Level of independence, Social relationships, Environment, Spirituality), and a generic
evaluative facet (Overall QOL and general health). Each Elcet is represented by four questions,
reflecting functional limitations and the respondent's personal evaluation of these limitations
(How satisfied .?, How much are you bothered ..?). The response scales are 5-point scales.
Scores on each facet and domain can range from 4 to 20. A high score indicates a good QOL.
except for the facets Pain en discomfort, Negative feelings, and Dependence on medication and
treatments, which have an inverse score. Reliability, validity3, as well as sensitivity25 are high
also in healthy elderly 6. In a preceding studyi7(see chapter 3), the instrument has been reduced
to  those 17 facets (68 questions),  that  are most relevant for patients  with PAOD. Because  the
original instrument was reduced by eliminating only entire facets, which itself are
independent components. the validity and reliability of the WHOQOL-100 were preserved.
The  scores  of the matched controls were collected  from the RAND-36 database  of the Northern
Centre for Health Care Research, Groningen. The Netherlands and from the WHOQOL




The RAND-36 and WHOQOL questionnaires were completed by the patients themselves or, if
necessary.   with  the  help  of a research assistant. Since the questionnaires together contain   104
questions, it was suspected that the last questions might be given less attention, biasing the study
results. To avoid this, the sequence ofcompletion was reversed halfway the inclusion period.
Statistics
Data are expressed in terms of means and standard deviations. Mann-Whitney U-tests were
used to detect statistically significant differences (P < 0.01) between patients and healthy
persons. Pearson correlations were calculated between the RAND-36 domains and the
WHOQOL domains/facets. To illustrate the most apparent similarities and differences
between health status and QOL, approximately  10% of the patients with the lowest  and  10%
with the highest scores on a WHOQOL facet or domain were selected. Their scores on
corresponding RAND-36 domains were divided into quartiles and visualised in stapled
histobars.
RESULTS
Compared with healthy controls, patients scored significantly worse on all RAND-36
domains (Table 2).
Table 2
Scores on the RAND-36 in 200 patients with intermittent ciaudication and 200 sex and age matched healthy
persons
Healthy persons Patients Significance
m                        sd                           m                        sd
Physical functioning 70,1 27,3 50,5 19,6 P <.01
Social functioning 85,3 21,8 74.2 24,4 P <.01
Role physical 73,0 39,9 46,3 42,1 P < .01
Role emotional 86,7 28,6 70,4 66,1 P<.01
Mental health 76,8 17,4 70,4 20,4 P <.01
Vitality 65,5 21,6 56,6 20,8 P<.01
Bodily pain 76,2 25,6 58,2 21,6 P<.01
General health perception. 63,7 23,7 56,3 20.3 P <.01
m = mean, sd = standard deviation
Concerning the WHOQOL results, patients evaluated their functioning significantly worse
than healthy persons with regard to Physical health and Level of independence. In addition,
patients experienced more negative feelings. The social domain was unaffected, but some
impairments were recorded in the environmental domain. Finally, Overall QOL and general




Scores on the reduced WHOQOL-100 in 200 patients with intermittent claudication and 200 sex and age matched
healthy persons
Healthy persons Patients Significance
m sd m         sd
-Overall QOL and general health 16.1 2.5 14.5 2.8 P <.01
Physical health 15.3 2.4 13.4 2.4 P<.01
- Pain and discomfort 9.4 2.8 12.1 2.6 P < .01
- Energy and fatigue 15.2 3.1 12.6 3.0 P<.01
- Sleep and rest 16.2 3.6 15.6 4.0 ns
Psychological health                             -
- Positive feelings 14.4 2.0 14.2 2.4 ns
- Thinking, learning, memory, concentration -                                          -
- Self-esteem 14.7 2.2 14.5 2.7 ns
- Body image and appearance                      -
- Negative feelings 8.9 2.8 10.1 3.1 P <.01
Level  of independence 16.8 2.4 13.1 2.6 P<.01
- Mobility 17.0 3.0 11.7 2.7 P <.01
- Activities ofdaily living 16.6 2.7 14.0 3.0 P<.01
- Dependence on medication and treatments    7.0       3.1 10.8 3.5 P <.01
- Working capacity 16.7 2.8 13.4 3.7 P <.01
Social relationships 15.3 2.6 15.2 2.7 ns
- Personal relationships 16.0 2.5 16.5 2.7 ns
- Social support                                   -
- Sexual activity 14.2 4.0 13.8 3.5 ns
Em,ironment
- Physical safety and security                          -                                          -
- Home environment 15.9 2.5 16.1 2.9 ns
- Financial resources                             -
- Health and social care
- Opportunities for acquiring
new information and skills 16.0 2.4 14.7 2.7 P <.01
- Recreation/leisure 15.9 2.7 14.9 3.1 P <.01
- Physical environment                            -
- Transport 17.5 3.0 16.5 3.7 ns
Spirituality, religion, personal beliefs          -
m = mean, sd = standard deviation, ns = not significant. The scores on the facets Pain and discomfort, Negative
feelings, and Dependence on medication and treatments are inverse. High scores reflect low QOL.
The correlations between the RAND-36 domains and the WHOQOL facets/domains ranged
between 0.20 and 0.74. The strongest correlations were found between RAND-36 Mental
health and WHOQOL facet Negative feelings, RAND-36 Vitality and WHOQOL facet
Energy and fatigue, RAND-36 General health perception and WHOQOL facet Energy and
fatigue, RAND-36 Role physical and WHOQOL domain Level of independence, particularly





Pearson correlations between the scores on the WHOQOL facets and domains and the RAND-36 domains in 200
patients with intermittent claudication
PhysF SocF RoPh RoEm MentH Vital Pain GH
- Overall QOL and general health .39 .53 .32 .35 .52 .57          .21          .57
Physical health .47 .50 .46 .39 .56 .57 .48 .53
- Pain and discomfort -.45 -.35 -.40 -.24 -.42 -40 -.60 -.30
- Energy and fatigue .44 .44 .41 .42 .43 .67 .31         .64
- Sleep and rest .20          .31 .25 .23 .38          .23          .22          .25
Psychological health
- Positive feelings .20 .45 ns .33 .56 .52 ns          .51
- Thinking, learning, memory
- Sel f-esteem ns .40 .22 .26     .51     .44 ns .40
- Body image and appearance
- Negative feelings -.20 -.43 -.20 -.38 -.74 -.49 ns -.36
Level of independence .59     .51 .60 .37 .39 .52 .50 .57
- Mobility .50 .40 .42 .25 .25          .35 .49 .34
- Activities ofdaily living .54 .59 .54 .40 .45          .57 .46 .57
- Dependence med/treatment -.34 -.22 -.34 ns -.26 -.25 -.23 -.42
- Working capacity .49          .41          .60 .41 .28 .47 .42 .47
Social relationships .28 .44 ns .26 .49 .45 ns .37
- Personal relationships .24 .44 ns     .21 .52 .44     ns     .33
- Social support
- Sexual activity ns .34 ns .27 .32 .37 ns .29
Environment
- Physical safety and security
- Home environment .27 .30 .24 .25 .37 .30 ns          .33
- Financial resources
- Health and social care
- Information/skills ns .28 ns ns .28 .29 ns          .28
- Recreation and leisure .30 .54 .25 .34 .44 .46 .22 .38
- Physical environment
- Transport .24 .36 .20 ns .26 .24 ns .22
Spirituality, religion, personal beliefs
Correlations are significant at P < 0.01, ns = not significant
Comparison   o f the health status response quartiles   with   the   best and worst    10%   of  the
corresponding QOL scores showed that there were patients with excellent and very poor
scores on various facets and domains of QOL in nearly all health status response quartiles
(Figs. 1-8, see pages   86-92). Most similarities were found   for the physical domains (Figs. 1
and 2), while there were discrepancies regarding Social functioning and Bodily pain (figs.3
and 4). The comparison of scores confirmed that RAND-36 Mental health (Fig.5) correlated
stronger with the WHOQOL facet Negative feelings, than with the other facets of the
WHOQOL domain Psychological health (Figs.6 and 7). Surprisingly, both the upper and
lower response quartiles of RAND-36 General health perception contained patients with
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excellent and very low scores on the WHOQOL facet Overall QOL and general health
(Fig.8).
DISCUSSION
In chronic conditions, relief of symptoms and amelioration of well-being are the main goals of
treatment. Therefore, treatment modalities and their outcomes should not be evaluated in terms
of technical possibilities and clinical success, but rather in view of the patient's perception of
health and QOL. In patients with IC, many aspects of health status and QOL are affected.
which may give the impression that the concepts measure the same problem with apparently
similar results. Indeed. both health status and QOL assessments disclosed impairments in
physical and psychological functioning. and in daily activities. The RAND-36 domains
Physical functioning and Role physical showed acceptable correlations with the WHOQOL
domain Level of independence. However, the correlations are  far from 1.0, which illustrates
that common variance is not very high. The agreement between the RAND-36 response
quartiles and the upper and lower  10% of the WHOQOL scores confirmed that with regard to
the physical domains both assessments comparably discriminate between high and low
performance (health status) and high and low satisfaction with performance (QOL) (Figs. 1
and 2). However, health status and QOL differed with respect to social functioning. Whereas
patients reported significant limitations in RAND-36 Social functioning, the same patients
indicated not to feel socially impaired in the corresponding WHOQOL domain. This
paradoxical finding may be explained by looking at the content and the accent of the
questions assessing health status and QOL. The social domain of the RAND-36 asks how
often and to what extent physical health and emotional problems have interfered with
(unspecified) social activities. Consequently, the frequency and the intensity of the events
that have interfered with social activities will determine the score for Social functioning.
Patients with few social contacts score low and thus are considered to have a bad social life
or to function on a low social level. The social domain of the WHOQOL incorporates the
facet Personal relationships with questions about feeling lonely. about one's satisfaction with
relationships in general and with family in particular, and about satisfaction with the ability
to support and care for others (Fig.3). Since satisfaction with social contacts is not related to
the size of someone's social network28, few social contacts not necessarily represent social
deprivation, but may reflect a patient's preference. Furthermore, the feeling to be appreciated
by others for providing care and support may contribute to social well-being as well.
Practically, this means that attempts to improve social functioning in patients with IC based
solely on health status results may not contribute to a better QOL per se, because patients do
not feel socially impaired.
The pain scores for both instruments show a similar pattern. The 2nd and 3rd response
quartiles of the RAND-36 domain Bodily pain contain patients with excellent scores on the
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corresponding WHOQOL facet Pain and discomfort. indicating to experience no problems in
daily life as a result of pain (Fig.4). This finding illustrates the difference between only
recording the frequency and intensity of pain. as reflected in health status, and also asking the
patient whether his/her life is actually affected by having pain (QOL). In other words, health
status may indicate whether there are limitations or not. and QOL also reflects to which
extent patients experience these limitations as a problem in daily life. Individual expectations
regarding health, the ability to cope with limitations, and the threshold for the tolerance of
discomfort modulate objective health status facts into subjective values. which represents
one's QOL29. Consequently. two persons with identical restrictions in functioning (health
status) may evaluate these restrictions (QOL) differently. In other words. a low health status
score can coincide with a high score on the corresponding domain of a QOL measure within
the same person.
The possibility to appreciate subjective feelings of patients, in addition to objective recording
of their frequency and intensity, permits to uncover hidden problems. For example. the
RAND-36 scores indicate restrictions in patients' Mental health. The questions concerning
Mental health ask the respondent to rate objectively the frequency of feeling nervous, down,
calm and quiet, depressed, and happy. However, the feelings that are actually affected cannot
be recognised from the aggregated Mental health score. The corresponding facets of the
WHOQOL domain Psychological health allow specifying the subjective content of those
feelings. The responses showed that patients with IC experience specifically more negative
feelings than healthy persons. A stronger correlation between RAND-36 Mental health and
the WHOQOL facet Negative feelings, compared to correlations with other facets of the
corresponding WHOQOL domain„ confirmed this finding. Moreover, all patients in the
lowest and the highest quartiles of RAND-36 Mental health belonged to the  10% of patients
with the most and the least Negative feelings, respectively (Fig.5). These findings confirm
that an excess of negative feelings in claudicants is responsible for the low RAND-36 Mental
health score. As a consequence. therapy directed at reducing negative feelings would rather
meet these patient's needs than efforts to increase self-esteem.
QOL measurement revealed a significant dependency on medication and treatments in
claudicants. The relationship of this finding with the high incidence of risk factors and
comorbidity in patients with IC has recently been made plausible and deserves attention
27.30
in treatment strategy. The burden of concomitant disease  and the notion to depend on medical
services seem to moderate the relevance of walking for the claudicants'  QOL and stresses the
need for risk factor management and treatment ofcomorbidity.
An important characteristic of health status measures is the tendency to assess infirmity or
disability. rather than health31. Questions focus predominantly  on the negative consequences
of disease and disregard the remaining positive aspects of life. The fact that claudicants did
not report less positive feelings or a negative self-esteem in the WHOQOL compared to
healthy controls. and the finding that all response quartiles of the RAND-36 domain Mental
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health contain patients  in the upper  10%  of the scores  for the facets Positive feelings  and
Self-esteem illustrate that there are remaining positive evaluations of QOL, despite a broadly
deteriorated health status (Figs.6 and 7). Another drawback of health status measures is the
disregard of the mutual influence of health and non-health-related aspects of life. like
environmentz.6.7 Claudicants indicated to feel impaired in common, but apparently important
aspects of everyday life like acquiring information/skills or the participation in recreation and
leisure activities. Assessment of disease impact with health status measures only would miss
these problems and prevent subsequent attention.
It has been advocated to supplement health status measures with "global QOL" to reflect
patients' individual values and preferencesi. However, for the interpretation of impaired
"global QOL" it should be clear what the term represents. Our data show that the WHOQOL
facet "Overall QOL and general health" and the closest corresponding RAND-36 domain.
General health perception, correlated better with the RAND-36 domain Vitality and its
corresponding WHOQOL facet Energy and fatigue, respectively, than with each other. In
addition, all response quartiles of the RAND-36 General health perception contained patients
with excellent WHOQOL Overall QOL and general health scores (Fig.8). The bare fact that
unspecified terms like "General" or "Global" QOL are affected by a certain disease, is too
vague to be interpreted and does not add to the understanding of disease impact. Since
patients with similar "global QOL" scores may experience different underlying problems,
this score will not provide relevant information for disease management. Knowledge of the
causal relationships with other aspects of life that actually determine general QOL and health
perception may help to interpret these findings and contribute to meaningful treatment.
If health status and QOL measures are used in clinical practice, a problem arises in case the
results do not match. Should treatment be based on the functional limitations as indicated by
the patient, or be guided by the importance that subjectively has been attributed to these
limitations? The answer seems to depend on the kind of disease and the type of study. If
functional impairments are mainly responsible for disease impact, which consequently will
be reduced by functional improvement, health status may adequately reflect disease impact
and serve as a marker of QOL in patient groups4 However, in chronic progressive conditions
without options for cure, when functional improvement may not reduce disease impact
substantially, individual evaluation of all elements that constitute the chronic condition is
required to assess a person's QOL. Therefore, to ensure that treatment plans and evaluations
focus on the patient rather than on the disease, subjective appraisal should be incorporated in
QOL measures5,32
In conclusion, our data confirm that health status and QOL are significantly impaired in
patients with IC. The subjective character of QOL measurement allowed to identify the
problems that are responsible for impaired health status in patients with IC and thus may be
given attention. In addition, QOL measurement revealed that an objectively impaired social
health status was not necessarily considered as a problem by patients with IC. The
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incorporation of positive evaluations and non-health-related aspects of life in the QOL
questionnaire disclosed aspects of life that would have been missed with health status
measures. Health status measures uncover health-related restrictions that are associated with
a certain disease. However, objective health status impairments not necessarily translate into
lower levels of QOL. In the present study, the subjective character of QOL measurement
allowed to identifj' the problems that are responsible for the impaired health status in patients
with IC and might be given attention. Unexpected positive evaluations, feelings of
dependency, and problems with non-health-related aspects of life illustrate that the subjective
evaluation of QOL dimensions offers an additional value to the mere recording of functional
impairments. QOL assessment without taking account of the claudicants' subjective opinion
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RAND-36 Social functioning
RAND-36 Domain Social functioning:
During the past 4 weeks. to what extent has your physical health or emotional problems interfered with your
normal social activities with family, friends, neighbours, or groups?
Not at all - Slightly - Moderately - Quite a bit - Extremely
WHOOOL-100 facet Personal relationships:
How alone do you feel in your life?
Not at all - Slightly - Moderately - Very much - Extremely
Do you feel happy about your relationship with your family members?
Very unhappy - Unhappy - Neither happy nor unhappy - Happy - Very happy
How satisfied are you with your personal relationships?
Very dissatisfied -  Dissatisfied -  Neither  satisfied  nor  dissatisfied -  Satisfied -  Very  satisfied
How satisfied are you with your ability to provide for or support others?
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RAND-36 Domain Bodily pain:
How much bodily pain have you had during the past 4 weeks?
None - Very mild - Mild - Moderate - Severe - Very severe
WHOQOL-100 facet Pain and discomfort:
How often do you suffer (physical) pain?
Never - Seldom - Quite often - Very often - Always
Do you worry about your pain or discom fort?
Not al all - A little - A moderate amount - Very much - An extreme amount
How difficult is it for you to handle any pain or discomfort?
Not at all- Slightly - Moderately - Very - Extremely
To what extent do you feel that (physical) pain prevents you from doing what you need to do?
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RAND-36 Domain Mental health:
Have you been a very nervous person?
Have you felt so down in the dumps that nothing could cheer you up?
Have you felt calm and peaceful?
Have you felt downhearted and blue?
Have you been a happy person?
All of the time - Most of the time - A good bit of the time - Some of the time - A little qfthe time - None ofthe
time
WHOQOL-100 facet Negative feelings
How often do you have negative feelings, such as blue mood, despair, anxiety, depression?
Never - Seldom - Quite often - Very often - Always
How worried do you feel?
Not  at  all - Slightly -  Moderately -  Very - Extremely
How much  do any feelings of sadness or depression interfere with your everyday functioning?
Not al all - A little - A moderate amount - Very much - An extreme amount
How much do any feelings of depression bother you?
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RAND-36 Mental health
RAND-36 Domain Mental health:
Have you been a very nervous person?
Have you felt so down in the dumps that nothing could cheer you up?
Have you felt calm and peaceful?
Have you felt downhearted and blue?
Have you been a happy person?
All of the tine - Most of the time - A good bit of the time - Some of the time - A little of the time - None of the
time
WHOQL-100 facet Positive feelings :
How much do you enjoy life?
Not al all - A little - A moderate amount - Very much - An extreme amount
Do you generally feel content?
Never - Seldom - Quite often - Very often - Always
How positive do you feel about the future?
Not at all - Slightly - Moderately - Very - Extremely
How much do you experience positive feelings in your life?
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RAND-36 Mental health
RAND-36 Domain Mental health:
Have you been a very nervous person?
Have you felt so down in the dumps that nothing could cheer you up?
Have you felt calm and peaceful?
Have you felt downhearted and blue?
Have you been a happy person?
All  of the  line  -  Most  of the  time - A  good  bit  of the  time -  Some  of the  time -  A  little  of the  time      None  of the
time
WHOQOL- 100 facet Set f-esteem:
How much do you value yourself?
Not al all - A little - A moderate amount - Very much - An extreme amount
How much confidence do you have in yourself?
Not al all - A little - A moderate amount - Very much - An extreme amount
How satisfied are you with yourself'?
Ven' dissatisfied - Dissatisjied - Neither satisfied nor dissatisfied - Satisfied - Very satisfied
How satisfied are you with your abilities?
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RAND-36 Domain General health perception:
In general, what would you say your health is?
Excellent - Very good - Good - Fair -  Poor
How true or false is each of the following statements for you?
I seem to get sick a little easier than other people.
I am as healthy as anybody 1 know.
I expect my health to get worse.
My health is excellent.
Dejinitely true  -  Mostly  true  -  Don't  know -  Mostly false -  Definitely false
WHOQOL-100 facet Overall quality of life and general health:
How would you rate your quality of life?
Very poor - Poor - Neither poor nor good - Good -  Very good
How satisfied are you with the quality of your life?
Very dissatisfied - Dissatisfied - Neither satisjied nor dissatisfied - Satisfied - Very satisfied
In general, how satisfied are you with your life?
Very dissatisfied - Dissatisfied - Neither satisfied nor dissatisfed - Satisjied - Very satisfied
How satisfied are you with your health?
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Objective: To assess quality of life (QOL) in patients with intermittent claudication (IC).
Design: A prospective study in the vascular outpatient clinic ofa teaching hospital.
Material and methods: One hundred and fifty-one consecutive patients with IC (100 men,
51 women) completed a reduced version of the World Health Organisation Quality of Life
assessment instrument-100. Results were compared with those of an age-matched group of
161 healthy persons (70 men and 91 women).
Resu Its: Patients scored significantly worse   on the domains Physical health and Level   o f
independence, and on the facets Pain and discomfort, Energy and fatigue, Mobility, Activities
of daily living. Dependence on medication and treatments, Working capacity, Negative
feelings. Recreation and leisure, and Overall QOL and general health. Increasing disease to
incapacitating claudication affected only the facet Mobility and the domain Level of
independence.
Conclusion: QOL in patients with IC is reduced in many aspects. Where comorbidity seems
to affect QOL strongly. the effect of walking distance on QOL might be small. These
tindings may jusufy a reserved attitude towards invasive. even minimally invasive treatment
o f these patients.
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INTRODUCTION
Intermittent claudication (IC) is a symptom of peripheral arterial occlusive disease (PAOD),
one  of the expressions of atherosclerosis, disabling, non-fatal,  and  with  a high prevalence'.
The severity of claudication is usually assessed by means of the treadmill-walking distance
and the ankle brachial pressure index (ABPI). However, neither of these variables correlates
well with patient reported functional impairmentsz-4. An alternative way to assess the
impairment is therefore required.
Quality of life (QOL) is increasingly recognised as an important and independent measure of
disease impact  and a measure of outcome of treatment5.6,  and is recommended as a guideline
for treatment policy in vascular disease7. In the literature, QOL is often used as a
comprehensive concept, i.e., concepts like functional status and health status are labeled as
QOL. However, functional status refers to physical functioning, for instance, walking distance in
claudicants. Health status assesses the influence of disease on physical, social. and emotional
functioning; it measures restrictions in functionings.9. Health status measures like the Medical
Outcome Study Short Form-36 (SF-36)10, the Nottingham Health Profile" and the Euroqol,2 are
frequently used in studies on health status in vascular disease. QOL, as defined by the World
Health Organisation (WHO)13, is a broader concept comprising the personW evaluation Of
»ctioning with regard to physical health, psychological state, level of independence, social
relationships, personal beliefs, and relationships to salient features in the environment. QOL
assesses functioning in relation to the patients' own criteria.
The aim ofthis study was to measure QOL, as defined by the WHO, in patients with IC.
MATERIALS AND METHODS
Patients
Between January  1999 and December  1999,  QOL was assessed  in 151 consecutive patients
(100 men, 51 women, mean age 63 years, range 43-83 years) presenting with IC at the
vascular outpatient clinic of the Department of Surgery at the St. Elisabeth Hospital in
Tilburg, The Netherlands. The diagnosis was made on history, physical examination,
treadmill-walking distance, and ankle blood pressure. The impairment was recorded
according to a slightly modified version of the reporting standards as recommended by the
Society for Vascular Surgery/ the North American Chapter of the International Society for
Cardiovascular Surgery (SVS/ISCVS)14 as mild, 26 patients; moderate, 72 patients; severe,




Distribution of risk-factors and comorbidity, specified  into "rione". "mild", "moderate" and "severe", according
to the SVS/ISCVS" in 1 5 1 patients with intermittent claudication, studied for QOL
none mild moderate severe
Diabetes mellitus 127 (84%) 9(6%) 11 (7%) 4 (3%)
Tobacco use 27 (18%) 27 (18%) 52 (34%) 45 (30%)
Hypertension 82 (54%) 41 (27%) 20 (13%) 8 (5%)
Hyperlipidaemia 77 (51%) 28 (19%) 15 (10%) 31 (21%)
Cardiac status 99 (66%) 35 (23%) 16(1196) 1 (1%)
Carotid disease 124 (82%) 8 (5%) 14 (9%) 5 (3%)
Renal status 146 (97%) 3 (2%) 1 (1%) 1 (1%)
Pulmonary status 135 (89%) 9 (6%) 6 (4%) 1 (1%)
SVS/ISCVS grading system for cardiovascular risk factors and comorbidity: see Appendix IlI
Measure
QOL was assessed using the WHO Quality of Life Assessment Instrument-100 (WHOQOL-
100)
15-17
. This is a generic, multidimensional, self-report QOL measure with good psychometric
properties that is easy to score 18. The instrument has been developed simultaneously and cross-
culturally in 15 centres around the world'3. It consists of 100 items assessing 24 facets of QOL
within six domains (Physical health, Psychological health Level of independence, Social
relationships, Environment, Spirituality) and a generic evaluative facet (Overall QOL and
general health). Each facet is represented by four items. The responses are expressed in 5-point
scales. Scores on each facet and domain can range from 4 to 20. The reliability and validity of
the instrument are high", also in healthy elderly'7.
To adapt the instrument for patients with PAOD and to limit patient burden of completing
100 questions, the original WHOQOL-100 was reduced to the facets and domains that were
relevant to this patient group. After a pilot study (see chapter 3) in 22 patients, using criteria
for the distribution of answers (kurtosis, which describes the peakedness of the distribution,
and skewness, which means that the length of one of the tails of the distribution, relative to the
central section, is disproportionate to the other), and internal consistency (Cronbach's alpha, a
measure  for the reliability  of the instrumentzO), the instrument could be reduced  to 17 facets
(68 questions), covering the domains Physical health, Psychological health, Level of inde-
pendence, Social relationships, and Environment and the generic evaluative facet Overall QOL
and general health. Because the original instrument was reduced by eliminating only entire
facets, which itself are independent components, the validity and reliability of the
WHOQOL-100 were preserved.
The patients completed the questionnaire and a research assistant was available for help, if
needed. The QOL scores of the examined patient population was put into perspective by
comparing  them with an age-matched, community based sample  of 161 healthy persons,  (70
101
Quality of life in patients with intermittent claudication
men, 91  women, mean age 62 years, range 40-91 years) from the validation study of the
Dutch version ofthe WHOQOL-10019
Statistics
Data are expressed as means and standard deviations. In order to detect statistically
significant differences between patients and healthy persons, data were analysed with Mann-
Whitney U-tests. Due to the number of facets in the WHOQOL-100 and thus the number of
analyses examined, a probability value of less than 0.01 was considered to be statistically
significant. The statistical differences between the three categories of IC were analysed with
Kruskal-Wallis tests.
RESULTS
Compared with healthy persons, patients scored worse on the domains Physical health and
Level of independence, and the facets Pain and discomfort. Energy and fatigue. Mobility.
Activities of daily living, Dependence on medication and treatments, and Working capacity.
Moreover, patients experienced more negative feelings (Psychological health), as well as
problems with respect to Recreation and leisure (Environment). Finally, patients scored
significantly lower on Overall QOL and general health (Table 2).
There were no statistically significant differences in the distribution of risk factors and
comorbidity between the three categories of IC. The three categories (mild, moderate, and
severe claudication) were comparable with regard to QOL, except for the facet Mobility
(Table 3). The difference between severe and mild claudication on the domain Level of
independence reached a P-value of 0.025. Since the number of domains is much smaller than
the number of facets and thus the number of analyses examined, a probability value of less
than 0.05 might be accepted to reach statistical significance for the domain Level of
independence.
DISCUSSION
The present study highlights the personal and subjective evaluation of functioning in patients
with IC. As we reduced the WHOQOL-100, by means of parameters for distribution of
answers and internal consistency, the remaining questions are supposed to reflect those facets
oflife that are ofparticular importance to these patients.
Analogous to the health status studies, it appears that PAOD, even in its mildest expression,
has a detrimental effect on QOL as experienced by the patient, compared with healthy
persons. The main part of the difference is found in the facets and domains evaluating




Scores on the reduced WHOOOL-100  in 1 5 1 patients with intermittent claudication
Healthy Patients Significance
m sd m         sd
- Overall QOL and general health 16.4 2.1 14.4 2.9 P < .001
Physical health 15.5 2.1 13.2 2.6 P < .001
- Pain and discomfort 9.2 2.8 12.2 2.8 P < .001
- Energy and fatigue 15.4 3.0 12.3 3.3 P <.001
- Sleep and rest 16.4 3.2 15.5 4.3 ns
Psychological health                                                     -
- Positive feelings 14.4 2.0 14.0 2.5 ns
- Thinking, learning, memory, concentration         -                    -
- Self-esteem 14.6 2.1 14.7 2.7 ns
- Body image and appearance                                                         -
- Negative feelings 9.0 2.7 10.1 3.2 P < .005
Level of independence 17.0 2.3 12.7 2.6 P < .001
- Mobility 17.0 2.8 11.4 2.7 P < .001
- Activities ofdaily living 16.9 2.5 13.8 3.4 P < .001
- Dependence on medication. treatments 6.5 2.6 11.4 3.6 P < .001
- Working capacity 16.8 2.9 13.2 3.8 P <.001
Social relationships 15.6 2.3 15.3 2.8 ns
- Personal relationships 16.3 2.4 16.5 2.8 ns
- Social support                                           -                    -
- Sexual activity 14.8 3.7 13.8 3.9 ns
Environment                                                                                           -
- Physical safety and security                                 -                        -
- Home environment 15.9 2.4 15.9 3.2 ns
- Financial resources                                                          -
- Health and social care.                                     -                     -
- Opportunities for acquiring
new information and skills 15.5 2.5 14.8 2.8 ns
- Participation in and opportunities
for recreation/leisure 15.9 2.6 14.9 3.2 P =.01
- Physical environment                                -                  -
- Transport 17.4 3.1 16.3 3.7 ns
Spirituality, religion, personal beliefs                -
m = mean, sd = standard deviation, ns = not significant
The scores on the facets Pain and discomfort, Negative feelings and Dependence on medication and treatments
are inverse. High scores reflect low QOL.
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Table 3
Scores  on the domain Level of independence  and the facet Mobility of the WHOQOL- 100 according  to  the
grade of intermittent claudication  in 1 5 1 patients
Domain  Level  of independence:
m sd m sd Significance
Mild claudication 13.7 2.4 compared with Moderate 12.8 2.7 ns
Severe 12.0 2.4 P = .025
Moderate claudication 12.8 2.7 compared with Severe 12.0 2.4 ns
Facet Mobility:
m sd m sd Significance
Mild claudication 12.6 2.7 compared with Moderate 12.0 2.7 ns
Severe 10.1 2.0 P <.001
Moderate claudication 12.0 2.7 compared with Severe 10.1 2.0 P <.001
m = mean, sd = standard deviation, ns = not significant
The significantly greater dependence on medication and treatments in claudicants as
expressed in the results is not directly related to an impaired walking distance and suggests
an impact of comorbidity on QOL.  This  is not surprising since patients suffering from PAOD
are   known  to be affected with important comorbidityz 1. There are several reports   in   the
literature on health status in patients with IC. Pe1122, Currie23 and Chetter 4.25 using the SF-36
and Euroqol, found that patients were impaired in physical, psychological, and social
functioning, deteriorating with the severity of claudication. This was especially the case in
multi-level disease. The explicit negative feelings as reported by the patients in this study did
not emerge from the health status studies, because health status measures do not evaluate
subjective feelings of patients.  We  feel that disregarding subjective feelings of patients  is one
of the important disadvantages of merely assessing health status in chronically ill patients,
especially when treatment is mainly palliative.
Surprisingly, the three categories of claudicants differed only significantly with regard to the
facet Mobility. In addition, the patients with the mildest and the patients with the most severe
form of claudication differed on the domain Level of independence. With regard to the other
domains and facets of QOL the categories were comparable. This means that, with increasing
disease to incapacitating claudication, QOL only deteriorates on these two aspects. The
severity of claudication does not  seem to  be  related to the level of QOL other than Mobility
and Level of independence. Apparently, the presence of IC, irrespective of the severity, is
enough to create a significant difference on the various domains and facets of QOL compared
with the healthy population.
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It  is  important to realise that the scores  on QOL as presented in this study are the result of all
influences of PAOD and comorbidity. The relative impact of comorbidity, in addition to the
impaired walking distance on QOL, has not yet been elucidated. The observation that
increasing claudication only affects Mobility and Level of independence suggests that
successful treatment in terms of improving the walking distance may have a limited effect on
QOL on the whole. Although not proven yet, it seems that comorbidity may have a dominant
effect  on the  QOL of patients with IC, whereas the impaired walking distance might be  no
more than the expression ofa more complex underlying disease.
Considering the above, the importance of the walking distance as the principal factor in the
assessment of patients with IC should be questioned. The importance of comorbidity is
generally underestimated in the literature and that is why we feel that invasive therapy, even
minimally invasive, is questionable in patients with IC and serious comorbidity. Future
studies should determine the influence of all factors affecting QOL in patients with IC, as it
seems to depend on more than walking a few hundred metres more or less.
Because functional assessment and subjective evaluation of functioning are considered
complementary conceptsi6. they should be used together in order to evaluate the impact of
PAOD  on the life of patients IC. Since this is the first study to evaluate QOL in patients with
IC with a true QOL questionnaire, further study is necessary to determine the complementary
value of QOL on health status in these patients.
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Objective: To assess the impact of walking impairment, cardiovascular risk factors, and
comorbidity on quality of life (QOL) in patients with intermittent claudication (IC).
Design: A prospective study in the vascular outpatient clinic ofa teaching hospital.
Material and methods: QOL was assessed in 200 consecutive patients with IC, with a
reduced version of the World Health Organisation Quality of Life Assessment Instrument-100.
The reduced instrument assesses 17 facets  of QOL within five domains (Physical health.
Psychological health, Level of independence, Social relationships, Environment). Age, sex.
degree of IC, risk factors and comorbidity, as recommended by the Society for Vascular
Surgery/ North American Chapter of the International Society for Cardiovascular Surgery
(SVS/ISCVS), and the presence of back. hip, or knee symptoms were analysed as possible
predictors of QOL. Multiple regression analyses were run with each of the QOL facets and
domains as dependent variable. A probability value of less than 0.05 was considered to be
statistically significant.
Results: Male sex was found to be a predictor of better scores for the facets Energy and
fatigue, and Sleep and rest. Women experienced more negative feelings. The presence ofback,
hip, or knee symptoms was of significant predictive value for many aspects of QOL. With
more concomitant diseases, patients had lower scores on the facets Overall QOL and general
health and Energy and fatigue. and showed more dependence on medication and treatments.
The severity of IC, as expressed in the SVS/ISCVS classification, was a statistically significant
predictor of QOL for the domain Level of independence and its facets Mobility, Activities of
daily living, and Working capacity and the facets Pain and discomfort, Sexual activity, and
Transport. Hypertension was the second most important single predictor of QOL in patients
with IC.
Conclusion:   QOL in patients   with  IC   is only partially determined  by the degree  o f IC   as
expressed in the SVS/ISCVS classification. The significant impact of cardiovascular risk
factors and comorbidity and the presence of back, hip, or knee symptoms on QOL should be
recognised and taken into account in the treatment policy.
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INTRODUCTION
Intermittent claudication (IC) is a frequently occurring expression of peripheral arterial
occlusive disease (PAOD), usually with a benign course  for the legs'. Although the presenting
complaint may seem innocent, concomitant coronary and cerebrovascular disease are serious
threats to the claudicant's life . Treatment results in patients with IC are traditionally
expressed as changes in ankle blood pressures and walking distance: Because atherosclerosis
is a chronic progressive and incurable disease, relief of complaints was the main goal of
treatment,  for a long time. However, during the last years, quality of life (QOL) has become
an accepted measure of disease impact and therapeutic outcome in patients with vascular
4-7
disease . Accordingly, the goal of treatment in patients with IC has shifted from mere
palliation of symptoms to the preservation or improvement of QOL. The impact of IC on
8-10
QOL has been highlighted in several studies . However. in these studies the role of
cardiovascular risk factors and the impact of concomitant disease on the QOL of these
patients are generally not included  as a variable. Therefore,  the aim o f this study was to assess
the relative impact of age, sex, severity of claudication, cardiovascular risk factors,
comorbidity, and the presence ofback, hip, or knee symptoms on QOL in patients with IC.
MATERIAL AND METHODS
Patients
Between January  1999  and  June  2000  QOL was assessed in patients  with  IC, who agreed  to
participate in the study,  at the vascular outpatient clinic of the Department of Surgery at the
St. Elisabeth Hospital in Tilburg, The Netherlands. Two hundred patients were included in the
study: 135 men and 65 women, with a mean age of 63 years (range: 42 to 83 years).
Diagnosis was suspected on history and physical examination in 215 patients and could be
confirmed by treadmill performance, and ankle blood pressure  in 207 patients. Seven of them
refused or were not capable to participate. Apart from patients with dementia and those who
were blind or deaf, no patients were excluded from the study.  In all patients the degree of IC,
risk factors (smoking and hyperlipidaemia) and comorbidity (hypertension, cardiac, carotid,
renal and pulmonary status, diabetes mellitus) were recorded according to the Society for
Vascular Surgery/ North American Chapter of the International Society for Cardiovascular
Surgery (Svs/ISCVS)3 (Tables  1  and 2). Because  of the impact on mobility, the presence  of




Characteristics of 200 patients with intermittent claudication, studied for quality of li fe
mild moderate severe
claudication claudication claudication
Nr. ofpatients                       37                81                 82
Sex 3 1 M/6 F 53 M / 28 F 51 M / 31 F
Mean age 60.6 yrs. 63.7 yrs. 62.8 yrs.
ABI 0.70 (0.52-0.95) 0 68 (0.33-0.93) 0.53 (0.24-0.88)
Mild claudication: Completes modified treadmill exercise*; ankle pressure after exercise > 50 mm Hg, but at
least 20 mm Hg lower than resting value. Moderate claudication: Between mild and severe. Severe
claudication: Cannot complete modified treadmill exercise and ankle pressure after exercise < 50 mm Hg.
* 3,5 km/h on a 5% incline with a maximum of 1000 m.  ABI = ankle brachial index
Table 2
Distribution of risk factors and comorbidity, specified into "none", "mild", '*moderate" and "severe", according
to the SVS/ISCVS in 200 patients with intermittent claudication studied for quality of life
none mild moderate severe
Diabetes Mellitus 168 (84%) 11 (6%) 15 (8%) 6 (3%)
Tobacco use 25 ( 13%) 43 (22%) 73 (37%) 59 (30%)
Hypertension 106 (53%) 50 (25%) 34 (17%) 10 (5t)
Hyperlipidaemia 94 (47%) 38 (19%) 27 (14%) 41 (20%)
Cardiac status 136 (68%) 37 (19%) 25 (13%) 2 (1%)
Carotid status 172 (86%) 7 (4%) 15 (8%) 6 (3%)
Renal status 192 (96%) 3 (2%) 3 (2%) 2 (1%)
Pulmonary status 179 (90%) 12 (6%) 8 (4%) 1 (1%)
SVS/[SCVS grading system for cardiovascular risk factors and comorbidity: see Appendix III
Instrument
QOL was assessed with a reduced version of the World Health Organization Quality of Life
Assessment Instrument-100 (WHOQOL-100) . The WHOQOL-100 is a generic,
11-13
multidimensional, self-report QOL measure that is easy to score and has good psychometric
14
properties   . The instrument  has been developed simultaneously and cross-culturally  in  15
15centres around the world   . It consists  of 100 questions  for the assessment  of 24 facets  of
QOL within six domains (Physical health. Psychological health, Level of independence, Social
relationships, Environment, Spirituality/Religion/Personal beliefs) and a generic evaluative
facet, Overall QOL and general health. Each facet is represented by four questions. The
response scales are 5-point scales. Scores on each facet and domain can range from 4 to 20. A
higher score indicates that respondents evaluate their functioning on the respective domains
and  facets of QOL as being better, except  for the facets Pain and discomfort, Negative feelings
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and Dependence on medication and treatments, which have an inverse score. The reliability and
validity ofthe instrument are high' 6, also in healthy elderly'3.
After a pilot study in 22 patients with PAOD, using criteria for response distribution (kurtosis.
which describes the peakedness of the distribution, and skewness. which means that the length of
one  of the tails of the distribution, relative  to the central section, is disproportionate to the other),
and internal consistency (Cronbach's alpha, a measure  for the reliability of the instrument),  the
instrument could be reduced to 17 facets (68 questions), covering the domains Physical health.
Psychological health, Level ofindependence, Social relationships, and Environment and the generic
evaluative facet Overall QOL and general health (see chapter 3). Because the original instrument
was reduced by eliminating only entire facets, which itself are independent components. the
validity and reliability ofthe WHOQOL-100 were preserved.
Statistics
Age, sex, risk factors, comorbidity, and SVS/ISCVS classification of IC were tested as
possible predictors of QOL. Multiple regression analyses (MRAs) were run with each of the
QOL facets and domains as dependent variable. Each MRA (stepwise method) consisted of
four blocks ofvariables.
The demographic variables, sex and age. were entered in block  1. The second block consisted
of the presence of back, hip, or knee symptoms. Block 3 contained the risk factors smoking
and hyperlipidaemia. Two series of MRAs were run, with the fourth block containing the
number of concomitant diseases in the first series and nature of the concomitant disease
(hypertension, cardiac, carotid. renal and pulmonary status, diabetes mellitus) and the severity
of IC in the second series. Before performing MRA's. we examined the distributions of the
variables involved. In the case of carotid, renal, and pulmonary status, exploration revealed
extreme skewness and kurtosis scores that could not be improved satisfactory by logarithmic
transformations. Furthermore, additional data exploration pointed at violations of the linearity
assumption. Taken these results of evaluation together. it was decided to dichotomise the
measures of these variables to absent or present. The degree of IC and the severity of risk
factors and comorbidity are expressed as none, mild, moderate, or sever. which means that the
predictive value of these independent variables on QOL correlates with the change and
direction (increase or decrease)  o f the severity. Differences  in age, distribution o f risk factors.
and comorbidity between the three categories of claudication were tested with Kruskal-Wallis
tests. A possible difference in sex between the three categories of IC was examined using a





No statistically significant differences were found  in age and sex,  or in the distribution of risk
factors and comorbidity between the three categories of IC. Back, and hip, or knee symptoms
were present in 13% and 10% ofthe patients, respectively.
Male sex was a major predictor for higher scores on the domain Physical health and its
components, Energy and fatigue, and Sleep and rest. Female sex associated exclusively with
more negative feelings.
From the first series of MRAs (Table 3) patients with more concomitant diseases appeared to
have lower scores on Overall QOL and general health, Energy and fatigue, and Dependence
on medication/treatments. When patients had back. hip, or knee symptoms, their QOL scores
were lower on all facets except for Sleep and rest, Negative feelings, Dependence on
medication/treatments, Home environment, and Opportunities for acquiring new
information/skills.
The second series of MRAs (Table 4) showed that increasing IC predicted a lower QOL on
the domain Level of independence and its facets Activities of daily living and Working
capacity. Moreover, the severity of IC  was the only variable with a substantial predictive value
for the facet Mobility (domain Level of independence). In addition, more severe IC is
associated with more Pain and discomfort, lower scores on the facet Sexual activity, and more
problems with Transport. Hypertension emerged as an important factor for QOL with a
significant predictive value for various aspects such as Overall QOL and general health,
Energy and fatigue, the domain Level of independence and its facets Dependence on
medication/treatments and Working capacity, as well as for the facets Recreation/leisure and
Transport.
Specifically, non-smokers, patients with a mild smoking behaviour, and patients with a
compromised carotid or pulmonary status indicated that they felt more dependent on
medication and treatments. Patients with pulmonary restrictions had higher scores for the facet
Sleep and rest, while patients with hyperlipidaemia scored lower for Self-esteem.
Age and diabetes mellitus had no significant predictive value for any QOL aspects in patients
with IC. Finally, no significant predictors of QOL were seen on the domain Social
relationships and the facets Personal relationships and Home environment.
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Table 3
Results from stepwise multiple regression analysis with age, sex, non-vascular back, hip and knee symptoms,
risk factors, and number of concomitant diseases as independent variables (predictors of quality of life) and the
WHOQOL facets and domains as dependent variables in 200 patients with intermittent claudication
Dependent variable Predictor of QOL Beta R2 change R  Total
- Overall QOL and general health (P < .002)Back pain -.248 .068 .068
Comorbidity -.214 .046 .114
Physical health (P < .091) Sex -.348 .096 .096
Back pain -.312 .096 .192
- Pain and discomfort (P<.002) Back pain -.290 .084 .084
- Energy and fatigue (P < .001) Sex -.276 .054 .054
Back pain -.202 .044 .098
Comorbidity -.221 .049 .147
- Sleep and rest (P < .004) Sex -.270 .073 .073
Psychological health                            -
- Positive feelings (P < .046) Back pain -.191 .036 .036
- Thinking, learning, memory, concentr.     -                                     -
-Self-esteem (P < .024) Back pain -.217 .047 .047
- Body image and appearance                     -
- Negative feelings(P < .003) Sex .282 .079 .079
Level  of independence CP < .005) Back pain -.268 .072 .072
- Mobility (P < .020) Back pain .221 .049 .049
- Activities ofdaily living (P < .048) Hip/knee symptoms -.190 .036 .036
- Dependence on medication
and treatments (P < .005) Comorbidity .324 .168 .168
- Working capacity (P <.001) Back pain -.367 .158 .158
Hip/knee symptoms -.220 .047 .205
Social relationships 9 < .013) Back pain -.253 .054 .054
- Personal relationships (P < .041) Back pain -.195 .038 .038
- Social support                                 -                                                              -
- Sexual activity (P < .036) Back pain -.217 .047 .047
Environment                             -
- Physical safety and security                        -
- Home environment No significant predictors
- Financial resources
- Health and social care
- Opportunities for acquiring
new information/skills (P < .040) Smoking .196 .038 .038
- Recreation/leisure (P <.001) Back pain -.324 .105 .105
- Transport (P < .026) Hip/knee symptoms -.213 .045 .045
Spirituality, religion, personal beliefs         -




Results from stepwise multiple regression analysis with age, sex, non-vascular back, hip or knee symptoms,
cardiovascular risk factors, comorbidity (SVS/ISCVS classification), and degree of intermittent claudiaction
(SVS/1SCVS classification) as independent variables (predictors of quality of life) and the WHOQOL facets
and domains as dependent variables in 200 patients with intermittent claudication
Dependent variable Predictor of QOL Beta R2 change R2 Total
- Overall QOL and gen. health (P < .001) Hypertension -.248 .061 .061
Physical health CP < .001) Male sex -.306 .089 .089
Back pain -.206 .037 .126
Renal status -.174 .030 .156
- Pain and discomfort (P < .001) Back pain .312 .087 .087
IC classification .151 .023 .110
- Energy and fatigue (P < .007) Male sex -.173 .034 .034
Hypertension -.155 .024 .058
- Sleep and rest (P < .001) Male sex -.308 .091 .091
Pulmonary status .156 .024 .115
Psychological health                                  -
- Positive feelings (P < .007) Renal status -.207 .043 .043
- Thinking, learning, memory,
concentration
- Self-esteem (P < .008) Hyperlipidaemia -.205 .042 .042
- Body image and appearance                                -                        -
- Negative feelings (P < .001) Female sex .297 .088 .088
Level  of independence  (P <.001) Hypertension -.218 .053 .053
IC classification -.208 .043 .096
- Mobility (P < .001) IC classification -.290 .084 .084
- Act. daily living (P < .008) IC classification -.204 .042 .042
- Dependence on medication Smoking -.161 .036 .036
and treatments (P < .001) Hypertension .254 .073 .109
Pulmonary status .170 .032 .141
Carotid status .165 .026 .167
- Working capacity (P < .00 1) Back pain -.255 .040 .040
Hypertension -.226 .054 .094
IC classification -.166 .027 .121
Social relationships No significant predictors of QOL
- Personal relationships No significant predictors of QOL
- Social support
- Sexual activity (P < .006) Carotid status -.216 .033 .033
IC classification -.195 .037 .070
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Table 4 (cont)
Dependent variable Predictor ofQOL Beta Rz change R  Total
Environment                                                     -                                       -            -                           -
- Physical safety and security                           -                                                                                -
- Home environment No significant predictors of QOL
- Financial resources                              -                                                            -
- Health and social care
- Opportunities for acquiring Cardiac status -.175 .031 .031
new information/skills (P < .023)
- Recreation/leisure (P < .009) Hypertension -.201 .041 .041
- Physical environment                           -                                                            -
- Transport (P < .003) IC classification -.192 .041 .041
Hypertension -.162 .026 .067
Spirituality, religion, personal beliefs          -
Legend to tables 3 and 4:
Scores on the facets Pain and discomfort, Negative feelings, and Dependence on medication/treatments are
inverse. Higher scores indicate lower QOL.
IC classitication: mild, moderate, or severe IC according to a modification of the Svs/ISCVS:
Beta-value indicates whether relation between a predictor and a facet of QOL is positive or negative. In Table,
negative beta-value indicates that low scores on the independent variables (mild claudication, absence of back,
hip, or knee symptoms, absence of carotid, renal and pulmonary comorbidity, less severe diabetes mellitus,
tobacco use, hypertension, hyperlipidaemia and cardiac comorbidity) predict a higher score on the dependent
variables (i.e., the respective domains or facets of QOL). Negative beta-value for sex indicates male sex to be a
predictor of QOL, a positive beta-value means that female sex  is the predictor of OOL facet or domain.
R -change indicates proportion of variance of the dependent variable (i.e., facet or domain of QOL) that is
explained by independent variable in that row.
2-total reflects total proportion of variance of dependent variable that is explained by independent variables
that are included in model up to that point.
Signit}cance of used model is expressed with P-value. P-value <  0.05 was considered statistically significant.
DISCUSSION
QOL scores in patients with IC are the resultant of influences of PAOD and comorbidity.
Because the walking impairment is only one of the components of the clinical entity, other
aspects should be evaluated as well to understand the impact of IC on patient's QOL. These
results show that the predictive value of the walking impairment, as expressed in the modified
SVS/ISCVS classification,  for the claudicants'  QOL is limited to the physical aspects of QOL:
Pain and discomfort, Mobility, Activities of daily living, Working capacity, Sexual activity,
and Transport. This is in concordance with earlier reports, describing the limited effect of
1017increasing IC on QOL on the whole   '   . The importance of risk factors and comorbidity for
the development of PAOD and for the prognosis of patients with it has been documented
218.19extensively '    . For instance, IC appeared to be a substantial predictor of cardiovascular
morbidity and mortality, independent  of associated coronary ischaemia or other cardiovascular
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risk factors in ambulatory elderly,0 Although patients seek help for a walking problem, the
systemic risk of PAOD is the real threat to their lives. Facing this reduces IC to a relatively
innocent ailment marking a more serious underlying disease.
These data indicate that. in addition to the walking impairment. concomitant disease plays an
important role for most aspects of QOL in patients with IC. This does not detract from the
value of improved walking for a better functional status, which will be appreciated by the
patient, even in the presence of important comorbidity However, the gains with respect to
QOL  may be small. since the predictive value  of the walking impairment is limited to physical
aspects. Concerning the finding that increasing IC only affects QOL with regard to the facet
I 0Mobility , patients with IC and important comorbidity may gain some improvement in
functional status. but are unlikely to enjoy important QOL benefits from improving walking
distance only. Optimising their medical condition may be of greater importance  for  QOL.
Patients with pulmonary restrictions have better scores for Sleep and rest. Because QOL
assesses the personal evaluation of functioning, this subgroup of patients, with predominantly
mild to moderate pulmonary impairments (Table 2), apparently appreciate sleep to compensate
for the efforts ofdyspnoea.
Heavy smokers indicate less dependence on medication and treatments. Although this may
seem contradictory. one might speculate that the perception of dependence ofa person who  is
used to dependence on tobacco has been modulated. In other words, dependence as observed,
may not be experienced as such.
The importance of back, hip. or knee symptoms for QOL in patients with IC is in concordance
2i
with Feinglass et al.  , who reported on its negative predictive value for physical functioning.
Non-vascular back, hip, or knee symptoms are relatively frequent in patients with IC and
appeared significant predictors for many aspects of QOL. If present in claudicants. these
symptoms should not be ignored, but treated. Relief of these symptoms promises a more
profound influence on QOL than attempting to improve the peripheral vascular status.
I 7No significant predictive value was seen for age. Except for the study by Barletta et al.  , who
found a relation between age and health status in patients with IC, this finding is concordant
with most other studies. More surprising were the findings that diabetes mellitus neither has a
predictive value for QOL, while hypertension appeared to be a major predictor. This may be
explained by the fact that many of the usual risk factors and comorbidity that constitute QOL
in patients with IC are present in diabetics as well. QOL in patients with IC and diabetes
mellitus may be determined largely by the same factors. Moreover. the milder forms of
diabetes can be treated by diet and life style modification. with the purpose to keep glucose
level within limits. This relatively small interference with daily life and the knowledge that
severe complications of diabetes are not evident  for  15  to 20 years after its onset may account
for diabetes being  not a predictor of QOL in patients with IC. While the severity of diabetes
according to the SVS/ISCVS reporting standardsi. depends on the age ofonset ofthe disease
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and the method of treatment, the severity of hypertension is rated according  to the number  o f
drugs needed to control it. The number of anti-hypertension drugs needed every day directly
confronts the patient with the severity of this condition, generally known to be associated with
important implications for the vascular and cardiac status. The way of rating the severity of
diabetes and hypertension may be responsible for the counter-intuitive findings concerning the
predictive value ofthese two variables for QOL in patients with IC.
Although convincing evidence exists that conservative treatment should be the first choice for
22 23
patients with IC ' , the increasing possibilities of minimally invasive, percutaneous
procedures have contributed to more active ways of treatment. Studies that focus on patients
with IC have shown that percutaneous transluminal angioplasty (PTA) may produce
favourable results with respect to patency, ankle-brachial pressure indices, walking distance
24-26
and even health-related QOL in the short term . However, mid-term and long-term results
failed to demonstrate benefits from PTA over exercise training and sanitation of risk factors.
Deterioration of QOL, 12 months after a successful PTA. has been attributed to the impact of
2718
increasing comorbidity . The results of the present study show that risk factors and
comorbidity also have an important impact on QOL in patients with IC at baseline, before
treatment. Thus, successful treatment in terms of improving walking distance only will have a
limited effect on the patiems' QOL.
The clinical importance  of the statistically significant predictors  of QOL  in this study may be
questioned  due  to the modest strength o f the association between dependent and independent
variables. In the absence of an alternative method to assess the importance of these variables
and facing the fact that patients with IC are known to be suffering from important
comorbidity, the results of the present study may help to direct treatment options in a way to
satisfy patient's needs.
In the Transatlantic Inter-Society Consensus document (TASC)6, the statement is found that,
although the limitation in walking may be the only symptom of PAOD, the overriding issue in
the management of patients with IC is their risk of development of severe and often fatal
cardiovascular complications. In addition, this study indicates that the appraisal o f risk factors
and comorbidity in patients with IC is essential for the interpretation ofQOL assessments. It is
a challenge for those caring for patients  with IC to explain to  them the importance  of treating
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Objective: To measure the effects of conservative treatment on quality of life (QOL) and
health status in patients with intermittent claudication (IC).
Design: A prospective study in the vascular outpatient clinic ofa teaching hospital.
Material and methods: In addition to the pain free walking distance (PFWD) and maximum
walking distance (MWD) on a treadmill, QOL and health status were assessed with the
WHOQOL-100 and the RAND-36 in 76 patients with IC. at study entrance and after six and
12  months of conservative treatment. Treatment consisted of the advice to stop smoking,  to
start non-supervised exercise training, and anti-platelet medication. Paired t-tests were used
to test for changes in QOL, health status, and walking distances within the patient group.
Differences compared with samples of age and sex-matched healthy persons were tested with
Mann-Whitney-U tests.
Results: PFWD and MWD improved significantly in the first six months. At baseline, most
aspects of QOL and health status were significantly worse compared with healthy persons.
During follow-up, the recorded QOL improved with regard to the facets Pain and discomfort
and Mobility. Psychological effects became apparent with a decline in both positive and
negative feelings. Health status improved only with regard to Bodily pain, approaching the
level of healthy controls. No significant changes in QOL, health status, or walking distances
were recorded between six and 12 months follow-up.
Conclusion: Conservative treatment resulted in improved walking, better mobility,   and   less
pain after the first six months without further improvement thereafter. However, QOL and
health status remained broadly impaired in patients   with IC after 12 months. Apparently,
QOL and health status impairments can only partially be attributed to the walking problem.
To improve QOL and health status, health care providers should supplement efforts to
improve walking with care for other health- and non-health-related aspects of life that are
relevant to patients with IC.
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INTRODUCTION
Intermittent claudication  (IC)  is a common expression of peripheral arterial occlusive disease
(PAOD), caused by atherosclerosis, with a benign character for the legs, but important risks
of fatal cardiac and cerebrovascular eventsl.: The disease has a detrimental impact on a wide
range of aspects of daily life, as rellected in health status and quality of life (QOL)3.4 Since
atherosclerosis is incurable. relief of complaints is the best to be achieved. Therefore. the
preservation and improvement of QOL and health status have been recommended as
guidelines for treatment policy in vascular disease5.6 Several reports have highlighted the
effects of percutaneous transluminal angioplasty (PTA) and bypass surgery on health status
in claudicants -10 However, there is convincing evidence that, compared with invasive
treatment, the results of conservative treatment in patients with IC is equally effective with
regard to walking ability and health status . Since conservative treatment is the first option11-15
for patients with IC, it is our aim to measure its effects on QOL, health status, and walking
ability in a one-year prospective follow-up study.
MATERIAL AND METHODS
Patients
Between January  1999  and  June  2000,  QOL and health status were assessed  at the vascular
outpatient clinic of the Department of Surgery at the St. Elisabeth Hospital in Tilburg. The
Netherlands, in all patients presenting with IC and agreeing to participate in the study by
informed consent. The study was approved by the hospital's medico-ethical commission. IC
was suspected on history and physical examination in 215 patients and was confirmed by
treadmill performance and ankle blood pressure in 207 patients. Seven patients refused or
were not capable to participate. Apart from demented, blind, and deaf patients, no one was
excluded from the study. Fifty-two patients were treated primarily by PTA or bypass surgery.
Initial conservative treatment was changed to PTA or surgery because of progression to
incapacitating   IC   in 19 patients and deterioration to critical   ischaemia   in nine patients.
Failure to complete the questionnaires or inappropriate intervals were the reasons that
complete  QOL and health status data could be obtained  from  76  of 120 patients  that  were
treated conservatively  for at least  one year. There  were  57  men  and 19 women  with  a  mean
age of 65 years (range 46-82 years). The treadmill pain free walking distance (PFWD),
maximum walking distance (MWD), and ankle-brachial pressure indices (ABPI) were
recorded. The presence and the severity of risk factors and comorbidity were recorded





Distribution of risk factors and comorbidity, specified into "none", "mild", "moderate" and "severe", according
to the SVS/ISCVS.  in 76 patients with IC studied for health status and quality of life
none mild moderate severe
Diabetes mellitus 67 (88%) 3 (4%) 5 (7%) 1 (1%)
Tobacco use 10(13%) 23 (30%) 22 (29%) 21 (28%)
Hypertension 43 (57%) 15 (20%) 12 (16%) 6 (8%)
Hyperlipidaemia 42 (55%) 14 (18%) 7 (9%) 13 (17%)
Cardiac status 49 (64%) 16 (21%) 10 (13%) 1 (1%)
Carotid status 65 (86%) 3 (4%) 5(7%) 3 (4%)
Renal status 71 (93%) 1 (1%) 3 (4%) 1 (1%)
Pulmonary status 70 (92%) 5 (7%) 0 (0%) 1 (1%)
SVS/ISCVS grading system for cardiovascular risk lictors and comorbidity: see Appendix III
All patients were treated conservatively according to Housley's paradigm "stop smoking and
„17keep walking . Patients received instruction leaflets for exercise training, but supervised
programs were not provided. Unless using oral anticoagulants, all patients received anti-
platelet medication for the secondary prevention of atherosclerotic events and were referred
to the department of internal medicine for modification of risk factors and treatment of
comorbidity. Treadmill tests, ABPI recordings, QOL, and health status assessments were
performed at first presentation and after  six  and 12 months.  At  the  same time, patients  were
asked about their smoking habits. To put the scores into perspective, the patients' results
were compared with those of two groups of age and sex matched healthy persons for QOL
and health status (both groups, n = 76).
Measu res
QOL was assessed using the World Health Organisation Quality of Life Assessment
Instrument-100 (WHOQOL-100)18-20 This is a generic, multidimensional self-report QOL
measure that  is easy to score.  It has been used in a variety of patient populations, most recently
in IC4,21. The instrument has been developed simultaneously and cross-culturally in 15 centres
around the world. In a preceding pilot-study the instrument was reduced for PAOD patients to
16 relevant facets covering the domains Physical health„  Psychological health, Level of inde-
pendence, Social relationships, and Environment and the generic evaluative ihcet Overall QOL
and general healthz i (see chapter 3). Each facet is represented by four questions, reflecting
functional limitations and the respondent's personal evaluation of these limitations (How
satisfied..?, How much bothered ..?). The responses are expressed in 5-point scales. Scores on
each facet and domain can range from 4 to 20. The reliability, validity, and sensitivity of the
instrument are high22.23 Health status was measured with the RAND-3624.25 which is
practically identical to the Medical Outcome Study/Short Form-36 (SF-36)26, a 36-item generic
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measure. It assesses eight dimensions of health: Physical functioning, Social functioning,
Limitations in usual role activities due to physical problems (Role physical), Limitations in
usual role activities due to emotional problems (Role emotional), Mental health Vitality, Bodily
pain, and General health perception. In addition, Health changes over the last year are assessed.
Beside scores for each subscale, the testing yields a composite health status score on a scale
from 0 (worst)  to  100  (best). The RAND-/SF-36  has been widely used in patients with IC.  It  has
good reliability and validityi7 and has been recommended in patients with PAOD6.28.29
The scores of the matched controls were collected from the WHOQOL database of the
department of Psychology and Health of Tilburg University, Tilburg, The Netherlands,  and  from
the RAND-36 database of the Northern Centre for Health Care Research, Groningen, The
Netherlands.
Statistics
The walking distances, QOL, and health status data are expressed in terms of mean values
and standard deviations. Paired t-tests were used to detect statistically significant differences
within the patient group during follow-up. Changes between patients and healthy controls
were analysed with Mann-Whitney U-tests. A probability value of less than 0.05 was
considered to be statistically significant.
RESULTS
Clinical indicators
Compared with baseline performance, significant improvements in mean PFWD and mean
MWD were recorded after six months (Table 2). Between  six  and 12 months after baseline
measurement, no further significant changes were recorded. The mean ABPI did not change
significantly over the 12 months period. The initial 43% of the patients who indicated to
smoke remained constant with 42% and 44% smoking after six and twelve months,
respectively.
Table 2
Treadmill walking distances and ankle-brachial pressure indices before, and after six and twelve months of
conservative treatment in 76 patients with intermittent claudication
baseline 6 months 12 months
mean (sd) mean (sd) mean (sd)
PFWD 124 (146) 287 (306)* 321 (313)*
MWD 434 (354) 560 (372)* 580 (380)*
ABPI 0.62 (0.15) 0.64 (0.13) 0.64 (0.14)
PFWD = pain free walking distance, MWD = maximum walking distance, ABPI = ankle-brachial pressure
index, sd = standard deviation. Distances in meters. * Statistically significant difference (P < 0.05) compared




At baseline, patients' WHOQOL scores were significantly worse than those of sex- and age-
matched healthy controls on the facets Overall QOL and general health, Negative feelings,
Opportunities for acquiring new information and skills, Recreation and leisure, and the
domains Physical health and Level of independence (Table 3). Compared with healthy
persons and baseline results, the scores for the facets Positive feelings, Self-esteem, Sexual
activity, and the domain Social relationships had decreased significantly after six months.
During this interval, scores on the facet Mobility improved significantly. Between six and  12
months no significant QOL changes occurred.  After 12 months, the scores  for the facets Pain
and discomfort and Mobility were significantly better than at baseline, although still worse
than in healthy controls. The initial excess of Negative feelings, as indicated by the
claudicants at baseline and at six months, decreased to a non-significant difference with
healthy controls at 12 months.
Health status
The RAND-36 baseline scores of the patients with IC were significantly worse than those of
healthy controls on all domains, except Vitality and General health (Table 4). After six
months of conservative treatment, the scores for Bodily pain had improved significantly,
while those for General health had declined. Nevertheless, patients indicated a significant
positive Health change. Between   six   and 12 months, General health scores restored,    but
remained worse   than in healthy controls. After 12 months, the scores for Bodily   pain
remained significantly better than at baseline and the initial difference with healthy persons at
baseline disappeared. The scores for Vitality were comparable with those of the controls at
all assessments.
DISCUSSION
Encouraging exercise training and life style advice resulted in a substantial better walking
performance after six months. which persisted  at 12 months. This clinical benefit translated
into better scores for the WHOQOL facets Pain and discomfort and Mobility. The QOL
decrease in Positive feelings, Self-esteem, and Sexual activity, and the temporary drop in
RAND-36 General health illustrate the psychological effects of disease impact and the notion
to be a patient suffering from an incurable disease. The psychological adaptation to the new
situation is reflected in a slow QOL decline of Negative feelings to the level of healthy
controls, and a partial restoration ofthe RAND-36 General health score at 12 months.
Health status remained significantly impaired after  one  year of conservative treatment  with




Scores  on the reduced WHOOOL-100 domains and facets  in 76 patients treated conservatively for interm ittent
claudication
healthy patients patients patients             P
controls baseline 6 months 12 months
- Overall OOL and general health  16.0 (2.5) 14.4 (2.9)* 14.1 (2.6)* 14.2 (2.7)* ns
a. b
Physical health 15.4 (2.2) 13.6 (2.3)* 13.7 (2.5)* 13.7 (2.6)* ns
.b
- Pain and discomfort 9.1 (2.4) 12.0 (2.7)* 11.6 (2.9)* 11.2 (2.9)* 015 
- Energy and fatigue 15.3 (3.0) 13.1 (2.9)* 12.9 (3.2)* 12.8 (3.1)* ns
a.b
- Sleep and rest 16.1(3.6) 15.8(3.8) 15.7(4.1) 15.6 (4.1) ns
.b
Psychological liealth
- Positive feelings 14.5 (2.1) 13.9 (2.4) 13.3 (2.2)* 13.4 (2.3)* .Olga
- Thinking, learning, memor>      -                    -                    -                    -
and concentration
- Self-esteem 14.6 (2.6) 14.3 (2.8) 13.7 (2.2)* 14.0 (2.2) .0098
- Body image and appearance       -                     -                      -                     -
- Negative feelings 8.8 (2.9) 10.2 (3.2)* 10.0 (2.7)* 9.9 (3.2) ns
xb
Level of independence 16.7 (2.6) 13.4 (2.7)* 13.5 (2.9)* 13.4 (3.0)* ns
a.b
- Mobility 16.9(3.1) 11.9 (2.7)* 12.9 (3.3)* 12.8 (3.1)* .0078
- Activities of daily living 16.4 (2.9) 14.3 (3.1)* 14.0 (3.0)* 14.1 (2.8)* ns
a.h
- Dependence on medication
and treatments 6.9 (3.2) 10.3 (3.5)* 10.5 (3.6)* 10.5 (3.7)* ns
a.b
- Working capacity 16.4 (3.0) 13.6(3.8)* 13.4 (3.9)* 13.2 (3.9)* ns
a. b
Social relationships 15.2 (2.5) 14.9 (2.8) 14.3 (2.1)* 14.2 (2.0)* .043a
009
- Personal relationships 15.6 (2.4) 16.2 (3.1) 15.8 (2.7) 15.7 (2.4) ns
ab
- Social support                     -                                     -                  -
- Sexual activity 14.4 (3.6) 13.3 (3.5) 12.5 (3.3)* 12.5 (3.0)* .035'
·01 gb
Environment                                   -                          -                                                      -
- Physical safety and security        -                        -                        -                        -
- Home environment 16.2 (2.3) 16.0 (2.8) 15.4 (2.7) 15.6 (2.4) ns
ab
- Financial resources
- Health and social care   -
- Opportunities for acquiring
new information and skills 16.0 (2.5) 14.4 (2.6)* 14.4 (2.5)* 14.3 (2.7)* nsa. b
- Participation in and opportunities
for recreation/leisure 16.0 (2.8) 14.5 (3.2)* 14.6 (3.0)* 14.2 (2.9)* nsa-b
- Physical environment             -                                     -                  -
-Transpot 17.6 (2.6) 16.5 (3.5) 16.7 (3.5) 16.4 (3.1) ns
ab
Spirituality, religion, pers. beliefs -
Data are presented in terms of means and standard deviations. The scores on the facets Pain and discomfort.
Negative feelings and Dependence on medication and treatments are inverse. High scores reflect low QOL.
ns = not significant. * = statistically significant difference between healthy persons and patients (P < 0.05).
a = P-value for the difference between baseline and 6 months scores.




Scores on the RAND-36 domains in 76 patients treated conservatively for intermittent claudication
healthy patients patients patients Significance
controls baseline 6 months 12months
Physical functioning 67.6 (29.8) 54.5 (18.8)* 58.1 (23.0)* 60.5 (24.9)* nsa.b./
Social functioning 84.7 (23.0) 73.3 (26.3)* 74.6 (24.5)* 74.3 (26.0)* Ilsib.,
Role physical 74.0 (39.2) 52.4 (43.0)* 58.7 (40.0)* 54.1 (43.3)* ns'b..
Role emotional 87.7 (26.4) 72.8 (39.1)* 79.1 (83.3)* 64.9 (40.8)* n sab.:
Mental health 76.5 (17.0) 70.0 (18.7)* 69.2 (16.0)* 70.4 (19.3)* nsa.b.:
Vitality 63.2 (22.6) 59.5 (21.5) 58.9 (20.8) 60.1 (19.0) nsa.b.:
Bodily pain 75.7 (26.7) 58.8 (21.2)* 68.7(19.7)* 70.2 (21.4) P<.001:
P < .001 b
General health 62.6 (24.9) 58.0(19.8) 50.8 (18.4)* 55.7(17.3)* P = .0023
P =.008'
Health change 50.0 (22.7) 35.4 (20.0)* 46.2 (26.0) 46.4 (24.0) P =  .001.
P = .001 b
Data are presented in terms of means and standard deviations. ns: not significant
* = statistically significant difference between healthy persons and patients (P < 0.05).
a = P-value for the difference between baseline and 6 months scores.
b =  P-value for the difference between baseline and 12 months scores.
c =  P-value for the difference between 6 and 12 months scores.
Surprisingly. better walking, which would seem to be an essential aspect for patients with IC,
did not translate into better Physical functioning as measured with the RAND-36. This might
be explained by the questions of this domain that rather ask about restrictions to perform
activities of various intensity than evaluate walking abilities. In contrast. QOL measurement
did show significantly better scores   for the WHOQOL facet Mobility after   six   and    12
months. which illustrates the complementary value of subjective appraisal of functioning
compared with mere recording of functional limitations as in health status.
The present findings with respect to QOL and health status are in contrast with those of
Currie et al. who found no effects at all following non-supervised exercise training7. Some
studies showed minimal effects of conservative treatment , whereas Pell et al. described a10.32
further deterioration ofhealth status3: Differences in size ofthe patient groups, measures that
were used. compliance with the regimen. and duration of follow-up might be responsible for
the divergent outcomes. The modest effects on QOL and health status in the present study are
in contrast with the successful treatment in terms of walking performance. This is in
concordance with the finding that, in addition to the walking impairment. cardiovascular risk
factors and comorbidity have a major impact on QOL in patients with IC4. Moreover. it has
been shown that the clinical indicators of IC have a weak or no relationship with health status
and QOL3435, or only with certain aspects like Mobility4 and Physical Functioningg'36
Despite the fact that patients walked longer, recorded less pain (health status), experienced
less problems as a result of pain (QOL), and perceived a better mobility, most aspects of
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QOL and health status were unaffected by the walking benefits and remained significantly
worse than in healthy persons. This means that the QOL and health status benefits of
improved walking following conservative treatment are limited to pain and mobility.
Consequently, to focus on walking improvement only might be the wrong target to aim, if
QOL and health status are considered the main goals of treatment. In other words, patients
with IC may be treated successfully with respect to the walking impairment, but the
concurrent QOL and health status effects are limited. Since QOL is increasingly
recommended as the goal of treatment in patients with IC. it should be realised that current
treatment options for patients with IC are insu cient with respect to most of the QOL
impairments.
The persistent smoking habits as recorded suggest that a simple advise to stop smoking is not
enough and active support should be added to increase the effects ofconservative treatment.
Although no further improvements were recorded after six months, the initial effects of
conservative treatment on walking, QOL, and health status persisted for at least six additional
months. The practical implication of this finding may be that patients who attain an
acceptable walking distance, QOL, and health status after six months of conservative
treatment should be encouraged to continue exercise training. Patients who do not experience
su cient improvements after six months of conservative treatment are unlikely to benefit
from this form of treatment. As a consequence, invasive therapy may become the next
treatment option in these patients. However, if treatment aims not only to improve walking,
but also QOL of patients with IC, attention for risk factors and comorbidity, and
psychological and social support to accommodate with the impairments that are not relieved
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Traditionally, treatment efforts for patients with intermittent claudication (IC) have focused
on improvement of the walking distance. This seems rational with respect to the presenting
complaint, although the choice of therapy for individual patients may not always be evident.
The main problem is to find a balance between the patient's perception of disease, the
importance of additional manifestations of atheroscierosis and other comorbidity, and
treatment possibilities. In the past, little attention has been paid to subjective outcome
measures. However, in recent years, quality of life (QOL) assessment has been recommended
repetitively to supplement the imperfections of current management protocols for patients
with  ICI -5. Several attempts  have  been  made  to  meet this recommendation. Because  the  term
"QOL" has been used for different concepts - reports on QOL often concern health status -
study results. obtained with a variety of instruments, are difiicult to interpret and compare.
Health status usually expresses more or less objective assessments of functioning. which is
often erroneously equated  with good or bad QOL. Studies in which low levels of functioning
were paralleled by high-perceived QOL show that the one does not exclude the other6,7 This
means that  for the assessment  of QOL, the individual perception of disease and treatment not
only should be recorded, but also be evaluated by the patient. The World Health
Organisation (WHO) has defined QOL with an emphasis on subjective evaluation of
functioning and has instigated the development of a transcultural assessment instrument. the
WHO Quality of Life Assessment instrument-100 (WHOQOL-100)89. In the present study,
the Dutch version of this instrument 1' was used in patients with IC.  who were referred to  the
vascular outpatient clinic of the Department of Surgery at the St. Elisabeth Hospital in
Tilburg. The Netherlands, at first presentation and after a period of conservative treatment.
Health status was assessed with the RAND-36 , as recommended by the international11.12
vascular societies . Besides, the importance of walking impairment, usual risk factors. and4.5.13
comorbidity for the QOL of patients with IC was studied. The results show that IC has a
broad impact on QOL as defined by the WHO, that the walking problem is only of relative
importance. and that comorbidity has a major impact on QOL. Conservative treatment
appeared beneficial with regard to walking, mobility, and pain, but QOL and health status on
the whole remained substantially worse than in healthy controls.
CRITICAL REMARKS
How should a doctor approach the problem for which the patient consults him/her in daily
practice? According to the findings of this study, the patient's question for treatment of a
walking problem might almost be put aside. There are valid arguments to do nothing with
respect to the occluded blood vessels, and tell patients to walk (which they can not, due to
IC) and to live a healthier life (which, for a long time, they have not been able to).
Inadvertently, the initial demand for relief of symptoms has started a process to prevent
further deterioration of a systemic disease. Is this attitude fair to the patient? Does it
appreciate individual subjective QOL? With regard to the atherosclerotic threats to longevity.
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the answer is affirmative. However, the preseming symptom should not be disregarded in
view of the serious systemic complications of atherosclerosis. Because patients with IC
demand and will appreciate relief of their symptoms, efforts to improve walking, after
adequate modification of risk factors and treatment ofconcomitant disease, should be tailored
to the level  o f the individual patient, taking account  of personal abilities, needs, expectations,
and the physical situation. As has been shown in chapter 7, a single advice to stop smoking is
not effective, but repeated encouragement may have better results14 Similarly, exercise
training may be optimised with regular supportls. A "frapper toujours" approach towards
conservative treatment of patients with IC seems attractive, but will only succeed with the
help of family doctors and specialised supportive staff, and not in the last place partners,
family, and friends. A network close to the claudicant may be more adequate to provide
support on a day-to-day basis than a short hospital visit once or twice a year. This means that
claudicants who have been evaluated and treated for risk factors and concomitant disease.
and who respond well to conservative treatment should be discharged from clinical follow-
UP.
DRAWBACKS OF THE STUDY AND QUESTIONS TO BE ANSWERED
QOL scores have no units, like distances and weights, and can only be compared with
themselves. There are no "normal values" for QOL. However, extreme scores within a study
population indicate discrepancies from the average or "norm scores". Such sizeable
deviations of the mean scores of a healthy population are indicative for much better or worse
QOL. Summing scores from more than one person. however, eliminates individual values
and produces a distorted perspective of a non-existent average person, as pointed out by
Hunt 16. Except for the follow-up study in which paired t-tests were used, all results and
conclusions  in this study are based  on  the mean scores of patients and healthy controls. Since
individual variations are essential for QOL, a reserved attitude should be adopted towards
(these) scores that do not exclusively represent individual Q027 Unfortunately, individual
QOL at baseline can only be estimated against means from reference groups. The emcacy of
treatment with regard to an individual's QOL can more reliably be assessed by comparing
post-intervention scores with individual baseline scores.
It can be debated whether the recorded QOL improvements can be attributed to unsupervised
exercise training or even are related to improved walking at all. Response shift, which means
that the terms of reference by which QOL is judged change over time, may account for at
least  some of the improvements. Because QOL varies not only between individuals, but  also
within individuals across, success of treatment can also be explained by a downward
adjustment of wishes and expectations . In that case, improvements would not have to be18-20
less important from a patient's point of view, for it should be kept in mind that the recorded
QOL and health status improvements were obtained from the patients themselves. The up and
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down movement of health status and QOL scores during follow-up rellect adaptation to the
notion ofbeing a patient and may be regarded as an illustration ofthis phenomenon.
A difficult situation emerges if a self-confident patient makes the trade-off between risks to
life and comfort of walking, i.e. quantity versus quality of life. A demand for invasive
therapy to improve walking  may be beneficial for QOL, though at the cost of a few years life
expectancy if smoking and other unhealthy behaviour persist. For clinical relevance, the
goals  of treatment should agree  with the goals  of the patient.  Yet. the methods to achieve  the
goals should be acceptable  -  the  end  does not justify the means  -  and the results of treatment
should be relevant for the patientil. Persuasiveness and understanding of both parties are
required to serve functional improvement and future deterioration.
Based on the findings of this study, is seems reasonable to start with (unsupervised) exercise
training for six months in almost every patient with IC. It should be noted, however, that
conservative treatment  in this study mainly consisted of doing nothing  in the expectation that
the patient would start and proceed with exercise training. This policy probably comes close
to the natural course  o f IC. The possible benefits  o f a structured supervised exercise program
were not examined. Supervised exercise programs proved to be superior to non-supervised
programs with regard to walking performance, patiem reported walking ability, and physical
functioning . However, Patterson et al. in a study comparing supervised and home based
22.23
exercise programs concluded that a supervised program resulted in optimal walking benefits,
but a structured home-based program provided similar functional improvement and might be
24a satisfactory alternative for patients with lesser walking requirements  .
This study reported on the importance of walking, risk factors, and comorbidity for QOL in
patients with IC. In order to tailor treatment advice, it is relevant to know more about the
predictive value of patient characteristics  for the response to treatment. In other words, which
patients can be expected to improve after some form of treatment, and which cannot? Several
studies on patients with critical limb ischemia have shown that the preoperative functional
level and the patients' perception of functional status, health status, and well-being at
baseline are independent predictors of improved function and well-being after
revascularisation, even in the very elderly 5-28. The predictive value of patient characteristics
for treatment results may also contribute to a better treatment advice for claudicants. Since




FUTURE PROSPECTS. FURTHER STUDY, AND PRACTICAL CONSIDERATIONS
It is still too early for the wide implementation of QOL assessment in the clinical
management of patients with IC. A lot of missionary work has to be done to convince the
medical community of the value of QOL assessment  for the benefit of both the patient and
the doctor 9. Considering the gap between the traditional parameters for rating the severity of
IC and patient values, it seems no longer acceptable to exclude the latter from clinical
practice. However, the incorporation of QOL assessment in daily practice is a difficult and
time-consuming task for which there is hardly time in a busy outpatient clinic. Still. to assess
QOL in all patients with IC, it is necessary to develop short and simple questionnaires that
are relevant to the patient group, widely recognised, and easy to score. Questionnaires can be
(e-) mailed for home-completion or can be completed in the outpatient clinic. provided that
the recommended facilities as mentioned in chapter 3 are met. Swift calculation methods to
generate QOL profiles and reference values of different age groups,  that take risk factors and
comorbidity into consideration, should be available in a database to assure instant
interpretation of QOL, which allows guiding treatment in a way that corresponds with a
patient's wishes and expectations.
It is unnecessary to reinvent the wheel by developing disease-specific QOL measures, which
tend to focus on symptoms, rather than on the underlying disease30 Instead, generic
instruments are useful for monitoring patients with more than one condition and can be used
to compare patients with different conditions31. Moreover, it has been advocated to adapt
32.33instruments for specific patient populations from existing validated instruments
Regarding the discrepancy that appeared between health status and QOL in claudicants, it
seems unwise to persist in measuring QOL by means of health status instruments. no matter
how widely accepted, disease-specific, and validated. Only by recognising the importance of
personal, subjective evaluation of functional impairments and appreciation of aspects of life
that are not directly health-related, a picture will emerge of what is important for a patient.
Starting from the results of the present study, the next step will be a comparison of the
reduced PAOD version of the WHOQOL-100 with the instrument's validated short generic
version, the WHOQOL-bref. Subsequently, IC-specific facets can be attached to comply
with particular needs of the patient population. A study on the predictive value of patient
characteristics for the results of treatment should enable us to adjust treatment advice to the
individual patient. Since the proof of the pudding is in the eating, a study addressing the
results of treatment based on QOL assessment will reveal the real value of considering the
patient's point of view in clinical decision making. However, treatment advice based on QOL
assessment will always be limited by the patient's medical condition and technical
possibilities.
For the management of non-physical and practical QOL limitations that are encountered in
patients with IC, therapeutic options should be extended with less conventional means like
psychological methods to change life style and coping abilities, and to reduce negative
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feelings. Social interventions may assist to decrease problems that are experienced in leisure
activities and transport. The results of a study on personality characteristics and the
psychosocial context of PAOD patients are awaited to specify and support these aspects. The
feasibility of such an approach that. in addition to the traditional concept of "disease and
care", also takes account of the influence of individual aspects of illness through a "health
and behaviour" strategy has recently been described,5 Consequently, health care
professionals with specific capabilities are needed to support conventional medical care.
Physical therapists. nurse practitioners, psychologists. and social workers could contribute to
improve walking. to change lifestyle and acquired behaviour, and to adjust living conditions.
However. the transfer of non-medical tasks to other disciplines should not increase
therapeutic efforts and financial burden. but rather optimise treatment and reduce pressure on
surgical staff and hospital facilities. For, patients who are not satisfied with treatment results
are unlikely to refrain from medical services, whereas satisfied patients, even in the absence
of objective change in functional abilities, may become comfortable with their situation and
the way they have learned to live with limitations. Such an enterprise can only be successful
and mutual beneficial if academic and peripheral hospitals, social faculties, general
practitioners, patient organisations, and health insurance authorities collaborate.
CONCLUSION AND FINAL REMARKS
What does the present study add to the available knowledge on QOL in patients with IC and
what recommendations can be made?
-   For the first time. QOL. as defined by the WHO, has been measured in claudicants.
As a result,  a set  of baseline QOL data for patients with IC is available now.
-  The study provides an insight into the predictive value of walking limitation.
cardiovascular risk factors, and comorbidity for QOL in patients with IC.
-      The  results of a comparison between health status and  QOL in patients with IC stress
the importance of subjective evaluation in addition to mere functional assessment for
understanding and interpreting the influence of IC on patients' daily life.
-   The effects of conservative treatment on walking capacity, QOL, and health status
emerge in the first six months. Effects are limited to mobility and pain. Compared
with healthy persons, QOL and health status on the whole remain broadly impaired.
The present study is the first to report on QOL, as defined by the WHO. in patients with IC.
This means that the findings should be interpreted with caution, because a study can only be
appreciated if the results are reproducible. Based on these findings, it seems premature to
deduce definite guidelines. Nevertheless, the following suggestions can be made:
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-  The WHOQOL-100 should be further shortened and adapted, comprising disease-
specific aspects, to assist in clinical decision making for patients with IC.
-    Considering the relative importance of the walking limitation and the overwhelming
impact of comorbidity on QOL in patients with IC, a reserved attitude towards
invasive treatment is justified.
- Subjective evaluation of functional impairments should be directive in clinical
decision making in all patients with IC.
-    Patients who attain an acceptable level of performance, physical, psychological, and
social functioning, objectively and according to their own standards and expectations
after six months ofunsupervised exercise training, should be encouraged to continue.
-  Patients who consider treatment results to be insufficient after six months have an
indication for invasive treatment, provided that there are no medical contraindications
or objections with regard to QOL.
Future studies, as outlined above, should contribute to a better understanding of the
interaction between disease, functional impairments, repercussions on QOL and health status,
psychosocial context, and patient characteristics. Unravelling this highly individual network





1.    Joyce CRB. Health status and quality of life: 9. WHOQOL group (1995). The World Health
Which matters to the patient? J Cardiovasc Organization Quality of Life assessment
Pharmacol 1994:23(suppl.3):S26-S33 (WHOQOL): Position paper from the World
Health Organisation.  Soc Sci Med  1995:
2.   Rauwerda JA. Kasteleijn DGA, Van 41: 1403-1409
Oosterhout MJW. In: Vaatpatienten in beeld.
Hoofdstuk 2: Aanbeveling. Nederlandse 10.  De Vries J. Beyond health status.
Hartstichting. Den Haag, 1998 Construction and validation ofthe Dutch
WHO Quality of Life Assessment
3.   Golledge J. Garrat A. Greenhalgh RM, instrument. Doctoral dissertation. Tilburg:
Davies AH. Patient-assessed health outcome Tilburg University,  1996
in peripheral arterial disease. Eur J Vasc
Endovasc Surg 2000;19:109-110 11. Hays RD, Sherbourne CD, Mazel RM. The
RAND-36 item health survey 1.0. Health
4.McDaniel MD, Nehler MR, Santilli SM. et Econ 1993;2:217-227
al. Extended outcome assessment in the care
of vascular diseases: revising the paradigm 12. Van der Zee Kl, Sanderman R. Measuring
for the 21 st century. J  Vasc Surg general health status with the RAND-36: A
2000:32(6):1239-50 manual Groningen: Northern Centre for
Health Care Research; 1993
5.TASC working group. Treatment of
intermittent claudication. J Vasc Surg 13.  Chetter IC, Spark JI, Dolan P, Scott DJA.
2000:31: S77-S89 Kester RC. Quality of life analysis in
patients with lower limb ischaemia:
6.0'Boyle CA. The schedule for the Suggestions for European standardization.
evaluation of individual quality of life Eur J Vasc Endovasc Surg 1997;13:597-60
(SEIQoL). Int J Ment Health 1994:23:3-23
14.  Silagy C. Physician advice for smoking
7.Waldron D, O'Boyle CA, Kearny M, cessation. Cochrane Database Syst Rev.
Moriarty M, Carney D. Quality of life 2000;(2):CD000165
measurement in advanced cancer: Assessing
the individual. J Clin Oncol 1999;17:3603- 15. Gardner AW. Poehlman ET. Exercise
3611 rehabilitation programs for the treatment of
claudication pain. A meta-analysis. JAMA
8. WHOQOL group (1994). Development ofthe 1995 Sep 27.274(12):975-80




16.  Hunt SM. The problem with quality of life. 24. Patterson RB, Pinto B. Marcus B. Colucci A.
Qual Life Res 1997:6:205-212 Braun T. Roberts M. Value of a supervised
exercise program for the therapy of arterial
17. Testa MA, Simonson DC. Assessment of claudication. J Vasc Surg  1997
quality of life outcomes. Current Concepts Feb.25(2):312-8. discussion 318-9
1996:334:835-840
25. Nehler MR, Moneta GL, Edwards JM,
18. Allison PJ, Locker D, Feine JS. Quality of Yeager RA. Taylor LM. Porter JM. Surgery
life: a dynamic construct. Soc Sci Med 1997 for chronic lower limb ischemia in patients
Jul;45(2):221-30 eighty or more years of age: Operative
results and assessment of postoperative
19. Sprangers MA, Schwartz CE. Integrating independence. J Vasc Surg 1993:18:18-26
response shift into health-related quality of
life research: A theoretical model. Soc Sci 26. Gibbons GW, Burgess AM. Gusdagnoli E. et
Med 1999 Jun.48(11):1507-15 al. Return to well-being and function after
infrainguinal revascularisation. J Vasc Surg
20. Carr AJ, Bibson B, Robinson PG. Is quality 1995:21:35-45
of life determined by expectations or
experience? BMJ 2001;322:1240-1243 27. Abou-Zamzam AM, Lee RW, Moneta GL,
Taylor LM. Porter JM. Functional outcome
21. Ogles BM, Lunne KM. Bonesteel K. after infrainguinal bypass for limb salvage. J
Clinical significance: History, application Vasc Surg 1997.25:287-297
and current practice. Clin Psych Rev
2001.21:421-446 28.  Pomposelli FB, Arora S. Gibbons GW. et al.
Lower extremity arterial reconstruction in
22. Regensteiner JG, Meyer TJ. Krupski WC. the very elderly: Successful outcome
Cranford LS, Hiatt WR. Hospital versus preserves not only the limb but also resi-
home-based exercise rehabilitation for dential status and ambulatory function. J
patients with peripheral arterial occlusive Vasc Surg 1998,28:215-225
disease. Angiology  1997 Apr;48(4):291 -300
29.  De Vries J. Quality of life assessment.  In:
23. Gardner AW. Katzel LI, Sorkin JD. et al. Vingerhoets A.J.J.N. (ed.). Assessment in
Exercise rehabilitation improves functional behavioural medicine. Hove: Brunner-
outcomes and peripheral circulation in Routledge, 2001
patients with intermittent claudication: A
randomized controlled trial. J Am Geriatr 30.  Fraser SCA. Quality of life measurement in
Soc 2001 Jun.49(6):755-62 surgical practice. Br J Surg 1993:80:163-169
146
Chapter 8
3 1.  Stewart AL. Greenfield S, Hays RD et al.
Functional status and well-being of patients
with chronic conditions. JAMA
1989.262:907-913
32. Ware JE Jr. Standards for validating health
measures: Definition and content. J Chronic
Dis  1987;40(6):473-80
33. Aaronson NK. Quantitative issues in health-
related quality of life assessment. Health
Policy 1988,10(3):217-30
34. The WHOQOL Group. Development of the
World Health Organisation WHOQOL-
BREF quality of life assessment. Psychol
Med. 1998 May;28(3):551-8










Atherosclerosis is an incurable disease and most patients die of cardiac or cerebrovascular
complications. Peripheral arterial occlusive disease (PAOD) is caused by atherosclerosis and
intermittent claudication (IC) can be a first manifestation. Treatment of IC has usually been
focussed on the limited walking capacity rather than on the disease or on the patient. In spite
of the risks of atherosclerosis for life expectancy and the quality of remaining life, the
development of surgical techniques and interventional radiology have directed treatment of
IC predominantly to the restoration of blood flow. The appropriateness of such a policy
depends on the degree of the handicap, the relative impact of concomitant disease, and
patient characteristics. The severity of IC and the results of treatment are traditionally
expressed in terms of walking distance, ankle-brachial blood pressure indices. and patency.
Since IC, above all, affects functional abilities rather than bodily integrity or life expectancy.
an approach that takes account of the individual perception of illness, as a supplement to
traditional clinical end-points. is of particular importance for the understanding of disease
impact and the interpretation of treatment results. The current clinical parameters for the
assessment of IC do not provide such information. As a consequence, the appropriateness of
the traditional measures o f disease impact and treatment outcome, as mentioned above, must
be questioned with regard to the patients' view of illness. New methods should be developed
and used to assess disease severity and impact on daily life in patients who present with IC as
a symptom of PAOD. A way to assess the personal context of a patient is to use quality of
life (QOL) measures. This thesis is about  QOL in patients with IC and the role of risk factors
and comorbidity that are inherent to this particular patient group and might influence QOL.
Reports on QOL in patients with IC often concern health status rather than QOL. To avoid
confusion,  it is important to recognise health status as objective assessment of disease impact
on physical, psychological, and social functioning. QOL, as defined by the World Health
Organisation, is "an individual's perception of his/her position in life in the context of the
culture and value systems in which he/she lives and in relation to his/her goals, expectations,
standards, and concerns. It is a broad ranging concept incorporating in a complex way the
individual's physical health, psychological state, level of independence, social relationships,
personal belieB, and relationships to salient features in the environment".
Chapter 2 provides a comprehensive review of the definitions of the concepts that are
generally labelled as QOL, assessment instruments, and results of studies in patients with IC.
The  accumulated  data give a picture of the broad impact  of IC on daily life. Increasing IC  is
mainly responsible for the deterioration of physical aspects of QOL. Treatment may alleviate
symptoms and improve aspects of physical functioning. However, QOL levels after treatment
hardly ever approach those  of a non-diseased population. The enthusiasm for measuring QOL
before and after treatment in patients with IC is in contrast with the disappointing lack of
reports on the incorporation of QOL measures as guidelines in clinical practice.
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A  pilot-study  with the World Health Organisation Quality  o f Life Assessment instrument-100
(WHOQOL-100) was conducted in 22 patients with varying degrees of lower limb ischemia
to investigate its suitability for the assessment of QOL in patients with PAOD. The
instrument was chosen because the concept comes most closely to the WHO definition of
QOL. Another aim was to reduce patient burden of completing the full WHOQOL-100 by
limiting the instrument to aspects that provide relevant information for this particular patient
group. Because of the established value of assessing health status (or health-related QOL) in
patients with PAOD and the popularity of the instrument, the RAND-36 was also administered
to the patients. Finally, the actual process ofcompleting the questionnaires was studied.
Both instruments were tested. by means of parameters for response distribution and internal
consistency. Because a broad range of ischemia was required to obtain a range of answers. it
was decided to include patients with chronic critical and non-critical lower limb ischaemia.
The results of the pilot-study, as described in chapter 3, show that the WHOQOL-100 is a
satisfactory instrument for QOL assessment in PAOD patients. The instrumem could be reduced
to  16  out  of the original 25 facets covering the domains Physical health.  Psychological health.
Level of independence, Social relationships, and Environment, and the generic evaluative
facet Overall QOL and general health. Despite flaws with regard to the response distribution
of some questions, the RAND-36 was not reduced, because it is already short and widely
accepted throughout the medical community. Recommendations were made to overcome
practical problems that were encountered in completing the questionnaires by predominantly
elderly patients.
In the literature on QOL in patients with IC. the terms health status and QOL are often used
without further explanation. In chapter 4, an attempt is made to describes similarities and
differences between health status and QOL, based on data that were collected in 200 patients
with IC, who completed the RAND-36 and the reduced version ofthe WHOQOL-100.
There was agreement between the results of both assessments with regard to physical
limitations, but not for Social functioning and Pain. Patients with low scores on the RAND-
36 domains Social functioning and Bodily pain not necessarily felt socially impaired or
experienced pain as a major problem in daily life as indicated in the WHOQOL. QOL
assessment disclosed the background of impairments in the RAND-36 domains Mental health
and General health perception. The evaluation of non-health-related aspects and
environmental factors, as incorporated in the WHOQOL, revealed problems that otherwise
would have been missed. Based on the comparison of health status and QOL scores in
patients with IC, it was concluded that subjective evaluation of QOL dimensions offers an
additional value to mere recording of functional impairments. QOL assessment without
taking account of the claudicants' subjective opinion may be misleading and carries the risk
to direct treatment efforts at the wrong targets.
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The first study (chapter 5) that addressed QOL, as defined by the WHO, in patients with IC,
demonstrated a significant impact of IC on a broad range of QOL facets and domains.
Patients evaluated their functioning significantly worse than healthy persons with regard to
Physical health and Level of independence. In addition, patients experienced more negative
feelings and reported limitations in the environmental domain. Finally, Overall QOL and
general health were significantly worse than in healthy controls. The finding that increasing
claudication only affected the facet Mobility suggests that successful treatment in terms of
improving the walking distance may have a limited effect on QOL on the whole. The
significant dependence on medication and treatments is not directly related to impaired
walking and suggests a major impact of comorbidity on QOL.
This challenging finding was investigated in a study, described in chapter 6. on the predictive
value of demographic variables. the severity of IC, cardiovascular risk factors and
comorbidity. and the presence of non-vascular back, hip, or knee symptoms for QOL in
patients with IC. Surprisingly, the presence of non-vascular joint complaints had an
overwhelming predictive value for many aspects of QOL. With more concomitant diseases,
patients had a worse overall QOL and general health, had lower scores for the facet Energy
and  fatigue,  and  felt more dependent on medication and treatments. The severity of IC  was a
statistically significant predictor  of QOL  for the facets Mobility, Activities of daily living and
Working capacity, as well as the facets Pain and discomfort, Sexual activity, and Transport.
In conclusion, the study revealed that QOL in patients with IC is only partially determined by
the severity of IC and that the importance of cardiovascular risk factors, comorbidity, and the
presence of back, hip, or knee symptoms should be recognised and taken into account in the
treatment policy.
The relatively modest importance of the walking problem and the significant impact of
comorbidity on QOL in patients with IC seem to rationalize the reserved attitude towards
invasive treatment, as currently recommended. To explore the effects on QOL, health status,
and walking capacity. a follow-up study was performed in patients. who were treated
conservatively (chapter 7). After a year of the most basic form ofconservative treatment,  i.e.,
Housley's principle "stop smoking and keep walking", walking performance improved
significantly. Improvements with regard to the facets Mobility and Pain and discomfort
(reduced WHOQOL) and Bodily pain (RAND-36) paralleled the walking benefits. It was
remarkable that the changes in walking capacity, QOL, and health status all took place in the
first six months, and remained at that level for at least six additional months. To get an
impression of the relative importance of QOL and health status changes, scores were
compared with those of age and sex-matched healthy persons. QOL scores did not reach the
level of healthy controls, but conversely dropped significantly for the facet Positive feelings
after   six  and 12 months, compared with healthy controls. The initial excess of negative
feelings in patients with IC gradually decreased to a level that compared with healthy
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controls. After a year, RAND-36 Bodily pain scores approached the level of healthy
individuals. Despite improved walking, QOL and health status remained largely impaired
after one year of conservative treatment, confirming the conclusions in chapters 5 and 6 that
QOL impairments in patients with IC carl only partially be attributed to impaired walking. It
was concluded that patients who attain an acceptable walking capacity, QOL, and health
status after six months may be encouraged to continue unsupervised exercise training. In
contrast, patients who do not experience sufficient improvements after six months are
unlikely to benefit from this form of treatment. As a consequence, invasive therapy may
become the next treatment option. However, if treatment aims not only to improve walking,
but also the QOL of patients with IC, modification of risk factors, treatment of comorbidity,
and psychological and social support to accommodate with the impairments that are inherent
to IC and not relieved by better walking may offer important benefits.
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Atherosclerose is een ongeneeslijke ziekte, die leidt tot vernauwing en afsluiting van
slagaders in alle delen van het lichaam, waardoor organen onvoldoende van zuurstofrijk
bloed worden voorzien. De kransslagaderen van het hart, de halsslagaderen en de slagaderen
naar de benen zijn het vaakst aangetast. De meeste patienten met atherosclerose overluden
aan een hartinfarct  of een beroerte. Zeer slechte doorbloeding van de onderste ledematen kan
tot verlies van een been leiden, maar dit komt weinig voor. In minder ernstige gevallen
ontstaat  na het lopen van een bepaalde afstand pijn in de benen, die verdwijnt wanneer
gedurende enkele minuten rust wordt genomen. Dit ziektebeeld heet claudicatio intermittens
(CI) of"een etalagebeen". Alhoewel CI dus een milde uiting is van atherosclerose, is het een
teken van vaatlijden met potentieel levensbedreigende complicaties in andere organen. CI is
dus een mild symptoom van een ernstige ziekte. De ontwikkelingen van vaatchirurgie
(bypasses) en radiologie ("Dotteren") hebben ertoe geleid dat de behandeling van CI vooral
gericht is op het herstel van doorbloeding en niet zozeer op de atherosclerotische risico's
voor de levensverwachting en de kwaliteit van het resterend leven. De juistheid van een
dergelijke benadering hangt af van de ernst van de handicap, het relatieve belang van andere
aandoeningen en kenmerken van de patient. De ernst van CI en de resultaten van behandeling
worden traditioneel uitgedrukt in (verbetering van) de loopafstand, de enkel-arm index (een
maat voor de doorbloeding van de benen) en de duurzaamheid van het resultaat van operaties
en Dotterbehandelingen. De patient met CI wordt vooral beperkt in zijn/haar functionele
mogelijkheden als gevolg van de loopbeperking en veel voorkomende nevenaandoeningen
(hoge bloeddruk, hartklachten, suikerziekle, longaandoeningen, nierziekten, etc.). IIoewel het
risico om een been te verliezen klein is, vormt het onderliggend lijden„ atherosclerose, een
reele bedreiging voor de levensverwachting. De behandeling van patienten met CI dient
daarom niet alleen gericht te zijn op het verbeteren van de loopafstand, maar met name ook
op de risicofactoren van atherosclerose (roken, cholesterol, gewicht) en nevenaandoeningen.
Omdat de behandeling dus symptomatisch is ten aanzien van de loopbeperking en palliatief
ten aanzien van het onderliggend lijden, is het van belang om naast de traditionele, klinische
meetgegevens ook rekening te houden met de wijze waarop CI en de gevolgen van
behandeling door de individuele patient ervaren worden. Omdat de huidige, klinische
parameters die informatie niet geven, dienen er nieuwe methoden ontwikkeld en gebruikt te
worden die rekening houden met het perspectief van de patient met CI als manifestatie van
atherosclerotisch vaatlijden. Het meten van kwaliteit van leven (KvL) is een methode om dit
perspectief te evalueren. Dit proefschrift gaat over KvL bij patienten met CI en de rol die
risicofactoren en nevenaandoeningen daarbij spelen.
De publicaties over KvL bij patienten met CI gaan vaak over gezondheidstoestand in plaats
van over KvL. Voor een juiste interpretatie is belangrijk de concepten goed te onderscheiden.
Gezondheidstoestand is de objectieve waarneming van lichamelijk, geestelijk en sociaal
functioneren. Door de Wereld Gezondheidsorganisatie (WHO) is KvL gedefinieerd als "de
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waarneming die een individu heeft van zijn/haar positie in het leven, gezien in de context van
de cultuur en de waardesystemen waarin hij/zij leeft en in relatie tot zijn/haar doelen.
verwachtingen, normen en zorgen. Het is een breed concept dat op complexe wijze de
individuele lichamelijke gezondheid, psychologische toestand, mate van onafhankelijkheid,
sociale relaties, persoonlijke overtuigingen en verhouding tot omgevingsfactoren verenigt".
Eenvoudig gezegd: KvL meet niet alleen functionele tekortkomingen, maar ook hoe die
individueel ervaren worden. Bovendien houdt KvL ook rekening met omgevingsfactoren en
met aspecten die niet direct gerelateerd zijn aan gezondheid.
Hoofdstuk 2 geeft, naast een overzicht van de definities van functionele toestand,
gezondheidstoestand, KvL en respectieve meetinstrumenten, de resultaten van studies over
KvL bij patienten met CI. Uit het overzicht blijkt dat CI het dagelijks leven van de patient in
brede zin bernvloed. Toenemende CI leidt vooral tot verslechtering van de lichamelijke
aspecten van KvL, terwijl behandeling tot verlichting van symptomen en beter lichamelijk
functioneren kan leiden. Echter, het niveau van KvL na behandeling benadert slechts zelden
het niveau van de gezonde bevolking. Ondanks de aandacht voor het onderwerp.
weerspiegeld in een groot aantal publicaties over KvL voor en na behandeling, zijn er
eigenlijk geen studies verschenen waarin KvL metingen gebruikt worden als richtlijn voor de
klinische praktijk.
In een vooronderzoek werd, aan de hand van 22 patienten met doorbloedingsstoornissen van
de benen, de geschiktheid van de World Health Organisation Quality of Life Assessment
Instrument-100 (WHOQOL-100) voor het meten van KvL bij patienten met perifeer
vernauwend vaatlijden bestudeerd. De WHOQOL-100 meet 24 facetten van KvL op zes
domeinen (Lichamelijke en Psychologische gezondheid, Mate van onafhankelijkheid, Sociale
relaties, Omgeving en Spiritualiteit) en een evaluerend facet Algemene KvL en gezondheid.
Het instrument werd gekozen omdat het concept ervan de WHO-definitie van KvL het dichtst
benadert. Het tweede doel van het vooronderzoek was de belasting, die het invullen van de
volledige vragenlijst voor de patient betekent, terug te brengen door het instrument te
beperken tot aspecten die. voor de betreflende patientengroep, relevante informatie
verschaffen. Vanwege de gevestigde waarde die het meten van gezondheidstoestand bij
patienten met vernauwend vaatlijden heeft en de populariteit van het meetinstrument, is de
RAND-36 eveneens aan de deelnemers voorgelegd. De RAND-36 is een instrument dat aan
de hand van 36 vragen de gezondheidstoestand meet op acht domeinen (Fysiek functioneren,
Sociaal Functioneren, Rolbeperkingen als gevolg van lichameluke problemell, Rolbeperkingen
als gevolg van emotionele problemen, Mentale gezondheid, Vitaliteit, Pijn en Algemene
gezondheidsbeleving). Tevens worden gezondheidsveranderingen gedurende het voorgaande
jaar geevalueerd. Tenslotte is het eigenlijke invullen van de vragenlijsten door de patienten
door middel van observatie bestudeerd.
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Beide meetinstrumenten zijn getest aan de hand van parameters voor de verdeling van
antwoorden en interne consistentie. een maat voor de betrouwbaarheid van een instrument.
Omdat voor een grote verscheidenheid van antwoorden een grote variatie in de ernst van het
vaatlijden vereist was, is er voor gekozen om zowel patienten met ernstig vaatlijden. een
bedreigd been, als patienten met minder ernstige klachten, het etalagebeen, in de studie op te
nemen. De resultaten van het vooronderzoek, zoals beschreven in hoofdstuk 3. tonen dat de
WHOQOL-100 voldoet voor het meten van KvL bij patienten met vernauwend vaatlijden.
Het    instrument kon teruggebracht worden   tot    16   van de oorspronkelijke 24 facetten
betreffende de domeinen Lichamelijke gezondheid, Psychologische gezondheid, Mate van
onafhankelijkheid, Sociale relaties, Omgeving en het evaluerende facet Algemene KvL en
gezondheid. Hoewel de verdeling van antwoorden niet bevredigend was voor alle vragen van
de RAND-36 is dit instrument niet gereduceerd, enerzijds omdat het al kort is en anderzijds
omdat het reeds op grote schaal geaccepteerd is en gebruikt wordt. Tot slot zijn er
aanbevelingen gedaan met betrekking tot praktische problemen die naar voren kwamen
tijdens het invullen van de vragenlijsten door voornamelijk oudere patienten.
In de literatuur over KvL bij patienten met CI worden de termen gezondheidstoestand en
KvL vaak zonder verdere toelichting gebruikt. In hoofdstuk 4 wordt getracht overeenkomsten
en verschillen tussen gezondheidstoestand en KvL te beschrijven op basis van gegevens van
de RAND-36 en de verkorte versie van de WHOQOL-100, zoals ingevuld door 200 patienten
met CI. De resultaten van beide instrumenten kwamen overeen met betrekking tot
lichamelijke beperkingen, maar niet voor wat betreft sociaal functioneren en pijn. Patienten
met lage scores voor de RAND-36 domeinen Sociaal functioneren en Pijn bleken zich niet
noodzakelijkerwijs ook sociaal beperkt te voelen of pijn als een groot probleem in het
dagelijks leven te ervaren, zoals aangegeven in de WHOQOL. KvL meting gaf inzicht in de
achtergronden van beperkingen zoals aangegeven in de RAND-36 domeinen Mentale
gezondheid en Algemene gezondheidsbeleving. De evaluatie van omgevingsfactoren en van
aspecten die niet direct aan gezondheid gerelateerd zijn, zoals opgenomen in de WHOQOL,
bracht problemen aan het licht die in de gezondheidstoestand niet teruggevonden kunnen
worden. Op basis van de vergelijking tussen KvL en gezondheidstoestand bij patienten met
CI is geconcludeerd dat de subjectieve evaluatie van KvL domeinen een toegevoegde waarde
heeft ten opzichte van het louter registreren van functionele beperkingen. KvL meting
zonder rekening te houden met individuele waarden van de patient met CI kan misleidend
zijn en heeft het risico dat behandeling zich op verkeerde doelen richt.
De eerste publicatie (hoofdstuk 5) over CI en KvL, zoals gedefinieerd door de WHO, toonde
een belangrijke invioed van CI op een scala van KvL facetten en domeinen. Patienten
evalueerden hun functioneren aanzienlijk slechter dan gezonden voor de domeinen
Lichamelijke gezondheid en Mate van onafhankelijkheid. Bovendien ervoeren zij meer
negatieve gevoeiens en waren er beperkingen ten aanzien van recreatiemogelijkheden en
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vervoer. Algemene KvL en gezondheid waren beduidend slechter dan bij gezonden.
Verslechtering van CI bleek alleen van invloed op de score voor het facet Mobiliteit. De ernst
van de overige KvL beperkingen was onafhankelijk van de ernst van CI. Dit suggereert dat
succesvolle behandeling van CI, in de zin van een grotere loopafstand, slechts van beperkte
betekenis zou zijn voor de algehele KvL. De grote afhankelijkheid van medicatie en
behandelingen is niet direct gerelateerd aan de loopafstand en doet vermoeden dat
nevenaandoeningen een belangrijke invloed hebben op de KvL van patienten met CI.
Deze verrassende bevinding werd nader onderzocht in een studie naar de voorspellende
waarde van de demografische variabelen leeftijd en geslacht, de ernst van de claudicatie,
bekende risicofactoren voor hart- en vaatziekten, veel voorkomende nevenaandoeningen en
de aanwezigheid van niet door vaatlijden veroorzaakte rug-, heup- en knieklachten.
Het bleek dat de gewrichtsklachten een enorme invloed hadden op vele aspecten van KvL.
Patienten met meer nevenaandoeningen hadden een slechtere algemene KvL, minder energie
en voelden zich toenemend afhankelijk van medicatie en behandelingen. De ernst van de
claudicatie was een statistisch significante voorspeller van KvL voor de WHOQOL facetten
Mobiliteit, Alledaagse levensactiviteiten, Werkvermogen, Pijn en ongemak, Seksuele
activiteit en Vervoer. Samenvattend heeft de studie aangetoond dat KvL bij patienten met CI
slechts ten dele wordt bepaald door de ernst van de loopbeperking. Gezien het grote belang
van risicofactoren, nevenaandoeningen en bijkomende gewrichtsklachten voor KvL, dient bij
het opstellen van een behandelplan voor de patient met CI met deze factoren rekening
gehouden te worden.
De relatief bescheiden rol van de loopbeperking en de grote invloed van nevenaandoeningen
op de KvL bij patienten met CI lijken de terughoudendheid ten aanzien van chirurgische of
endovasculaire behandeling, zoals tegenwoordig aanbevolen, te rechtvaardigen. Om de
effecten op KvL, gezondheidstoestand en loopafstand te beoordelen, is een vervolgstudie
gedaan bij patienten met CI die conservatief zijn behandeld (hoofdstuk 7). Na een jaar van de
meest basale vorm van conservatieve behandeling,"niet roken, maar lopen", bleek de
loopafstand aanzienlijk toegenomen te zijn. Tegelijkertijd traden er verbeteringen op voor de
facetten Mobiliteit en Pijn en ongemak (verkorte WHOQOL-100) en het domein Pijn
(RAND-36). Het viel op dat de veranderingen in loopafstand, KvL en gezondheidstoestand
zich alle voltrokken in de eerste zes maanden van de behandeling, waarna de scores zich
gedurende minstens zes maanden op dat niveau handhaafden. Om een indruk te krijgen van
het relatieve belang van de veranderende scores voor KvL en gezondheidstoestand, werden
deze vergeleken met die van in leeftijd en geslacht overeenkomende gezonde personen. KvL
scores bereikten het niveau van gezonden niet, maar daalden zelfs belangrijk voor het facet
Positieve gevoelens, zowel na zes maanden als na een jaar, vergeleken met gezonden. De
aanvankelijke overmaat aan negatieve gevoelens bij patienten met CI nam geleidelijk af tot
het niveau van gezonden. De scores voor het RAND-36 domein Pijn benaderden na een jaar
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wel het niveau van gezonden. Ondanks een sterk verbeterde loopafstand bleven er na een jaar
conservatieve behandeling onverminderd beperkingen ten aanzien van de KvL en de
gezondheidstoestand. Dit bevestigt de conclusies van de hoofdstukken 5 en 6 dat een
slechtere KvL bij patienten met CI slechts ten dele toegeschreven kan worden aan een
beperkt loopvermogen. Daarom kunnen patienten, die een acceptabele loopafstand, KvL en
gezondheidstoestand bereiken na zes maanden conservatieve behandeling. aangemoedigd
worden om hiermee door te gaan. Bij patienten die na zes maan(len onvoldoende verbetering
ervaren is het onwaarschijnlijk dat deze behandelingsvorm baat gaat geven. Een volgende
stap zou dan een Dotterbehandeling of bypassoperatie kunnen zijn, vooropgesteld dat de
omstandigheden dat toelaten. Indien echter het doel van de behandeling niet beperkt blijft tot
het verbeteren van de loopafstand, maar ook gericht is op de KvL van patienten met CI.
kunnen behandeling van risicofactoren en nevenaandoeningen, maar ook psychologische en
sociale steun gericht op beperkingen die niet verbeterd worden door een grotere loopafstand,
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- facet 0 Algehele kwaliteit van leven en gezondheid
Domein I Lichamelijke gezondheid
- facet 1 Pijn en ongemak
- facet 2 Energie en vermoeidheid
- facet 3 Slaap en rust
- Domein II Psychologische gezondheid
- fheet 4 Positieve gevoelens
- 8cet 5 Cognitieve vermogens
- facet 6 Zelfwaardering
- facet 7 Lichaamsbeeld en uiterlijk
- facet 8 Negatieve gevoelens
- Domein III   Mate van onalhankelijkheid
- facet 9 Mobiliteit
-  facet 10 Alledaagse levensactiviteiten
-lacet 11 Afhankelijkheid van medicatie en behandelingen
-  facet 12 Werkvermogen
-Domein IV Sociale relaties
- facet 13 Persoonlijke relaties
-  facet 14 Sociale steun
- facet 15 Sexuele activiteit
-Domein V Omgeving
-  facet 16 Fysieke veiligheid
- facet 17 Woonomgeving
ket 18 Financiele bronnen
- facet 19 Beschikbaarheid en kwaliteit van gezondheidszorg
- facet 20 Mogelijkheden om nieuwe informatie en vaardigheden te verwerven
- facet 21 Recreatie/ vrije tijd
- facet 22 Fysieke omgeving (vervuiling, lawaai verkeer, klimaat)
- facet 23 Vervoer








Wij vragen u om in deze vragenlijst aan te geven wat u vindt van uw kwaliteit van leven, gezondheid
en andere levensgebieden. Beantwoord alstublieft alle vragen. Als u onzeker bent over het antwoord
dat u wilt geven op een vraag, kies dan het antwoord dat het meest toepasselijk lijkt. Dit kan vaak uw
eerste reactie zun.
Houd uw normen, hoop, genoegens en zorgen in gedachten. We vragen u te denken aan uw leven in
de afgelopen twee weken.
Bijvoorbeeld, met betrekking tot de laatste twee weken, zou een vraag kunnen luiden:
Hoeveel zorgen maakt u zich over uw gezondheid?
Helemaal Weinig Middelmatig Hevig Een extreme
niet hoeveelheid
1               2                   3                 4                   5
U moet het cijfer omcirkelen dat het beste past bij hoe vaak u zich in de afgelopen twee weken zorgen
heeft gemaakt over uw gezondheid. Dus u moet het cijfer 4 omcirkelen, als u zich veel ("Hevig")
zorgen heeft gemaakt over uw gezondheid,  of het cijfer  1  "Helemaal Niet" als u zich helemaal geen
zorgen heeft gemaakt over uw gezondheid. Leest u alstublieft elke vraag, ga uw gevoelens na en
omcirkel voor elke vraag het cijfer van de schaal dat het beste bij u past.
Dank u voor uw hulp.
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In de volgende vragen wordt gevraagd in welke mate (hoeveel) u in de afgelopen twee
weken bepaalde dingen hebt ervaren, bijvoorbeeld positieve gevoelens zoals geluk en
tevredenheid. Als u deze in een extreme hoeveelheid hebt ervaren, omcirkel dan het cijfer 5
onder "Een Extreme Hoeveelheid". Als u dergelijke zaken helemaal niet hebt ervaren,
omcirkel dan het cofer 1 onder "Helemaal Niet". De tussenliggende cijfers kunt u gebruiken
om aan te geven dat het ergens tussen "Helemaal Niet" en "Helemaal" in ligt. Vragen
verwijzen naar de afgelopen twee weken.
Fl.2 Maakt u zich zorgen over uw pijn  of ongemak?
Helemaal Weinig Middelmatig Hevig Een extreme
niet hoeveelheid
1              2              3                4               5
Fl.3 Hoe  moeilijk is  het voor  u  om  om  te  gaan  met pijn  of ongemak?
Helemaal Bijna Gemiddeld Nogal Helemaal
niet niet
12345
Fl.4 In welke mate vindt u dat pijn u ajhoudt van wat u moet doen?
Helemaal Weinig Middelmatig Hevig Een extreme
niet hoeveelheid
1             2            3                 4             5
Fl.1 Hoe gemakkelijk raakt u vermoeid?
Helemaal Bijna Gemiddeld Nogal Helemaal
niet niet
1 2 3 4 5
F3.2 In welke mate hebt u problemen met slapen?
Helemaal Weinig Middelmatig Hevig Een extreme
Niet hoeveelheid
12345
F3.4 Hoeveel zorgen maakt u zich over enigerlei problemen met slapen?





F4.1 Hoeveel geniet u van het leven?
Helemaal Weinig Middelmatig Hevig Een extreme
niet hoeveelheid
12345
F4.3 Hoe  positief ziet  u uw  toekomst?
Helemaal Bijna Gemiddeld Nogal Helemaal
niet niet
1 2 3 4 5
F4.4 Hoezeer ervaart u positieve gevoelens in uw leven?
Helemaal Weinig Middelmatig Hevig Een extreme
niet hoeveelheid
12345
F5.3 Hoe goed kunt u zich concentreren?
Helemaal Bijna Gemiddeld Nogal Helemaal
niet niet
1 2 3 4 5
F6. I Heeft u waardering voor uzelf?
Helemaal Weinig Middelmatig Hevig Een extreme
niet hoeveelheid
1              2              3                4              5
F6.2 Hoeveel vertrouwen hebt u in uzelf?
Helemaal Weinig Middelmatig Hevig Een extreme
niet hoeveelheid
12345
F7.2 Voelt u zich geremd door uw uiterlijk?
Helemaal Bijna Gemiddeld Nogal Helemaal
niet niet
1 2 3 4 5
F7.3 Is er iets in uw uiterlijk op grond waarvan u zich ongemakkelijk voelt?
Helemaal Weinig Middelmatig Hevig Een extreme
Niet hoeveelheid
1 2 3 4 5
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F8.2 Hoe bezorgd voelt u zich?
Helemaal Bijna Gemiddeld Nogal Helemaal
niet niet
1 2 3 4 5
F8.3 Hoezeer verstoren  gevoelens van droefheid of depressie uw alledaagse
functioneren?
Helemaal Weinig Middelmatig Hevig Een extreme
niet hoeveelheid
1              2              3                4              5
F8.4 Hoeveel last hebt u van depressieve gevoelens?
Helemaal Weinig Middelmatig Hevig Een extreme
niet hoeveelheid
12345
F10.2 In welke mate hebt u moeilijkheden met het doen van uw routine-activiteiten?
Helemaal Weinig Middelmatig Hevig Een extreme
niet hoeveelheid
12345
FIO.4 Hoeveel hinder ondervindt u van allerlei beperkingen in het doen van
alledaagse levensactiviteiten?
Helemaal Weinig Middelmatig Hevig Een extreme
Niet hoeveelheid
12345
Fll.2 Hoeveel behoefte hebt u aan enigerlei medicatie om in uw dagelijkse leven te
kunnen functioneren?
Helemaal Weinig Middelmatig Hevig Een extreme
niet hoeveelheid
12345
FII.3 Hoeveel behoefte hebt u aan medische behandeling om in uw dagelijkse leven
te  kunnen functioneren?





Fll.4 In welke mate hangt uw kwaliteit van leven afvan het gebruik van medicijnen
of medische hulpmiddelen?
Helemaal Weinig Middelmatig Hevig Een extreme
niet hoeveelheid
12345
F13.1 Hoe alleen voelt u zich in uw leven?
Helemaal Bijna Gemiddeld Nogal Helemaal
niet niet
12345
F15.2 Hoe goed zijn uw seksuele behoeften vervuld?
Helemaal Bijna Gemiddeld Nogal Helemaal
Niet niet
12345
F16.1 Hoe veilig voelt u zich in uw dagelijkse leven?
Helemaal Bijna Gemiddeld Nogal Helemaal
niet niet
1 2 3 4 5
F16.2 Vindt u dat u in een veilige omgeving woont?
Helemaal Bijna Gemiddeld Nogal Helemaal
niet niet
1 2 3 4 5
F16.3 Hoeveel zorgen maakt u zich over uw veiligheid?
Helemaal Weinig Middelmatig Hevig Een extreme
niet hoeveelheid
1 2 3 4 5
F17.4 Hoe erg bevalt het u waar u woont?





F18.2 Hebt u financiele moeilijkheden?
Helemaal Weinig Middelmatig Hevig Een extreme
niet hoeveelheid
1              2              3                4              5
F18.4 Hoeveel zorgen maakt u zich over geld?
Helemaal Weinig Middelmatig Hevig Een extreme
niet hoeveelheid
1             2             3               4             5
F19.1 Hoe gemakkelijk kum u goede medische zorg krijgen?
Helemaal Bijna Gemiddeld Nogal Helemaal
niet niet
1 2 3 4 5
F21.3 Hoeveel geniet u van uw wije tijd?
Helemaal Weinig Middelmatig Hevig Een extreme
niet hoeveelheid
1               2               3                4               5
F22.1 Hoe gezond is uw omgeving?
Helemaal Weinig Middelmatig Hevig Een extreme
niet hoeveelheid
1             2             3                4            5
F22.2 Hoeveel zorgen heeft u over het lawaai in het gebied waarin u woont?
Helemaal Weinig Middelmatig Hevig Een extreme
niet hoeveelheid
1              2              3                4                5
F23.2 In welke mate hebt u problemen met vervoer?
Helemaal Weinig Middelmatig Hevig Een extreme
niet hoeveelheid
1               2              3                4                5
F23.4 Hoe erg beperken moeilijkheden met vervoer uw leven?
Helemaal Weinig Middelmatig Hevig Een extreme
niet hoeveelheid
1              2              3                4                5
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Fl.4 Heeft u last van vermoeidheid?
Helemaal Weinig Middelmatig Hevig Een extreme
niet hoeveelheid
12345
F15.4 Heeft u last van moeilijkheden in uw seksleven?
Helemaal Weinig Middelmatig Hevig Een extreme
niet hoeveelheid
12345
In de volgende vragen wordt gevraagd naar de mate waarin u bepaalde dingen ervaart ofin
staat was te doen in de afgelopen twee weken, bijvoorbeeld alledaagse activiteiten zoals
wassen, aankleden of eten.  Als u in staat bent geweest deze dingen helemaal te  doen,
omcirkel dan het cijfer 5 onder "Helemaal". Als u niet in staat bent geweest om al deze
dingen te doen, omcirkel dan het cijfer 1 onder "Helemaal niet". De tussenliggende cijfers
kunt u gebruiken om aan te geven dat het ergens tussen "Helemaal Niet" en "Helemaal" in
ligt. Vragen verwijzen naar de afgelopen twee weken.
F2.1 Hebt u genoeg energie voor het leven van alledag?
Helemaal Bijna Gemiddeld Nogal Helemaal
niet nlet
1 2 3 4 5
F7.1 Kunt u uw lichamelijke uiterlijk accepteren?
Helemaal Bijna Gemiddeld Nogal Helemaal
niet niet
1 2 3 4 5
FIO. 1 In welke mate kunt u uw dagelijkse dingen doen?
Helemaal Bijna Gemiddeld Nogal Helemaal
niet niet
12345
Fll.1 Hoe afhankelijk bent u van medicaties?





F14.1 Krijgt u het soort steun dat u nodig hebt, van anderen?
Helemaal Bijna Gemiddeld Nogal Helemaal
niet niet
1 2 3 4 5
F14.2 In welke mate kunt u rekenen op uw vrienden als u ze nodig hebt?
Helemaal Bijna Gemiddeld Nogal Helemaal
niet niet
1 2 3 4 5
F17.1 Hoe comfortabel is de plaats waar u woont?
Helemaal Weinig Middelmatig Hevig Een extreme
niet hoeveelheid
1            2           3               4              5
F17.2 In welke mate komt de kwaliteit van uw huis tegemoet aan uw behoeften?
Helemaal Bijna Gemiddeld Nogal Helemaal
niet niet
1 2 3 4 5
F18.1 Hebt u genoeg geld om in uw behoeften te voorzien?
Helemaal Bijna Gemiddeld Nogal Helemaal
niet niet
1 2 3 4 5
F20. I Hoe beschikbaar voor u is de informatie, die u nodig hebt in uw dagelijkse
leven?
Helemaal Bijna Gemiddeld Nogal Helemaal
niet niet
12345
F20.2 In welke mate hebt u mogelijkheden om de informatie te verkrijgen waarvan u
vindt dat u die nodig heeft?





F21.1 Hebt u mogelijkheden tot recreatie?
Helemaal Bijna Gemiddeld Nogal Helemaal
niet niet
12345
F21.2 Hoe goed kum u zich ontspannen en uzelfvermaken?
Helemaal Bijna Gemiddeld Nogal Helemaal
niet niet
1 2 3 4 5
F23.1 In welke mate hebt u geschikte middelen van vervoer?
Helemaal Bijna Gemiddeld Nogal Helemaal
niet niet
12345
In de volgende vragen wordt gevraagd naar hoe tevreden of ontevreden u in de afgelopen
twee weken bent geweest met de verschillende aspecten van uw leven; bijvoorbeeld, uw
familieleven ofuw vermogen om met degenen om u heen te communiceren Beslis hoe
tevreden ofontevreden u bent met elk aspect van uw leven en omcirkel het cijfer dat het
beste past bij wat u hierover vindt.
62 Hoe tevreden bent u met de kwaliteit van uw leven?
Erg Ontevreden Tevreden Content Erg
ontevreden noch tevreden
ontevreden
1                  2                    3              4             5
63 Hoe tevreden bent u met uw leven in het algemeen?




64 Hoe tevreden bent u met uw gezondheid?






F2.3 Hoe tevreden bent u met de energie die u heeft?
Erg Ontevreden Tevreden Content Erg
ontevreden noch tevreden
ontevreden
1                  2                    3              4            5
F3.3 Hoe teweden bent u met uw slaap?
Erg Ontevreden Tevreden Content Erg
ontevreden noch tevreden
ontevreden
1                  2                    3              4             5
F5.2 Hoe tevreden bent u met uw vermogen om nieuwe informatie te leren?
Erg Ontevreden Tevreden Content Erg
ontevreden noch tevreden
ontevreden
1                2                  3             4            5
F5.4 Hoe tevreden bent u met uw vermogen om beslissingen te nemen?
Erg Ontevreden Tevreden Content Erg
ontevreden noch tevreden
ontevreden
1                2                  3             4            5
F6.3 Bent u tevreden met uzelf?
Erg Ontevreden Tevreden Con ten t Erg
ontevreden noch tevreden
ontevreden
1                2                  3             4            5
F6.4 Hoe tevreden bent u met uw bekwaamheden?
Erg Ontevreden Tevreden Content Erg
ontevreden noch tevreden
ontevreden
1                2                  3             4            5
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F7.4 Hoe tevreden bent u met uw uiterlijk?
Erg Ontevreden Tevreden Content Erg
ontevreden noch tevreden
ontevreden
1 2 3 4 5
FIO.3 Bent u tevreden met uw vermogen om alledaagse activiteiten te verrichten?




F13.3 Hoe tevreden bent u met uw persoonlijke relaties?




F15.3 In welke mate bent u tevreden met uw sexuele leven?




F14.3 Hoe tevre(len bent u met de steun die u krijgt van uw familie?
Erg Ontevreden Tevreden Content Erg
ontevreden noch tevreden
ontevreden
1 2 3 4 5
F14.4 Hoe tevreden bent u met de steun die u krijgt van uw vrienden?
Erg Ontevreden Tevreden Content Erg
ontevreden noch tevreden
ontevreden
1 2 3 4 5
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F13.4 Hoe  tevreden  bent u met uw vermogen om voor anderen te  zorgen  of hen  steun
te geven?
Erg Ontevreden Tevreden Content Erg
ontevreden noch tevreden
ontevreden
1                  2                    3              4             5
F16.4 Hoe tevreden bent u met uw lichamelijke veiligheid?
Erg Ontevreden Tevreden Content Erg
ontevreden noch tevreden
ontevreden
1                2                  3             4            5
F17.3 Bent u tevreden met uw leefomstandigheden?
Erg Ontevreden Tevreden Content Erg
ontevreden noch tevreden
ontevreden
1                  2                    3              4             5
F18.3 Hoe tevreden bent u met uw financiele situatie?
Erg Ontevreden Tevreden Content Erg
ontevreden noch tevreden
ontevreden
1                  2                    3              4             5
F19.3 Hoe tevreden bent u met uw toegang tot gezondheidsdiensten?
Erg Ontevreden Tevreden Content Erg
ontevreden noch tevreden
ontevreden
1                  2                    3              4             5
F19.4 Hoe tevreden bent u met de sociale diensten?
Erg Ontevreden Tevreden Content Erg
ontevreden noch tevreden
ontevreden
1 2 3 4 5
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F20.3 Bent u tevreden met uw mogelijkheden om nieuwe vaardigheden te
verwerven?
Erg Ontevreden Tevreden Content Erg
ontevreden noch tevreden
ontevreden
1 2 3 4 5
F20.4 Bent u tevreden met uw mogelijkheden om nieuve informatie te verwerven?
Erg Ontevreden Tevreden Content Erg
ontevreden noch tevreden
ontevreden
1                   2                     3                4              5
F21.4 Hoe tevreden bent u met de manier waarop u uw vrije tijd doorbrengt?
Erg Ontevreden Tevreden Content Erg
ontevreden noch tevreden
ontevreden
1                2                  3             4            5
F22.3 Hoe tevreden bent u met uw natuurlijke omgeving (bijv. vervuiling, klimaat.
lawaai, aantrekkelijkheid)?
Erg Ontevreden Tevreden Content Erg
ontevreden noch tevreden
ontevreden
1                  2                    3              4            5
F22.4 Hoe tevreden bent u met het klimaat in het gebied waarin u woont?
Erg Ontevreden Tevreden Content Erg
ontevreden noch tevreden
ontevreden
1                2                  3             4           5
F23.3 Hoe tevreden bent u met uw vervoer?
Erg Ontevreden Tevreden Content Erg
ontevreden noch tevreden
ontevreden
1                  2                   3              4            5
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F13.2 Voelt u zich gelukkig met uw relatie met uw familieleden?
Erg Tamelijk Gelukkiq Tamelijk Erg
ongelukkig ongelukkig noch gelukkig gelukkig
ongelukkig
1                  2                   3                 4              5
GI Hoe zou u uw kwaliteit van leven inschatten?
Erg slecht Tamelijk  Goed  Tamelijk Erg goed
slecht noch goed
slecht
1 2 3 4 5
F15.1 Hoe zou u uw seksleven beoordelen?




F3.1 Hoe goed slaapt u?




F19.2 Wat vindt u van de kwaliteit van de sociale diensten die u ter beschikking
staan?
Erg slecht Tamelijk  Goed  Tamelijk Erg goed
slecht noch goed
slecht
1               2             3          4               5
F5.1 Hoe zou u uw geheugen beoordelen?
Erg slecht Tamelijk  Goed  Tamelijk Erg goed
slecht noch goed
slecht
1 2 3 4 5
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De volgende vragen verwijzen naar hoe vaak u bepaalde dingen hebt gevoeld of ervaren,
bijvoorbeeld de steun van uw familie of vrienden of negatieve ervaringen, zoals zich onveilig
voelen. Als u deze dingen helemaal niet heeft ervaren in de afgelopen twee weken, omcirkel
dan het cijfer 1 onder "Nooit". Als u deze dingen wel heeft ervaren, beslis dan hoe vaak en
omcirkel het toepasselijke cijfer. Dus, bijvoorbeeld, als u de afgelopen twee weken de hele
tijd pijn hebt ervaren, omcirkel dan het cijfer 5 onder "Altijd". Vragen.verwijzen naar de
afgelopen twee weken.
FI. 1 Hoe vaak heeft u een gevoel van pijn gehad?
Nooit Zelden Zo nu en  Redelijk  Altijd
dan vaak
1             2                3               4             5
F4.2 Voelt u zich over het geheel genomen tevreden?
Nooit Zelden Zo nu en Redelijk Altijd
dan vaak
1             2                 3               4             5
F8.1 Hoe vaak heeft u negatieve gevoelens, zoals een sombere stemming, wanhoop,
angst, depressie?
Nooit Zelden Zo nu en  Redelijk  Altijd
dan vaak
1 2 3 4 5
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De volgende vragen verwijzen naar alle soorten "werk" die u verricht. Werk betekent hier
elke redelijk omvangrijke activiteit die u verricht. Dit omvat vrijwilligerswerk. voltijds
studeren, zorgen voor het huis, zorgen voor kinderen, betaald werk, onbetaald werk. Dus
werk, zoals het hier wordt gebruikt. slaat op die activiteiten waarvan u vindt dat ze een groot
deel van uw tijd en energie innemen. Vragen verwijzen naar de afgelopen twee weken.
F12.1 Bent u in staat om uw werkzaamheden te verrichten?
Helemaal Bijna Gemiddeld Nogal Helemaal
Niet niet
12345
F12.2 Voelt u zich in staat om aan uw dagelijkse verplichtingen te voldoen?
Helemaal Bijna Gemiddeld Nogal Helemaal
niet niet
12345
F12.4 Bent u tevreden met uw werkvermogen?
Erg Ontevreden Tevreden Content Erg
ontevreden noch tevreden
ontevreden
1                 2               3             4            5
F12.3 Hoe zou u uw werkvermogen inschatten?
Erg Slecht Tamelijk Goed Tamelijk Erg goed
slecht noch goed
slecht
1                  2               3            4             5
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In de volgende vragen wordt gevraagd naar hoe goed u in staat was om zich te verplaatsen
in de afgelopen twee weken. Dit verwijst naar uw lichamelijk vermogen om uw lichaam te
bewegen op zo'n manier dat het u in staat stelt rond te lopen en de dingen te doen die u zou
willen doen, alsook de dingen die u moet doen.
F9.3 Hoeveel last hebt u van problemen bij het zich verplaatsen?
Helemaal Weinig Middelmatig Hevig Een extreme
niet hoeveelheid
12345
F9.4 In welke mate beinvioeden moeilijkheden met beweging uw manier van leven?
Helemaal Weinig Middelmatig Hevig Een extreme
Niet hoeveelheid
12345
F9.2 Hoe tevreden bent u met de manier waarop u in staat bent zich te verplaatsen?
Erg Ontevreden Tevreden Content Erg
Ontevreden noch tevreden
ontevreden
2                                  3                        4                     5
F9. I Hoe goed kunt u zich verplacitsen?
Helemaal Weinig Middelmatig Hevig Een extreme
Niet hoeveelheid
1 2 3 4 5
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De volgende paar vragen gaan over uw persoonlijke overtuigingen en hoe deze uw leven
beYnvloeden. Deze vragen verwijzen naar geloo f. spiritualiteit ofenigerlei andere
overtuigingen die u zou kunnen hebben. Opnieuw verwijzen deze vragen naar de laatste twee
weken.
F24.1 Geven uw persoonlijke overtuigingen betekenis aan uw leven?
Helemaal Weinig Middelmatig Hevig Een extreme
Niet hoeveelheid
1              2              3                4              0
F24.3 In welke mate geven uw persoonlijke overtuigingen u de kracht om
moeilijkheden aan te kunnen?
Helemaal Weinig Middelmatjg Hevig Een extreme
Niet hoeveelheid
1 2 3 4 5
F24.4 In welke mate helpt uw persoonlijke geloof u om moeilijkheden in het leven te
begrijpen?
Helemaal Weinig Middelmatig Hevig Een extreme
niet hoeveelheid
1 2 3 4 5
F24.2 In welke mate voelt u dat uw leven betekenisvol is?
Helemaal Weinig Middelmatig Hevig Een extreme
niet hoeveelheid
1 2 3 4 5
De vragen die deel uit maken van de, voor patienten met perifeer arterieel occluderend vaatlijden, gereduceerde











In de vragenlijst wordt naar uw gezondheid gevraagd. Wilt u elke vraag beantwoorden door
het juiste hokje aan te kruisen? Wanneer u twijtelt over het antwoord op een vraag. probeer
dan het antwoord te geven dat het meest van toepassing is.
1. Wat vind u. over het algemeen genomen. van uw gezondheid?
Uitstekend                 0
Zeer goed               0
Goed                            0
Matig                   0
Slecht                        0
2. lIn vergelijking met een jaar geleden, hoe zou u nu uw gezondheid in het algemeen
beoordelen?
Veel beter dan een jaar geleden                                                  0
lets beter dan een jaar geleden                                        0
Ongeveer hetzelfde als een jaar geleden                          0
Iets slechter dan een jaar geleden                                        0
Veel slechter dan een jaar geleden                                  0
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3. De volgende vragen gaan over dagelijkse bezigheden.
Wordt u door uw gezondheid op dit moment beperkt bij deze bezigheden? Zo ja, in welke
mate?
Ja, ernstig Ja, een Nee, helemaal
beperkt beetje beperkt niet beperkt
a. forse inspanning,zoals                                   0                     0                        0
hardlopen, zware voorwerpen
tillen, inspannend sporten
b. Matig inspanning, zoals het verplaatsen        0                      0                        0
van een tafel, stofzuigen, fietsen
c. Tillen ofboodschappen dragen                        0                        0                          0
d. Een paar trappen lopen                                             0                              0                                 0
e. Een trap lopen                                          0                    0                      0
f. Buigen, knielen of bukken                                               0                                  0                                      0
g. Meer dan een kilometer  'pen                         0                        0                          0
h. Een halve kilometer lopen                          0                    0                      0
i Honderd meter lo'pen                                              0                           0                             0
j. Uzelfwassen ofaankleden                           0                    0                      0
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4. Had u ten gevolge van uw lichamelijke gezondheid, de afgelopen 4 weken een van de
volgende problemen bij uw werk ofandere dagelijkse bezigheden?
Ja                                 Nee
a. U heeft minder 14'd kunnen                            0                                      0
besteden aan werk of andere
bezigheden
b. U heeft minder bereikt dan u                  0                            0
zou willen
c. U was beperkt in het soort werk             0                          0
ofhet soort bezigheden
d. U had moeite met het werk of                0                            0
andere bezigheden (het kostte
u bijvoorbeeld extra inspanning)
5. Had u. ten gevolge van een emotioneel probleem (bijvoorbeeld doordat u zich depressief
ofangstig voelde), de afgelopen 4 weken een van de volgende problemen bij uw werk of
andere dagelijkse bezigheden?
Ja                              Nee
a. U heeft minder tild kunnen                            0                                      0
besteden aan werk ofandere
bezigheden
b. U heeft minder bereikt dan u zou             0                               0
willen
c. U heeft het werk ofandere                    0                          0
bezigheden niet zo zorgvuldig
gedaan als u gewend bent
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6. In hoeverre heeft uw lichamelijke gezondheid ofhebben uw emotionele problemen u de
afgelopen 4 weken belemmerd in uw normale sociale bezigheden met gezin, vrienden,
buren ofanderen?
Helemaal niet            0
Enigszins               0
Nogal                    0
Veel                           0
Heel erg veel           0
7. Hoeveel pijn had u de afgelopen 4 weken?
Geen                          0
Heel licht                   0
Licht                          0
Nogal                   0
Ernstig                  0
Heel emstig             0
8. In welke mate heeft pijn u de afgelopen 4 weken belemmerd bij uw normale
werkzaamheden (zowel werk buitenshuis als huishoudelijk werk)?
Helemaal niet           0
Een klein beetje         0
Nogal                   0
Veel                           0
Heel erg veel           0
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9. Deze vragen gaan over hoe u zich de afgelopen 4 weken heeft gevoeld. Wilt u bij elke
vraag het antwoord aankruisen dat het beste aansluit bij hoe u zich heefi gevoeld?
Hoe vaak gedurende de afgelopen 4 weken
Voortdurend Meestal Vaak Soms Zelden Nooit
a. Voelde u zich levenslustig?                         0        0        0     0      0        0
b. Voelde u zich erg zenuwachtig?                      0          0         0      0        0         0
c. Zat u z o erg in de put dat niets                        0          0         0      0        0         0
u kon opvrolijken?
d. Voelde u zich kalm en rustig?                         0          0         0      0        0         0
e. Voelde u zich energiek?                                 0          0         0      0        0         0
f. Voelde u zich neerslachtig en somber?              0          0         0      0        0         0
g. Voelde u zich uitgeblust?                               0          0          0      0        0         0
h. Voelde u zich gelukkig?                                 0          0         0      0        0         0
i. Voelde u zich moe?                                     0         0         0     0       0         0
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10. Hoe vaak hebben uw lichamelijke gezondheid ofemotionele problemen gedurende de
afgelopen 4 weken uw sociale activiteiten (zoals bezoek aan vrienden) belemmerd?
Voortdurend              0
Meestal                     0
Soms                         0
Zelden                       0
Nooit                         0
11.  Wilt u het antwoord kiezen dat het beste weergeeft hoe juist of onjuist u elk van de
volgende uitspraken voor uzelf vindt?
volkomen groten- weet groten- volkomen
jlliSt deels ik niet deels onjuist
juist onjuist
a. Ik lijk gemakkelijker ziek te                           0           0         0           0          0
worden dan andere mensen
b. Ik ben net zo gezond als andere                   0          0        0          0         0
mensen die ik ken
c. Ik verwacht dat mijn gezondheid                   0           0         0           0          0
achteruit zal gaan
d. Mijn gezondheid is uitstekend                    0         0        0         0         0
1993 Noordelijk Centrum voor Gezonheidsvraagstukken, Rijksuniversiteit Groningen.
Deze lijst betreft een Nederlandse vertaling van de RAND-36 item health survey 1.0 (RAND,  1992)
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GRADING SYSTEM FOR CARDIOVASCULAR
RSIK FACTORS AND COMORBIDITY
OF







SVS/ISCVS grading system for cardiovascular risk factors and comorbidity:
Diabetes mellitus: 0 - none.  1 = adult onset. controlled by diet or oral agents. 2 - adult onset. insulin controlled. 3 =
juvenile onset.
Tobacco  use: 0 = none or none for last 10 years.  1  = none current, but smoked  in  last 10 years.  2 = current (includes
abstinence less than 1 year), less than 1 paclo/day. 3 = current greater than I pack/day.
H,pertension: 0 - diastolic usually lower than 90 mm Hg. 1 = controlled with a single drug. 2 = controlled with two
drugs. 3 = requires more than two drugs. or is uncontrolled.
Hvpertipidemia: 0 - cholesterol (low density lipoprotein and total) and triglyceride levels within normal limits for
age.  1  = readily controllable by diet. 2 = requiring strict dietary control. 3 = same as mild, but severe enough to
require dietary and drug control.
Cardiac status: 0 = asymptomatic with normal electrocardiogram (ecg). 1 = asymptomatic. but with either
remote myocardiac infarction (MI) by history (> 6 months), occult Ml by ecg, or fixed defect on dipyridamole
thallium or similar scan. 2 = any one of the following: stable angina, no angina. but significant reversible
perfusion defect on dipyridamole thallium scan, significant silent ischemia (2-1% ofthe time) on Holter
monitoring, ejection fraction 25-45%, controlled ectopy or asymptomatic arrythmia, history of congestive heart
failure that is now well compensated. 3 = any one of the following: unstable angina, symptomatic or poorly
controlled ectopy/arrhythmia (chronic/recurrent), poorly compensated or recurrent congestive heart failure,
ejection fraction less than 25%, myocardial infarction within 6 months.
Carotid disease:  0  = no symptoms, no evidence of disease:  1  =  asvmptonzatic  but with evidence of disease
determined by duplex scan or other accepted noninvasive test or arteriogram: 2 = transient or temporary stroke;
3 - completed stroke with permanent neurologic deficit or acute stroke.
Renal status: (refers to stable levels. not transient drops or elevations in response to intravenous medication,
hydration. or contrast media) 0 = no known renal disease, normal serum creatinine level: 1 = moderately
elevated creatinine level, as high as 2.4 mg/dl; 2 = creatinine level. 2.5 to 5.9 mg/dI: 3
= creatinine level greater
than 6.0 mg/dl. or on dialysis or with kidney transplant.
Pulnionan, status  0 - asymptomatic, normal chest x-ray film. pulmonary function tests within 20% of
predicted:  1 = asymptomatic or mild dyspnea on exertion, mild chronic parenchymal x-ray changes. pulmonary
function tests 65% to 80% of predicted; 2 = between  1 and 3.3  = vital capacity less than  l.85 L, FEV i  less than
1.2 L or less than 35% of predicted, maximal voluntary ventilation less than 50% of predicted, Pco2 greater than
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behorend bij het proefschrift
Quality of Life and Health Status
in Patients with Intermittent Claudication
1.   De kwaliteit van leven van patienten met claudicatio intermittens wordt slechts ten
dele bepaald door de loopbeperking; van inspanningen die gericht zijn op het
vergroten van de loopafstand mag dus slechts een beperkt effect op de algehele
kwaliteit van leven verwacht worden. (dit proefschrift)
2.  Naast het verbeteren van de loopafstand zijn de behandeling van nevenaandoeningen,
psychologische aanpassingen en steun vanuit de sociale omgeving instrumenten die
kunnen bijdragen aan het behoud en de verbetering van de kwaliteit van leven van
patienten met claudicatio intermittens. (dit proefschrift)
3.   De objectieve ernst van functionele beperkingen komt bij patienten met claudicatio
intermittens slechts ten dele overeen met de mate waarin deze als belemmerend
ervaren worden. (dit proefschrift)
4.   Wanneer een patient met claudicatio intermittens na zes maanden conservatieve
behandeling een aanvaardbare loopafstand en kwaliteit van leven heeft en wanneer
bovendien nevenaandoeningen en risicofactoren adequaat behandeld zijn, is er geen
reden tot voortgezette specialistische controle. (dit proefschrift)
5.   De inspanningen om patienten met claudicatio intermittens te overtuigen van het
relatieve belang van de presenterende klacht ten opzichte van de levensbedreigende
complicaties van voortschrijdende vaatziekte dienen vooral de kwantiteit en niet
zozeer de kwaliteit van het resterend leven.
6.    Het besef dat inspanningsgebonden pijn in de benen bijzaak is in het kader van een
chronische, levensbedreigende aandoening heeft meetbare effecten op de kwaliteit
van leven van patienten met claudicatio intermittens. (dit proefschrift)
7.   De wettelijk verplichte voorlichting over risico's en gevolgen van en alternatieven
voor een bepaalde ingreep leidt dikwijls tot verwarring en het verzoek dat te doen wat
de dokter het beste vindt.
8.   Een zieke is vaak niet mondig maar bang en verdient aandacht en hulp bij het nemen
van levensbepalende beslissingen.
9. Zich bekommeren om kwaliteit van leven is voorbehouden aan hen die zich verzekerd
weten van de primaire levensbehoeften.
10. Draaglijk wordt het leven door het te aanvaarden zoals het is; er niet in berusten
verhoogt wellicht de kwaliteit.
J.C. Breek, januari 2004
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